



# **STIC Search Report**

## **Biotech-Chem Library**

**STIC Database Tracking Number: 166757**

**TO: Patricia Duffy**  
**Location: rem/3B05/3C18**  
**Art Unit: 1645**  
**Friday, September 30, 2005**  
**Case Serial Number: 09/770943**

**From: Barb O'Bryen**  
**Location: Biotech-Chem Library**  
**Remsen 1a69**  
**Phone: 571-272-2518**

*BOB*  
**barbara.obryen@uspto.gov**

### **Search Notes**

**THIS PAGE BLANK (USPTO)**

Access DB# 166757 = A  
167436 = str

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: PATRICK DUFFY Examiner #: 72440 Date: 9/25/05  
Art Unit: 1645 Phone Number 30 20855 Serial Number: 091770, 943  
Mail Box and Bldg/Room Location: 3C18 3805 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. me

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: pharmaceutical compositions inhibitors of DNA immunostim  
Inventors (please provide full names): Raz, E Roman, M

Earliest Priority Filing Date: 1997

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search the Registry for:

- ① RR[TGAUI][ACGTUI]YY/<sup>SSSN</sup> AND SQL <= 45
- ② RR I[IG]YY/<sup>SSSN</sup> AND SQL <= 45
- ③ RR[GI][ACGTUI]YY/<sup>SSSN</sup> and SQL <= 45

Please cross file reg<sup>results</sup> into HCAPLUS + USPATFULL + restrict output to

I need only documents with {therapeutic or  
therapeutic or  
pharmaceutical or  
pharmaceutical uses}

I need documents whose publication year is  
< 1997


-Thank you- Pat Duffy

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher: <u>me</u>	NA Sequence (#) <u>1</u>	STN <u>409 / str 450</u>	
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____	
Searcher Location: _____	Structure (#) <u>1</u>	Questel/Orbit _____	
Date Searcher Picked Up: <u>9-28</u>	Bibliographic _____	Dr.Link _____	
Date Completed: <u>9-28-05</u>	Litigation _____	Lexis/Nexis _____	
Searcher Prep & Review Time: <u>1 hr 30</u>	Fulltext _____	Sequence Systems _____	
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____	
Online Time: <u>30 51</u>	Other _____	Other (specify) _____	


**THIS PAGE BLANK (USPTO)**







Page 2-B



Page 3-A

VAR G1=67/76

VAR G3=67/76/88/94

VAR G5=11/NH

VAR G6=H/ME

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 1

CONNECT IS E1 RC AT 8

CONNECT IS E1 RC AT 11

CONNECT IS E2 RC AT 12

CONNECT IS E1 RC AT 19

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY LOQ SAT AT 7

GGCAT IS MCY LOQ SAT AT 18

GGCAT IS MCY LOQ SAT AT 32

GGCAT IS MCY LOC SAT AT 37

GGCAT IS MCY LOC SAT AT 42

GGCAT IS MCY LOC SAT AT 47

GGCAT IS UNS AT 99

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E1 O AT 7

ECOUNT IS E1 O AT 18

ECOUNT IS E1 O AT 32

ECOUNT IS E1 O AT 37

ECOUNT IS E1 O AT 42  
ECOUNT IS E1 O AT 47  
ECOUNT IS M2 N AT 99

## GRAPH ATTRIBUTES:

RSPEC 12 5  
NUMBER OF NODES IS 99

## STEREO ATTRIBUTES: NONE

L22 2568 SEA FILE=REGISTRY SSS FUL L20

100.0% PROCESSED 25240 ITERATIONS  
SEARCH TIME: 00.00.11

2568 ANSWERS

(FILE 'HOME' ENTERED AT 12:20:06 ON 30 SEP 2005)

FILE 'LREGISTRY' ENTERED AT 12:20:12 ON 30 SEP 2005

L1 69 SEA ABB=ON RR[TGAUI] [ACGTUI]YY|RRI [IG]YY|RR [GI] [ACGTUI]YY/SQSN

FILE 'STNGUIDE' ENTERED AT 12:21:48 ON 30 SEP 2005

FILE 'REGISTRY' ENTERED AT 12:25:13 ON 30 SEP 2005

FILE 'LREGISTRY' ENTERED AT 12:25:17 ON 30 SEP 2005

L2 0 SEA ABB=ON I/SQSN  
L3 79 SEA ABB=ON INOSINE  
L4 0 SEA ABB=ON L3 AND NS/FS  
E NS/FS  
D KWIC L3 1-5  
D L3 1-5

FILE 'CAPLUS' ENTERED AT 12:37:52 ON 30 SEP 2005

SET LINE 250  
SET DETAIL OFF  
E US2000-770943/AP,PRN 25  
E US2001-770943/AP,PRN 25  
SET NOTICE 1000 SEARCH  
L5 3 SEA ABB=ON US2001-770943/AP  
SET NOTICE LOGIN SEARCH  
SET LINE LOGIN  
SET DETAIL LOGIN  
D SCAN  
SEL RN

FILE 'REGISTRY' ENTERED AT 12:38:55 ON 30 SEP 2005

L6 97 SEA ABB=ON (217312-57-7/BI OR 217312-58-8/BI OR 217312-59-9/BI  
OR 217312-60-2/BI OR 127437-18-7/BI OR 132194-16-2/BI OR  
141185-26-4/BI OR 141185-27-5/BI OR 184024-78-0/BI OR 206654-99  
-1/BI OR 206655-00-7/BI OR 206655-01-8/BI OR 206655-02-9/BI OR  
206655-03-0/BI OR 206655-04-1/BI OR 206655-05-2/BI OR 206655-06  
-3/BI OR 206655-08-5/BI OR 206655-09-6/BI OR 211096-26-3/BI OR  
217439-38-8/BI OR 217439-39-9/BI OR 217439-40-2/BI OR 217439-42  
-4/BI OR 217439-43-5/BI OR 217439-44-6/BI OR 217439-45-7/BI OR  
217439-46-8/BI OR 217439-47-9/BI OR 217447-23-9/BI OR 217447-24  
-0/BI OR 217447-25-1/BI OR 217447-26-2/BI OR 217447-27-3/BI OR

217638-04-5/BI OR 217638-05-6/BI OR 217638-06-7/BI OR 2240-25-7  
/BI OR 251901-47-0/BI OR 251901-49-2/BI OR 251901-50-5/BI OR  
264875-63-0/BI OR 264875-64-1/BI OR 264875-65-2/BI OR 264875-66  
-3/BI OR 264875-67-4/BI OR 264875-68-5/BI OR 264875-69-6/BI OR  
264875-70-9/BI OR 264875-71-0/BI OR 264875-72-1/BI OR 264875-73  
-2/BI OR 264875-74-3/BI OR 264875-75-4/BI OR 264875-76-5/BI OR  
264875-77-6/BI OR 264875-78-7/BI OR 264875-79-8/BI OR 264875-80  
-1/BI OR 264875-81-2/BI OR 264875-82-3/BI OR 264875-83-4/BI OR  
264875-84-5/BI OR 264875-86-7/BI OR 264875-87-8/BI OR 264875-88  
-9/BI OR 264875-89-0/BI OR 264875-90-3/BI OR 552901-86-7/BI OR  
552901-87-8/BI OR 552901-88-9/BI OR 552901-89-0/BI OR 552901-90  
-3/BI OR 552901-91-4/BI OR 552901-92-5/BI OR 552901-93-6/BI OR  
554461-69-7/BI OR 554461-70-0/BI OR 554461-71-1/BI OR 554461-72  
-2/BI OR 554461-73-3/BI OR 554461-74-4/BI OR 554461-75-5/BI OR  
554461-76-6/BI OR 554461-77-7/BI OR 554461-78-8/BI OR 554461-79  
-9/BI OR 554461-80-2/BI OR 554461-81-3/BI OR 71-30-7/BI OR  
75586-90-2/BI OR 82855-46-7/BI OR 82870-55-1/BI OR 82870-56-2/B  
I OR 83026-06-6/BI OR 94854-97-4/BI OR 94855-02-4/BI)  
D SCAN

FILE 'STNGUIDE' ENTERED AT 12:39:25 ON 30 SEP 2005

FILE 'REGISTRY' ENTERED AT 12:40:13 ON 30 SEP 2005

L7 0 SEA ABB=ON L6 AND ?INOSIN?  
L8 0 SEA ABB=ON L6 AND DEOXYINOSIN?

FILE 'STNGUIDE' ENTERED AT 12:40:42 ON 30 SEP 2005

FILE 'REGISTRY' ENTERED AT 12:51:28 ON 30 SEP 2005

L9 6618 SEA ABB=ON INOSIN? OR DEOXYINOSIN?  
L10 494 SEA ABB=ON L9 AND NS/FS  
L11 35 SEA ABB=ON L10 AND 17/SQL  
L12 34 SEA ABB=ON L11 NOT RSD/FA  
D SQIDE  
E GIG/SQEN

FILE 'STNGUIDE' ENTERED AT 12:54:41 ON 30 SEP 2005

FILE 'LREGISTRY' ENTERED AT 12:55:42 ON 30 SEP 2005

L13 69 SEA ABB=ON RR[TGAUI][ACGTUI]YY/SQSN

FILE 'STNGUIDE' ENTERED AT 12:56:37 ON 30 SEP 2005

FILE 'REGISTRY' ENTERED AT 13:07:09 ON 30 SEP 2005

E 1/SQL  
L14 6113380 SEA ABB=ON SQL<46 AND NS/FS  
L15 1667 SEA ABB=ON RRI[IG]YY/SQSN  
L16 1612 SEA ABB=ON L14 AND L15  
SAVE TEMP L16 DUF943SEQ1/A  
L\*\*\* DEL STR  
L17 STR  
SAVE TEMP L17 DUF943STR/Q  
L18 STR L17  
SAVE TEMP L18 DUF943STR/Q  
L19 0 SEA SSS SAM L18

FILE 'STNGUIDE' ENTERED AT 13:55:07 ON 30 SEP 2005

D QUE L18

FILE 'REGISTRY' ENTERED AT 14:03:46 ON 30 SEP 2005

L20 STR L18  
L21 50 SEA SSS SAM L20  
L22 2568 SEA SSS FUL L20  
SAVE TEMP L22 DUF943FULL/A

FILE 'CAPLUS' ENTERED AT 14:05:34 ON 30 SEP 2005  
L23 166 SEA ABB=ON L16  
L24 1716 SEA ABB=ON L22  
L25 1073 SEA ABB=ON (L23 OR L24) NOT P/DT  
L26 834 SEA ABB=ON L25 NOT PY>1997  
L27 802 SEA ABB=ON (L23 OR L24) NOT L25  
E 1994/AY  
L28 173 SEA ABB=ON L27 NOT AY>1997  
L29 1007 SEA ABB=ON L26 OR L28  
L30 146 SEA ABB=ON (L23 OR L24) (L) (THU OR BAC OR PAC OR PKT OR  
DMA)/RL  
L31 383 SEA ABB=ON (L23 OR L24) AND PHARMAC?/SC,SX  
L32 134 SEA ABB=ON (L30 OR L31) AND L29  
D SCAN L5  
L33 55668 SEA ABB=ON (IMMUNOSTIM? OR IMMUNOMOD? OR IMMUNOSUPPRES?)/CW  
L34 50 SEA ABB=ON L31 AND L33  
L35 51 SEA ABB=ON (L30 OR L34) AND L29

FILE 'USPATFULL' ENTERED AT 14:10:23 ON 30 SEP 2005  
L36 639 SEA ABB=ON L16 OR L22  
L37 185 SEA ABB=ON L36 NOT AY>1997  
L38 10501 SEA ABB=ON (IMMUNOSTIM? OR IMMUNOMOD? OR IMMUNOSUPPRES?)/IT  
L39 8 SEA ABB=ON L37 AND L38  
L40 64 SEA ABB=ON L36 (L) (PHARMAC? OR THERAP?)/IT  
L41 13 SEA ABB=ON L37 AND L40  
L42 16 SEA ABB=ON L39 OR L41

FILE 'STNGUIDE' ENTERED AT 14:12:01 ON 30 SEP 2005

FILE 'REGISTRY' ENTERED AT 14:12:15 ON 30 SEP 2005  
D QUE L14  
D QUE L16  
D STAT QUE L22

FILE 'CAPLUS' ENTERED AT 14:15:02 ON 30 SEP 2005  
D QUE NOS L35

FILE 'USPATFULL' ENTERED AT 14:15:02 ON 30 SEP 2005  
D QUE NOS L42

FILE 'CAPLUS, USPATFULL' ENTERED AT 14:15:08 ON 30 SEP 2005  
L43 63 DUP REM L35 L42 (4 DUPLICATES REMOVED)  
ANSWERS '1-47' FROM FILE CAPLUS  
ANSWERS '48-63' FROM FILE USPATFULL

FILE 'STNGUIDE' ENTERED AT 14:15:42 ON 30 SEP 2005

FILE 'CAPLUS' ENTERED AT 14:17:15 ON 30 SEP 2005  
D QUE NOS L35  
L44 37 SEA ABB=ON L35 AND L24

FILE 'USPATFULL' ENTERED AT 14:17:29 ON 30 SEP 2005  
D QUE NOS L42  
L45 16 SEA ABB=ON L42 AND L22

L46 FILE 'CAPLUS, USPATFULL' ENTERED AT 14:17:46 ON 30 SEP 2005  
53 DUP REM L44 L45 (0 DUPLICATES REMOVED)  
ANSWERS '1-37' FROM FILE CAPLUS  
ANSWERS '38-53' FROM FILE USPATFULL  
D IBIB ED ABS HITSTR 1-53

FILE 'CAPLUS' ENTERED AT 14:18:57 ON 30 SEP 2005  
D QUE NOS L35  
L47 14 SEA ABB=ON (L35 AND L23) NOT L44

FILE 'USPATFULL' ENTERED AT 14:19:24 ON 30 SEP 2005  
D QUE NOS L42  
L48 0 SEA ABB=ON (L42 AND L16) NOT L45

FILE 'CAPLUS' ENTERED AT 14:19:56 ON 30 SEP 2005  
D IBIB ED ABS HITSEQ L47 1  
D IBIB ED ABS HITSEQ L47 2-14

FILE 'HOME' ENTERED AT 14:20:59 ON 30 SEP 2005  
D SAVED  
D STAT QUE L22

FILE HOME

FILE LREGISTRY  
LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE STNGUIDE  
FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 23, 2005 (20050923/UP).

FILE REGISTRY  
Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2005 HIGHEST RN 864227-43-0  
DICTIONARY FILE UPDATES: 29 SEP 2005 HIGHEST RN 864227-43-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

## FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Sep 2005 VOL 143 ISS 15  
FILE LAST UPDATED: 29 Sep 2005 (20050929/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

## FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 29 Sep 2005 (20050929/PD)  
FILE LAST UPDATED: 29 Sep 2005 (20050929/ED)  
HIGHEST GRANTED PATENT NUMBER: US6951031  
HIGHEST APPLICATION PUBLICATION NUMBER: US2005217002  
CA INDEXING IS CURRENT THROUGH 29 Sep 2005 (20050929/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 29 Sep 2005 (20050929/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

```
>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>

**THIS PAGE BLANK (USPTO)**



All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:09:07 ON 08 AUG 2005

=> f reg

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:09:49 ON 08 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2005 HIGHEST RN 858781-12-1

DICTIONARY FILE UPDATES: 7 AUG 2005 HIGHEST RN 858781-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s RR[TGAUI][ACGTUI]YY/SQSN AND sql<=45

3532138 RR[TGAUI][ACGTUI]YY/SQSN

7175039 SQL<=45

L1 3532138 RR[TGAUI][ACGTUI]YY/SQSN AND SQL<=45

=> s RR[TAU][GI]YY/SQSN AND sql<=45

SYSTEM LIMITS EXCEEDED - SEARCH ENDED



FILE 'HCAPLUS' ENTERED AT 13:21:35 ON 08 AUG 2005

FILE 'REGISTRY' ENTERED AT 13:21:45 ON 08 AUG 2005

L1 15735 S AAGGTT/SQSN AND SQL<=45

FILE 'HCAPLUS' ENTERED AT 13:24:22 ON 08 AUG 2005

L2 3029 S L1

L3 418 S L2 AND PY<=1998

L4 673 S L1 AND (BACTERIA? OR EUBACTERIA OR EUBACTER? OR MICROB?)

L5 111 S L3 AND (BACTERIA? OR EUBACTERIA OR EUBACTER? OR MICROB?)

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

427.28

540.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-88.33

-88.33

STN INTERNATIONAL LOGOFF AT 13:38:19 ON 08 AUG 2005



=> d his full

(FILE 'HOME' ENTERED AT 14:04:45 ON 04 AUG 2005)

FILE 'REGISTRY' ENTERED AT 14:05:30 ON 04 AUG 2005

L\*\*\* DEL 17 RRCGY/SQSP  
D SQIDE

L\*\*\* DEL 14 RRCGY/SQEN  
D SQIDE

L1 198145 SEA ABB=ON PLU=ON RRCGY/SQSN AND SQL<=45

FILE 'HCAPLUS' ENTERED AT 14:11:36 ON 04 AUG 2005

L2 19430 SEA ABB=ON PLU=ON L1

L3 4359 SEA ABB=ON PLU=ON L2 AND (PY<=1997 OR AY<=1997 OR PRY<=1997)

L\*\*\* DEL 2052 L3 AND US/PC

L\*\*\* DEL 1243 L3 AND US/PC.B  
E EUBACTERIA/CT  
E E3+OLD,NT1

L4 241 SEA ABB=ON PLU=ON (EUBACTERIA+OLD,NT1/CT OR (EUBACTER? OR  
BACTER?)/CW) AND L3

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 AUG 2005 HIGHEST RN 858181-56-3

DICTIONARY FILE UPDATES: 3 AUG 2005 HIGHEST RN 858181-56-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
the American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 4 Aug 2005 VOL 143 ISS 6

FILE LAST UPDATED: 3 Aug 2005 (20050803/ED)



The search profile you entered was too complex or gave too many answers. Simplify or subdivide the query and try again. If you have exceeded the answer limit, enter DELETE HISTORY at an arrow prompt (=>) to remove all previous answers sets and begin at L1. Use the SAVE command to store any important profiles or answer sets before using DELETE HISTORY.

=> DELETE L1  
DELETE L1? (Y)/N:Y  
'L1' DELETED

=> s RR[TAU][GI]YY/SQSN AND sql<=45  
1014220 RR[TAU][GI]YY/SQSN  
7175039 SQL<=45  
L1 1014220 RR[TAU][GI]YY/SQSN AND SQL<=45

	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	71.51	71.72

FILE 'HCAPLUS' ENTERED AT 13:20:15 ON 08 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Aug 2005 VOL 143 ISS 7  
FILE LAST UPDATED: 7 Aug 2005 (20050807/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L1  
TOO MANY TERMS FOR FILE CROSSOVER IN L1  
There are limits on the size of an answer set being crossed over from one file to another. Enter HELP CROSSOVER at an arrow prompt (=>) for specific information.

=> S AGGTT/SQSN AND SQL<=45  
**REGISTRY INITIATED**  
Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SYSTEM LIMITS EXCEEDED - SEARCH ENDED  
=>  
=> DELETE L1  
DELETE L1? (Y)/N:Y  
'L1' DELETED





692852-60-1	692852-61-2	692852-62-3	692852-63-4	692852-64-5
692852-65-6	692852-66-7	692852-67-8	692852-68-9	692852-69-0
692852-70-3	692852-71-4	692852-72-5	692852-73-6	692852-74-7
692852-75-8	692852-76-9	692852-77-0	692852-78-1	692852-79-2
692852-80-5	<b>692852-81-6</b>	692852-82-7	692852-83-8	
692852-84-9	692852-85-0	692852-86-1	692852-87-2	692852-88-3
692852-89-4	692852-90-7	692852-91-8	692852-92-9	692852-93-0
692852-94-1	692852-95-2	692852-96-3	692852-97-4	<b>692852-98-5</b>
692852-99-6	692853-00-2	692853-01-3	692853-02-4	692853-03-5
692853-04-6	692853-05-7	692853-06-8	692853-07-9	692853-08-0
692853-09-1	692853-10-4	692853-11-5	692853-12-6	692853-13-7
692853-14-8	692853-15-9	692853-16-0	692853-17-1	692853-18-2
692853-19-3	692853-20-6	692853-21-7	692853-22-8	692853-23-9
692853-24-0	692853-25-1	692853-26-2	692853-27-3	692853-28-4
692853-29-5	692853-30-8	692853-31-9	692853-32-0	692853-33-1
692853-34-2	692853-35-3	692853-36-4	692853-37-5	692853-38-6
692853-39-7	692853-40-0	692853-41-1	692853-42-2	692853-43-3
692853-44-4	692853-45-5	692853-46-6	692853-47-7	692853-48-8
692853-49-9	692853-50-2	692853-51-3	692853-52-4	692853-53-5
692853-54-6	692853-55-7	692853-56-8	692853-57-9	692853-58-0
692853-59-1	692853-60-4	692853-61-5	692853-62-6	692853-63-7
692853-64-8	692853-65-9	692853-66-0	692853-67-1	692853-68-2
692853-69-3	692853-70-6	692853-71-7	692853-72-8	692853-73-9
692853-74-0	692853-75-1	692853-76-2	692853-77-3	692853-78-4
692853-79-5	692853-80-8	692853-81-9	692853-82-0	692853-83-1
692853-84-2	692853-85-3	692853-86-4	692853-87-5	692853-88-6
692853-89-7	692853-90-0	692853-91-1	692853-92-2	692853-93-3
692853-94-4	692853-95-5			

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(DNAzyme specific for human KDR VEGFR mRNA; ribozymes for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor)

L3 ANSWER 10 OF 418 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:355661 HCAPLUS  
 DN 140:332450  
 ED Entered STN: 03 May 2004  
 TI Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor  
 IN Pavco, Pamela; McSwiggen, James; Stinchcomb, Dan; Escobedo, Jaime  
 PA Ribozyme Pharmaceuticals, Inc., USA  
 SO U.S. Pat. Appl. Publ., 357 pp., Cont.-in-part of U.S. Ser. No. 870,161.  
 CODEN: USXXCO

DT Patent  
 LA English

IC A61K048-00; C07H021-04; A61K009-127; C12N015-88

=> S L1 AND (BACTERIA? OR EUBACTERIA OR EUBACTER? OR MICROB?)

3029 L1  
 439847 BACTERIA?  
 27957 EUBACTERIA  
 1 EUBACTERIAS  
 27958 EUBACTERIA  
 (EUBACTERIA OR EUBACTERIAS)  
 30497 EUBACTER?  
 400100 MICROB?

L4 673 L1 AND (BACTERIA? OR EUBACTERIA OR EUBACTER? OR MICROB?)

=> D HIS

(FILE 'HOME' ENTERED AT 13:09:07 ON 08 AUG 2005)

FILE 'REGISTRY' ENTERED AT 13:09:49 ON 08 AUG 2005

FILE 'HCAPLUS' ENTERED AT 13:20:15 ON 08 AUG 2005



=> fil reg  
FILE 'REGISTRY' ENTERED AT 14:12:15 ON 30 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2005 HIGHEST RN 864227-43-0  
DICTIONARY FILE UPDATES: 29 SEP 2005 HIGHEST RN 864227-43-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> => s rr[tgauil][acgtui]yy/sqsn  
SYSTEM LIMITS EXCEEDED - SEARCH ENDED

=> s rr[gi][acgtui]yy/sqsn  
SYSTEM LIMITS EXCEEDED - SEARCH ENDED

=> d que l14  
L14 6113380 SEA FILE=REGISTRY ABB=ON SQL<46 AND NS/FS



=> s l14 and rr[tgauil][acgtui]yy/sqsn  
SYSTEM LIMITS EXCEEDED - SEARCH ENDED

=> s l14 and rr[gi][acgtui]yy/sqsn  
SYSTEM LIMITS EXCEEDED - SEARCH ENDED


=> d que l16; d stat que l22  
L14 6113380 SEA FILE=REGISTRY ABB=ON SQL<46 AND NS/FS  
L15 1667 SEA FILE=REGISTRY ABB=ON RRI[IG]YY/SQSN  
L16 1612 SEA FILE=REGISTRY ABB=ON L14 AND L15

*This was the only sequence  
specific (narrow) enough  
to run*


L20 STR




Page 1-A



Page 2-A



Page 2-B



searched structure of  
RR [TGAUI] [ACGTUI] YY

Hy = heterocycle

Page 3-A

VAR G1=67/76

VAR G3=67/76/88/94

VAR G5=11/NH

VAR G6=H/ME

NODE ATTRIBUTES:

CONNECT IS E2 F

CONNECT IS E1 F

CONNECT IS E1 F

CONNECT IS E2 F

CONNECT IS E1 F

DEFAULT MLEVEL 1

GGCAT IS MCY

GGCAT IS MCY

GGCAT IS MCY

GGCAT IS MCY

GGCAT IS MCY

GGCAT IS MCY

GGCAT IS UNS


DEFAULT ECLEVEL

ECOUNT IS E1 O

ECOUNT IS E1 O


ECOUNT IS E1 O

ECOUNT IS E1 O



2-2518

Page 2-B



**THIS PAGE BLANK (USPTO)**

ECOUNT IS E1 O AT 42  
 ECOUNT IS E1 O AT 47  
 ECOUNT IS M2 N AT 99

## GRAPH ATTRIBUTES:

RSPEC 12 5  
 NUMBER OF NODES IS 99

## STEREO ATTRIBUTES: NONE

L22 2568 SEA FILE=REGISTRY SSS FUL L20

100.0% PROCESSED 25240 ITERATIONS  
 SEARCH TIME: 00.00.11

2568 ANSWERS

=> fil capl; d que nos l35

FILE 'CAPLUS' ENTERED AT 14:17:15 ON 30 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Sep 2005 VOL 143 ISS 15  
 FILE LAST UPDATED: 29 Sep 2005 (20050929/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L14 6113380 SEA FILE=REGISTRY ABB=ON SQL<46 AND NS/FS  
 L15 1667 SEA FILE=REGISTRY ABB=ON RRI[IG]YY/SQSN  
 L16 1612 SEA FILE=REGISTRY ABB=ON L14 AND L15  
 L20 STR  
 L22 2568 SEA FILE=REGISTRY SSS FUL L20  
 L23 166 SEA FILE=CAPLUS ABB=ON L16  
 L24 1716 S  
 L25 1073 S  
 L26 834 S  
 L27 802 SI  
 L28 173 SI  
 L29 1007 SE  
 L30 146 SE  
 PK  
 L31 383 SE  
 L33 55668 SE  
 PRI  
 L34 50 SEA FILE=  
 L35 51 SEA FILE=

THU = therapeutic use  
 BAC = biological activity  
 PAC = pharmacologic activity  
 PKT = pharmacokinetics  
 MA = drug mechanism  
 of action

↑  
 C OR PAC OR

/SC, SX  
 ? OR IMMUNOSUP

version of structure  
 for access to view  
 fold down

Searched

**THIS PAGE BLANK (USPTO)**



=> s l35 and l24

L44 37 L35 AND L24

*structure  
sequence search answers*

=> fil uspatf; d que nos l42

FILE 'USPATFULL' ENTERED AT 14:17:29 ON 30 SEP 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 29 Sep 2005 (20050929/PD)

FILE LAST UPDATED: 29 Sep 2005 (20050929/ED)

HIGHEST GRANTED PATENT NUMBER: US6951031

HIGHEST APPLICATION PUBLICATION NUMBER: US2005217002

CA INDEXING IS CURRENT THROUGH 29 Sep 2005 (20050929/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 29 Sep 2005 (20050929/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

```
>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<
```

```
>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L14 - 6113380 SEA FILE=REGISTRY ABB=ON SQL<46 AND NS/FS
L15 1667 SEA FILE=REGISTRY ABB=ON RRI[IG]YY/SQSN
L16 1612 SEA FILE=REGISTRY ABB=ON L14 AND L15
L20 STR
L22 2568 SEA FILE=REGISTRY SSS FUL L20
L36 639 SEA FILE=USPATFULL ABB=ON L16 OR L22
L37 185 SEA FILE=USPATFULL ABB=ON L36 NOT AY>1997
L38 10501 SEA FILE=USPATFULL ABB=ON (IMMUNOSTIM? OR IMMUNOMOD? OR
IMMUNOSUPPRES?)/IT
L39 8 SEA FILE=USPATFULL ABB=ON L37 AND L38
L40 64 SEA FILE=USPATFULL ABB=ON L36(L) (PHARMAC? OR THERAP?)/IT
L41 13 SEA FILE=USPATFULL ABB=ON L37 AND L40
L42 16 SEA FILE=USPATFULL ABB=ON L39 OR L41
```

=> s l42 and l22

568 L22

L45 16 L42 AND L22

*sequence structure search answers*

=> dup rem l44,l45

FILE 'CAPLUS' ENTERED AT 14:17:46 ON 30 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:17:46 ON 30 SEP 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

PROCESSING COMPLETED FOR L44

PROCESSING COMPLETED FOR L45

L46 53 DUP REM L44 L45 (0 DUPLICATES REMOVED)

ANSWERS '1-37' FROM FILE CAPLUS

ANSWERS '38-53' FROM FILE USPATFULL

=> d ibib ed abs hitstr 1-53

L46 ANSWER 1 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:488123 CAPLUS

DOCUMENT NUMBER: 137:73234

TITLE: Oligonucleotides specific for hepatitis C virus treatment

INVENTOR(S): Kilkuskie, Robert L.; Frank, Bruce L.; Goodchild, John; Wolfe, Jia L.; Roberts, Peter C.; Hamlin, Henry A.; Roberts, Noel A.; Walther, Debra M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 74 pp., Cont.-in-part of U.S. Ser. No. 471,968.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002081577	A1	20020627	US 1997-887505	19970702
EP 1331267	A2	20030730	EP 2003-5364	19960604
EP 1331267	A3	20031203		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.:	US 1995-471968	A2 19950606
	US 1996-21104P	P 19960702
	EP 1996-920788	A3 19960604

ED Entered STN: 28 Jun 2002

AB The invention discloses synthetic oligonucleotides complementary to contiguous and non-contiguous regions of the HCV RNA. Also disclosed are methods and kits for inhibiting the replication of HCV, inhibiting the expression of HCV nucleic acid and protein, and for treating HCV infections.

IT 185946-81-0


RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oligonucleotides specific for hepatitis C virus treatment)

RN 185946-81-0 CAPLUS


CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



L46 ANSWER 2 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:479637 CAPLUS  
 DOCUMENT NUMBER: 129:91399  
 TITLE: Methods for detecting and inhibiting the RNA component  
 of telomerase with antisense oligonucleotides and  
 clinical use  
 INVENTOR(S): Kim, Nam Woo; Wu, Fred; Kealey, James T.; Pruzan,  
 Ronald; Weinrich, Scott L.  
 PATENT ASSIGNEE(S): Geron Corp., USA  
 SOURCE: PCT Int. Appl., 80 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828442	A1	19980702	WO 1997-US23619	19971219
W: AU, CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5846723	A	19981208	US 1996-770565	19961220
CA 2274586	AA	19980702	CA 1997-2274586	19971219
AU 9856148	A1	19980717	AU 1998-56148	19971219
AU 733610	B2	20010517		
EP 951568	A1	19991027	EP 1997-952568	19971219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001507229	T2	20010605	JP 1998-529003	19971219
PRIORITY APPLN. INFO.:			US 1996-770564	A 19961220

US 1996-770565  
WO 1997-US23619

A 19961220  
W 19971219

ED Entered STN: 03 Aug 1998

AB Disclosed are methods of using the oligonucleotide for detecting the RNA component of telomerase, diagnosing cancer, determining its prognosis, and inhibiting telomerase activity using polynucleotides that hybridize to the RNA component of mammalian telomerase. Also provided are antisense oligonucleotides specifically hybridize to nucleotide residues 137-196, 290-319, and 350-380 of the cDNA (SEQ. ID 1) encoding human telomerase, and the primers for determination of the RNA component in human telomerase. Pharmaceutical composition containing expression vectors for the antisense oligonucleotides is also claimed.

IT 209627-13-4P


RL: ARG (Analytical reagent use); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(nucleotide sequence; antisense oligonucleotide for detecting and inhibiting RNA component of human telomerase and clin. use)

RN 209627-13-4 CAPLUS

CN Guanosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B


Me  
|

PAGE 2-A

Me  
|



PAGE 2-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 3 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:163701 CAPLUS

DOCUMENT NUMBER: 128:240364

TITLE: CD95 gene regulatory sequences and transcription factors binding thereto and methods for modulating CD95 gene expression and apoptosis

INVENTOR(S): Watson, James D.; Rudert, Fritz

PATENT ASSIGNEE(S): Genesis Research & Development Corporation Limited, N. Z.

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808965	A2	19980305	WO 1997-NZ107	19970829
WO 9808965	A3	19980507		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5912168	A	19990615	US 1996-713557	19960830
CA 2263824	AA	19980305	CA 1997-2263824	19970829
AU 9740367	A1	19980319	AU 1997-40367	19970829
AU 732766	B2	20010426		

EP 956358 A2 19991117 EP 1997-937917 19970829  
 R: CH, DE, FR, GB, IT, LI, NL, SE  
 NZ 334359 A 20000825 NZ 1997-334359 19970829  
 JP 2000517183 T2 20001226 JP 1998-511517 19970829  
 PRIORITY APPLN. INFO.: US 1996-713557 A 19960830  
 WO 1997-NZ107 W 19970829

ED Entered STN: 19 Mar 1998

AB Regulatory DNA sequences that silence and enhance transcription of the CD95 gene, which is instrumental in apoptosis, are disclosed. Proteinaceous transcription factors that bind to the silencer and enhancer regulatory sequences are also disclosed. The regulatory sequences and transcription factors may be used to modulate expression of the CD95 gene. Methods for regulating apoptosis have therapeutic and prophylactic applications for a variety of disorders, including cancer, viral and retroviral infections, neurodegenerative disorders, immune system dysfunction, and other disorders. YB-1 and Pura transcription factors were found to bind to the CD95 silencer while YB-1 and hnRNP D bound to the enhancer. Using electrophoretic mobility shift assays, UV crosslinking, and Southwestern anal. complexes with mol. weight 59, 113 and 200-300 kDa were demonstrated to form with the enhancer while complexes with mol. weight 47, 77 and 100 kDa formed with the silencer.

IT **204200-42-0**  
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)  
 (CD95 gene enhancer element; CD95 gene regulatory sequences and transcription factors binding thereto and methods for modulating CD95 gene expression and apoptosis)


RN 204200-42-0 CAPLUS

CN Adenosine, 2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



L46 ANSWER 4 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:629748 CAPLUS  
 DOCUMENT NUMBER: 129:271516  
 TITLE: DNA spacer regulatory elements responsive to cytokines involving STAT factors (Signal Transducers and Activators of Transcription) and methods for their use in expression cloning  
 INVENTOR(S): Seidel, H. Martin; Lamb, I. Peter  
 PATENT ASSIGNEE(S): Ligand Pharmaceuticals, Inc., USA  
 SOURCE: U.S., 58 pp., Cont.-in-part of U. S. Ser. No. 228,935, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5814517	A	19980929	US 1995-410779	19950327
PRIORITY APPLN. INFO.:			US 1994-228935	B2 19940414

ED Entered STN: 06 Oct 1998

AB Many cytokines activate STAT transcription factors (Signal Transducers and Activators of Transcription) that can bind to similar sequences (GAS/APREs) that regulate distinct sets of genes. This suggests that there is specificity with respect to the response elements in some of these genes, such that they respond only to one of these cytokines. Specific DNA sequences that show selectivity with respect to their ability to bind cytokine-activated proteins, including STAT proteins, would be useful tools allowing the responses mediated by different cytokine-activated DNA-binding proteins to be assayed selectively. Therefore, DNA constructs comprising oligonucleotide sequences containing the general regulatory element TTNxAA were synthesized and assayed for their ability to control the expression of structural genes, for the detection and recovery of transcriptional regulatory proteins, and for measuring the ability of compds. to act as agonists and antagonists of gene transcription.

172652-91-4


(Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)

RN 172652-88-9 CAPLUS


CN Adenosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAM

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 172652-89-0 CAPLUS


CN Adenosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 172652-90-3 CAPLUS


CN Adenosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-B






PAGE 3-B



PAGE 3-C




RN 172652-91-4 CAPLUS


CN Adenosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-  
 2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 5 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:214317 CAPLUS

DOCUMENT NUMBER: 128:279586

TITLE: Reagents and methods for modulating gene expression through RNA mimicry

INVENTOR(S): Ecker, David J.; Bruice, Thomas W.; Vickers, Timothy A.

PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 497,090, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5736294	A	19980407	US 1991-724500	19910627
CA 2078659	AA	19910922	CA 1991-2078659	19910319
HU 62658	A2	19930528	HU 1992-3010	19910319
US 5874564	A	19990223	US 1995-461418	19950605
PRIORITY APPLN. INFO.:			US 1990-497090	B2 19900321
			US 1992-927505	B1 19920916


ED Entered STN: 16 Apr 1998

AB Expression of genes may be modulated by employment of compns. which are capable of RNA mimicry. A portion of RNA coded by the gene whose expression is to be modulated is selected which is capable of interacting with one or more proteins. An oligonucleotide or oligonucleotide analog is then prepared in such a way as to mimic the portion of the RNA. Cells containing the gene are then contacted with the oligonucleotide or oligonucleotide analog to effect the modulation. Therapeutic compns. and methods, especially for the treatment of human immunodeficiency, are disclosed in which oligonucleotide mimics of the TAR element interfere with binding of the TAR element to Tat protein and thus inhibit HIV replication. The oligonucleotide mimics are modified with 2'-O-Me groups or within the pyrimidine moiety (5-bromouridine, 6-azauridine, etc.) for improved nuclease resistance within the cell.


IT 138029-68-2 138072-09-0 138072-09-0D,  
 oligonucleotide or analog containing 138072-10-3D, oligonucleotide  
 or analog containing  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (modulating gene expression through RNA mimicry for inhibition of HIV  
 TAR element interaction with the Tat protein)  
 RN 138029-68-2 CAPLUS  
 CN Guanosine, cytidylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-  
 (5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-  
 (5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-  
 (5'→3')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




PAGE 2-B


NH<sub>2</sub>

NH<sub>2</sub>

PAGE 3-A



PAGE 3-B




RN 126596-01-8 CAPLUS



CN DNA, d(G-G-G-G-T-T-G-G-G-G) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-B




PAGE 1-C



PAGE 2-A



PAGE 2-B





AB Comps. and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

IT 126208-94-4 126596-01-8 155902-32-2

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(antisense oligonucleotides for treating infections from herpes viruses)

RN 126208-94-4 CAPLUS

CN Thymidine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-


deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-

deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-


(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 3-B




L46 ANSWER 21 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1996:333023 CAPLUS  
 DOCUMENT NUMBER: 125:49274  
 TITLE: Oligonucleotide therapies for modulating the effects of herpes viruses  
 INVENTOR(S): Draper, Kenneth G.; Crooke, Stanley T.; Mirabelli, Christopher K.; Ecker, David J.; Hanecak, Ronnie C.; Anderson, Kevin P.; Brown-Driver, Vickie L.; Wyatt, Jacqueline R.  
 PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA  
 SOURCE: U.S., 28 pp., Cont.-in-part of U.S. 5, 248, 670.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5514577	A	19960507	US 1993-31147	19930312
US 5248670	A	19930928	US 1990-485297	19900226
US 6310044	B1	20011030	US 1992-852132	19920428
EP 1016715	A1	20000705	EP 1999-203835	19930929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
WO 9419945	A1	19940915	WO 1994-US2471	19940307
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9463619	A1	19940926	AU 1994-63619	19940307
EP 692930	A1	19960124	EP 1994-910879	19940307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08503959	T2	19960430	JP 1994-520254	19940307
US 5658891	A	19970819	US 1994-329212	19941026
PRIORITY APPLN. INFO.:			US 1990-485297	A2 19900226
			US 1992-852132	A2 19920428
			US 1992-954185	B2 19920929
			WO 1991-US1327	W 19910225
			US 1993-31147	A 19930312
			US 1993-122328	B1 19930916
			EP 1993-922788	A3 19930929
			WO 1994-US2471	W 19940307


ED Entered STN: 08 Jun 1996

Searched by Barb O'Bryen, STIC 2-2518


PAGE 2-A



PAGE 2-B



PAGE 3-B




RN 138072-09-0 CAPLUS


CN Adenosine, cytidylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 138072-09-0 CAPLUS  
 CN Adenosine, cytidyl-(3'→5')-uridylyl-(3'→5')-guanylyl-  
 (3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 138072-10-3 CAPLUS


CN Cytidine, uridylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-  
 (3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-  
 (3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B





REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 6 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:75991 CAPLUS

DOCUMENT NUMBER: 128:162858

TITLE: Oligoribonucleotide assays for novel antibiotic screening

INVENTOR(S): Stern, Seth; Purohit, Prakash

PATENT ASSIGNEE(S): University of Massachusetts Medical Center, USA

SOURCE: U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 294,450, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5712096	A	19980127	US 1995-498402	19950705
CA 2198261	AA	19960229	CA 1995-2198261	19950823
CA 2198261	C	20031028		
WO 9606106	A1	19960229	WO 1995-US10721	19950823
W: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RO, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9534134	A1	19960314	AU 1995-34134	19950823
EP 804454	A1	19971105	EP 1995-930926	19950823
EP 804454	B1	20040526		
R: CH, DE, FR, GB, IT, LI				

PRIORITY APPLN. INFO.:  
 US 1994-294450 B2 19940823  
 US 1995-498402 A 19950705  
 WO 1995-US10721 W 19950823

ED Entered STN: 09 Feb 1998

AB The oligoribonucleotide analogs of the invention are relatively small, three-dimensional structures derived from larger parental RNA mols. The analogs include a first nucleic acid structure including one or more nucleotide sequences that are derived from a region of parental RNA, wherein in its native state, the region binds to a ligand, e.g., an aminoglycoside, with a parental RNA ligand binding pattern, and a second nucleic acid structure including one or more nucleotide sequences combined with the first nucleic acid structure to form the analog and provide the analog with a conformation that binds the ligand with a ligand binding pattern that is substantially identical to the parental RNA ligand binding pattern. These analogs can be used to identify novel therapeutic compds.

IT 169174-34-9


RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)  
 (oligoribonucleotide assays for novel antibiotic screening)

RN 169174-34-9 CAPLUS


CN Guanosine, cytidylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 7 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:512115 CAPLUS  
 DOCUMENT NUMBER: 129:134769  
 TITLE: Jumping translocation-related gene of human and use for diagnosis of chromosome aberrations  
 INVENTOR(S): Ishikawa, Fuyuki  
 PATENT ASSIGNEE(S): Kirin Brewery Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10210983	A2	19980811	JP 1997-33078	19970131
PRIORITY APPLN. INFO.:			JP 1997-33078	19970131
ED Entered STN: 18 Aug 1998				

AB The gene associated with jumping translocation has been identified in chromosome 1q21 from a patient with myelomonocytic leukemia that had transformed from myelodysplastic syndrome. Amino acid sequence deduced from the coding region and introns of the gene are also disclosed. Probes derived from the cDNA or the gene are also provided for detecting chromosome aberrations such as jumping translocations in mammals, which may be used for the diagnosis of cancer.

IT 117490-04-7P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(oligonucleotide probe; jumping translocation-related gene of human and use for diagnosis)

RN 117490-04-7 CAPLUS

CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9737669	A1	19971016	WO 1997-US6104	19970404
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5837854	A	19981117	US 1996-628422	19960405
AU 9728014	A1	19971029	AU 1997-28014	19970404
PRIORITY APPLN. INFO.:			US 1996-628422	A 19960405
			WO 1997-US6104	W 19970404

ED Entered STN: 29 Oct 1997

AB Oligonucleotides that inhibit Epstein-Barr virus functions, pharmaceutical comps. containing such oligonucleotides, and methods of using these comps. to treat Epstein-Barr virus-associated diseases are disclosed.

IT 198065-19-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (oligonucleotides with anti-Epstein-Barr virus activity)

RN 198065-19-9 CAPLUS

CN Cytidine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A





Searched by Barb O'Bryen, STIC 2-2518


PAGE 2-A



PAGE 2-B



PAGE 3-A



L46 ANSWER 9 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:739370 CAPLUS

DOCUMENT NUMBER: 128:19359

TITLE: Methods and reagents for lengthening telomeres

INVENTOR(S): West, Michael D.; Shay, Jerry; Wright, Woodring E.

PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA

SOURCE: U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 151,477.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 21

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5686306	A	19971111	US 1994-337684	19941110
US 5489508	A	19960206	US 1993-38766	19930324
US 5695932	A	19971209	US 1993-60952	19930513
US 5645986	A	19970708	US 1993-153051	19931112
US 5830644	A	19981103	US 1993-151477	19931112
PRIORITY APPLN. INFO.:			US 1992-882438	B2 19920513
			US 1993-38766	A2 19930324
			US 1993-60952	A2 19930513
			US 1993-151477	A2 19931112
			US 1993-153051	A2 19931112

ED Entered STN: 24 Nov 1997

AB A method for increasing telomere length in normal cells is described. It can be used to increase the proliferative capacity of cells and to delay the onset of cellular senescence. This method has applications in the fields of chemical, pharmacol., biol., mol. biol., and medical therapeutic and diagnostic technol. With this method, cells are cultivated in the presence of a therapeutically effective amount of a GTR (G-rich Telomeric repeat) oligonucleotide substrate for telomerase under conditions such that the oligonucleotide substrate enters the cells and acts to lengthen telomeric DNA. It is especially useful for cells expressing telomerase and for hybrids between immortal and mortal cells. It could also be used to reduce the level of chromosomal fusions and other chromosomal aberrations by increasing the telomere repeat length in cells.

IT 157961-44-9

RL: BUU (Biological use, unclassified); PRP (Properties); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(nucleotide sequence of useful GTR (G-rich Telomeric repeat)

oligonucleotide; methods and reagents for lengthening telomeres)

RN 157961-44-9 CAPLUS

CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-



deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-2'-deoxy-, double-stranded complementary  
(9CI) (CA INDEX NAME)


CM 1

CRN 117490-04-7


CMF C60 H75 N24 O35 P5

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




CM 2

CRN 89802-96-0


CMF C57 H74 N21 O33 P5

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



L46 ANSWER 10 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:689159 CAPLUS

DOCUMENT NUMBER: 128:917

TITLE: Functional analysis of the promoter for the human CYP1B1 gene

AUTHOR(S): Wo, Yu-Yuan P.; Stewart, Jane; Greenlee, William F.

CORPORATE SOURCE: Department of Molecular Pharmacology and Medicinal Chemistry, Purdue University, West Lafayette, IN, 47907, USA

SOURCE: Journal of Biological Chemistry (1997), 272(42), 26702-26707

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 31 Oct 1997

AB Our laboratory has previously cloned the cDNA for human CYP1B1, a new member of the cytochrome P 450 superfamily. Here, we report on the mapping and function of the CYP1B1 promoter. The CYP1B1 promoter is fully functional, when it is uncoupled from upstream enhancer elements. Deletion anal. and site-directed mutagenesis identified four regulatory elements required for maximum promoter activity: two antisense Sp1 sites (-84 to -89 and -68 to -73), a TATA-like box (-34 to -29), and an initiator motif (-5 to +3). The initiator and the TATA-like elements are both required for basal promoter activity, with enhanced activity mediated by the two antisense Sp1 elements. The CYP1B1 initiator was demonstrated by in vitro transcription anal. to be a positioning element that maintained fidelity of transcription from a single site. Specific binding to a CYP1B1 initiator probe by human nuclear extract proteins was competed either by the

highly homologous murine terminal deoxynucleotidyl transferase initiator or, to a lesser extent, by the adenovirus major late initiator. Taken together, these results indicate that the structure and function of the CYP1B1 promoter confers constitutive expression of the gene and assures fidelity of transcription initiation from a single site. The CYP1B1 promoter is distinct from the promoters of the closely related cytochrome P450s CYP1A1 and CYP1A2 and is structurally and functionally similar to the promoters of constitutively expressed genes and at least two viruses.

IT 188643-00-7


RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)  
(nucleotide sequence; functional anal. of the promoter for the human CYP1B1 gene, identification of four regulatory elements required for maximum promoter activity)

RN 188643-00-7 CAPLUS


CN Adenosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 11 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:758163 CAPLUS

DOCUMENT NUMBER: 128:112183

TITLE: Superactive oligonucleotide derivatives

AUTHOR(S): Sergeyev, D. S.; Vorobjev, P. E.; Zarytova, V. F.

CORPORATE SOURCE: Siberian Division of RAS, Novosibirsk Institute of Bioorganic Chemistry, Novosibirsk, 630090, Russia

SOURCE: Nucleosides & Nucleotides (1997), 16(7-9), 1575-1577

CODEN: NUNUD5; ISSN: 0732-8311

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 05 Dec 1997

AB The conjugate of antitumor antibiotic bleomycin A5 with the tetranucleotide catalytically cleaves 20-mer ssDNA target in the presence of flanking octanucleotides. Each mol. of the conjugate cleaves, on average, three mols. of the target.

IT 177079-71-9

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); BIOL (Biological study)


(effector; site-specific DNase activity of bleomycin A5-oligonucleotide conjugate)

RN 177079-71-9 CAPLUS


CN 3'-Adenylic acid, 5'-O-[hydroxy[[3-[[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-, 3'-[2-[[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] ester, bis(inner salt) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A







PAGE 2-B



PAGE 3-A



PAGE 3-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 12 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:758153 CAPLUS

DOCUMENT NUMBER: 128:112002

TITLE: Mini-antisense oligonucleotides

AUTHOR(S): Pyshnyi, D. V.; Pyshnaya, I. A.; Lokhov, S. G.;  
Ivanova, E. M.; Zarytova, V. F.

CORPORATE SOURCE: Siberian Division of RAS, Novosibirsk Institute of  
Bioorganic Chemistry, Novosibirsk, 630090, Russia

SOURCE: Nucleosides & Nucleotides (1997), 16(7-9), 1565-1569  
CODEN: NUNUD5; ISSN: 0732-8311

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 05 Dec 1997

AB A new strategy of selective DNA target modification was proposed. The using of reactive derivs. of short oligonucleotides in the presence of flanking effector pair allows one to modify DNA target only when the perfect complementary complex of DNA target and oligonucleotide tandem is formed.

IT 177079-71-9 197095-57-1

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); BIOL (Biological study)


(short oligonucleotides in the presence of flanking effector pair modifies DNA target)

RN 177079-71-9 CAPLUS


CN 3'-Adenylic acid, 5'-O-[hydroxy[[3-[[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-, 3'-[2-[[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] ester, bis(inner salt) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




RN 197095-57-1 CAPLUS

CN Adenosine, 5'-O-phosphonothymidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 13 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:148456 CAPLUS


Searched by Barb O'Bryen, STIC 2-2518

DOCUMENT NUMBER: 128:318408  
TITLE: Interaction of short oligonucleotide derivatives with nucleic acids. IV. Modification of DNA by an alkylating tetranucleotide reagent in the presence of effectors in perfect and imperfect complexes  
AUTHOR(S): Pyshnyi, D. V.; Pyshnava, I. A.; Lokhov, S. G.; Ivanova, E. M.; Zarytova, V. F.  
CORPORATE SOURCE: Novosibirsk Institute of Bioorganic Chemistry, Siberian Division, Russian Academy of Sciences, Novosibirsk, 630090, Russia  
SOURCE: Bioorganicheskaya Khimiya (1997), 23(11), 895-902  
CODEN: BIKHD7; ISSN: 0132-3423  
PUBLISHER: MAIK Nauka  
DOCUMENT TYPE: Journal  
LANGUAGE: Russian  
OTHER SOURCE(S): CASREACT 128:318408  
ED Entered STN: 12 Mar 1998  
AB It was demonstrated that any mismatches in a complex formed by an ssDNA target and a tetranucleotide at 25 or 37° can be discriminated by alkylating the DNA with a tetranucleotide carrying a 4-[N-methyl-N-(2-chloroethyl)]aminobenzylethylamine residue at the 5'-terminal phosphate in the presence of a pair of flanking effectors, octanucleotide di-N-(2-hydroxyethyl)-phenazinium derivs. The discrimination factor (ratio of the extent of the target modification in the perfect and mismatch-containing complexes) for a single mismatch in the tetranucleotide binding site at 25° varied between 4 and 500 depending on the type of mismatch and its location in the complex and exceeded 400 at 37° for all the investigated mismatches. The DNA target modification by the alkylating derivative of the 3'-estrone ester of tetranucleotide pCAGX(X = C, T, A or G) was selective in the presence of a pair of hydrophobic effectors, octanucleotide 5'-cholesteryl-3'-phenazinium derivs. The discrimination factors for 3'-terminal mismatches T·G, A·G, and G·G were 1,8,400, and 400, resp.  
IT 177079-71-9P 204335-58-0P  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)  
(interaction of short oligonucleotide derivs. with nucleic acids)  
RN 177079-71-9 CAPLUS  
CN 3'-Adenylic acid, 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] ester, bis(inner salt) (9CI) (CA INDEX NAME)


Absolute stereochemistry.





PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




RN 204335-58-0 CAPLUS


CN 3'-Adenylic acid, 5'-O-[[[(3 $\beta$ )-cholest-5-en-3-yloxy]hydroxyphosphinyl]thymidylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-2'-deoxyguanylyl-(3' $\rightarrow$ 5')-2'-deoxyguanylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxy-, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] ester, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B







PAGE 2-A




PAGE 3-A




PAGE 3-B



PAGE 4-A



PAGE 4-B



IT 206977-68-6 206977-69-7 206977-71-1  
 206977-82-4 206977-84-6 206977-86-8  
 206977-87-9 206977-88-0 206977-89-1  
 206977-95-9 206978-00-9 206978-01-0  
 206978-02-1 206978-07-6 206978-08-7  
 206978-09-8 206978-11-2

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP  
 (Properties); BIOL (Biological study); PROC (Process)  
 (interaction of short oligonucleotide derivs. with nucleic acids)

RN 206977-68-6 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 197095-65-1


CMF C49 H65 Cl N18 O23 P4

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Me

PAGE 2-A



PAGE 2-B



CM 2


CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.




PAGE 1-A




PAGE 1-B

NH<sub>2</sub>


PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206977-69-7 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-51-8


CMF C50 H66 Cl N17 O24 P4

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Me

PAGE 2-A

HO

PAGE 2-B




CM 2

CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.

PAGE 1-A







PAGE 1-B

NH<sub>2</sub>


PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3 - B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9  
 CMF Unspecified  
 CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206977-71-1 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidyl-(3'→5')-

2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and  
 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]  
 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-  
 yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-  
 adenylyl bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-53-0


CMF C50 H65 Cl N20 O22 P4

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Me

PAGE 2-A

HO

PAGE 2-B




CM 2

CRN 177079-72-0


CMF C111 H133 N40 O51 P9

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B







PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206977-82-4 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-55-2


CMF C50 H65 Cl N20 O23 P4

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




CM 2

CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B


NH<sub>2</sub>

PAGE 2-A







PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206977-84-6 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-

2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and  
 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]  
 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-  
 yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-  
 adenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-57-4


CMF C49 H66 Cl N15 O25 P4

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Me

PAGE 2-A

HO

PAGE 2-B




CM 2

CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

NH<sub>2</sub>

PAGE 2-A




PAGE 2-B






PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206977-86-8 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-59-6



CMF C48 H65 Cl N16 O24 P4

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




CM 2

CRN 177079-72-0


CMF C111 H133 N40 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B




PAGE 3-A





PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206977-87-9 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-

2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and  
 3'-[2-[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]  
 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-  
 yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-  
 adenylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-61-0


CMF C49 H65 Cl N18 O24 P4

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Me

PAGE 2-A

HO

PAGE 2-B



CM 2


CRN 177079-72-0

CMF C111 H133 N40 O51 P9


Absolute stereochemistry.




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 3


CRN 177079-71-9

CMF C110 H133 N38 O52 P9


Absolute stereochemistry.





PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206977-88-0 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-63-2


CMF C49 H66 Cl N15 O24 P4

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A




CM 2

CRN 177079-72-0


CMF C111 H133 N40 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 052 P9

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A







PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206977-89-1 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-65-4


CMF C49 H65 Cl N18 O22 P4

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Me

PAGE 2-A

HO

PAGE 2-B




CM 2

CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

NH<sub>2</sub>


PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A



PAGE 2-A




PAGE 2-B






PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9  
 CMF Unspecified  
 CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206977-95-9 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-

2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and  
 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]  
 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-  
 yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-  
 adenylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-67-6


CMF C48 H65 Cl N16 O23 P4

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A




CM 2

CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

NH<sub>2</sub>


PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A



PAGE 2-B




PAGE 3-A





PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206978-00-9 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 206431-69-8


CMF C50 H66 Cl N17 O24 P4

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

HO

PAGE 2-B




CM 2

CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

NH<sub>2</sub>


PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206978-01-0 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenosine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-



2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and  
 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]  
 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-  
 yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-  
 adenylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 201488-14-4

CMF C50 H65 Cl N20 O22 P4

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

—CH<sub>2</sub>Cl

PAGE 2-A



PAGE 2-B




CM 2

CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

$\text{NH}_2$



PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206978-02-1 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanosine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 206431-73-4

CMF C50 H65 Cl N20 O23 P4

Absolute stereochemistry.




PAGE 1-A




PAGE 1-B

—CH<sub>2</sub>Cl

PAGE 2-A



PAGE 2-B




CM 2

CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

NH<sub>2</sub>


PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206978-07-6 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3β)-cholest-5-en-3-yloxy]hydroxyphosphinyl]-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate inner salt, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3β)-cholest-5-en-3-

yloxy]hydroxyphosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylate  
 inner salt and 3'-(17-oxoestra-1,3,5(10)-trien-3-yl) 5'-O-[[[4-[(2-  
 chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-3'-thymidylate (1:1:1:1) (9CI) (CA INDEX  
 NAME)


CM 1

CRN 206431-79-0

CMF C68 H87 Cl N17 O28 P5


Absolute stereochemistry.

PAGE 1-A







PAGE 1-B



PAGE 2-A



PAGE 3-A




CM 2

CRN 204335-58-0


CMF C120 H159 N34 O52 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B






PAGE 2-A




PAGE 3-A




PAGE 3-B



PAGE 4-A



PAGE 4-B




CM 3

CRN 204335-57-9


CMF C121 H159 N36 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B

NH<sub>2</sub>

PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9  
 CMF Unspecified  
 CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206978-08-7 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3β)-cholest-5-en-3-yloxy]hydroxyphosphinyl]-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate inner salt, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3β)-cholest-5-en-3-yloxy]hydroxyphosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylylate inner salt and 3'-(17-oxoestra-1,3,5(10)-trien-3-yl) 5'-O-[[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-

deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-2'-deoxy-3'-adenylate (1:1:1:1) (9CI) (CA  
INDEX NAME)


CM 1

CRN 206431-83-6


CMF C68 H86 Cl N20 O26 P5

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 2-A



PAGE 3-A




CM 2

CRN 204335-58-0


CMF C120 H159 N34 O52 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B






PAGE 2-A




PAGE 3-A




PAGE 3-B



PAGE 4-A



PAGE 4-B




CM 3

CRN 204335-57-9


CMF C121 H159 N36 O51 P9

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



PAGE 2-B


NH<sub>2</sub>



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206978-09-8 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3 $\beta$ )-cholest-5-en-3-yloxy]hydroxyphosphinyl]-2'-deoxyguanylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-thymidylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-2'-deoxy-3'-guanylate inner salt, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3 $\beta$ )-cholest-5-en-3-yloxy]hydroxyphosphinyl]thymidylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-2'-deoxyguanylyl-(3' $\rightarrow$ 5')-2'-deoxyguanylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxy-3'-adenylate inner salt and 3'-(17-oxoestra-1,3,5(10)-trien-3-yl) 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl)methyl]methylamino]hydroxyphosphinyl]-2'-

deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-2'-deoxy-3'-guanylate (1:1:1:1) (9CI) (CA  
INDEX NAME)


CM 1

CRN 206431-77-8


CMF C68 H86 Cl N20 O27 P5

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 2-A



PAGE 3-A




CM 2

CRN 204335-58-0


CMF C120 H159 N34 O52 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B






PAGE 2-A




PAGE 3-A




PAGE 3-B



PAGE 4-A



PAGE 4-B



CM 3


CRN 204335-57-9

CMF C121 H159 N36 O51 P9

Absolute stereochemistry.




PAGE 2-A



PAGE 2-B


NH<sub>2</sub>



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 206978-11-2 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3β)-cholest-5-en-3-yloxy]hydroxyphosphinyl]-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate inner salt, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3β)-cholest-5-en-3-yloxy]hydroxyphosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy-3'-adenylylate inner salt and 3'-(17-oxoestra-1,3,5(10)-trien-3-yl) 5'-O-[[[4-[(2-chloroethyl)methylamino]phenyl]methyl]methylamino]hydroxyphosphinyl]-2'-

deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-2'-deoxy-3'-cytidylate (1:1:1:1) (9CI) (CA  
INDEX NAME)


CM 1

CRN 204335-58-0


CMF C120 H159 N34 O52 P9

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B









PAGE 2-A




PAGE 3-A




PAGE 3-B



PAGE 4-A



PAGE 4-B



CM 2


CRN 204335-57-9

CMF C121 H159 N36 O51 P9

Absolute stereochemistry.




PAGE 2-A



PAGE 2-B


NH<sub>2</sub>



PAGE 3-A



PAGE 3-B




CM 3

CRN 197095-68-4


CMF C67 H86 Cl N18 O27 P5

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 3-A



CM 4

CRN 150227-65-9  
 CMF Unspecified  
 CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L46 ANSWER 14 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:39494 CAPLUS

DOCUMENT NUMBER: 128:240835

TITLE: Interaction of short oligonucleotide derivatives with  
 nucleic acids. III. Photomodification of DNA targets  
 using tandems of short oligonucleotide derivatives

AUTHOR(S): Tabatadze, D. R.; Tret'yakova, L. V.; Levina, A. S.;  
 Pyshnyi, D. V.; Ivanova, E. M.; Zarytova, V. F.

CORPORATE SOURCE: Novosibirsk Institute Bioorganic Chemistry, Siberian  
 Division, Russian Academy Sciences, Novosibirsk,  
 630090, Russia


SOURCE: Bioorganicheskaya Khimiya (1997), 23(8), 642-647  
 CODEN: BIKHD7; ISSN: 0132-3423

PUBLISHER: MAIK Nauka

DOCUMENT TYPE: Journal  
 LANGUAGE: Russian  
 OTHER SOURCE(S): CASREACT 128:240835  
 ED Entered STN: 24 Jan 1998  
 AB High efficiency was demonstrated for the photomodification of a DNA target by a 5'-p-azidotetrafluorobenzoyl reagent based on a tetranucleotide and its 3'-phosphoestrone ester in the presence of a pair of flanking effectors. These effectors are oligonucleotide derivs. with N-(2-hydroxyethyl)phenazinium groups or those connected to cholesterol residues at the terminal phosphates.  
 IT 177079-71-9 204335-58-0  
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent)  
 (effector; interaction of short oligonucleotide derivs. with nucleic acids)  
 RN 177079-71-9 CAPLUS  
 CN 3'-Adenylic acid, 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] ester, bis(inner salt) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A








PAGE 2-A




PAGE 2-B



PAGE 3-A




PAGE 3-B




RN 204335-58-0 CAPLUS  
 CN 3'-Adenylic acid, 5'-O-[[[(3β)-cholest-5-en-3-yloxy]hydroxyphosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] ester, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B






PAGE 2-A




PAGE 3-A




PAGE 3-B



PAGE 4-A



PAGE 4-B



IT 204711-82-0P 204712-02-7P 204712-08-3P  
 204712-30-1P 204712-84-5P 204803-23-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (interaction of short oligonucleotide derivs. with nucleic acids)  
 RN 204711-82-0 CAPLUS  
 CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen  
 phosphate), complex with 5'-O-[[[2-[(4-azido-2,3,5,6-  
 tetrafluorobenzoyl)amino]ethyl]amino]hydroxyphosphinyl]-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxyguanosine and 3'-[2-[[10-(2-

hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylate bis(inner salt) (1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 204335-56-8


CMF C47 H55 F4 N21 O24 P4

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




CM 2

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A







PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 3

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 204712-02-7 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[2-[(4-azido-2,3,5,6-tetrafluorobenzoyl)amino]ethyl]amino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanosine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3β)-cholest-5-en-3-yloxy]hydroxyphosphinyl]-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate inner salt and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3β)-cholest-5-en-3-yloxy]hydroxyphosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylate inner salt (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 204335-58-0


CMF C120 H159 N34 O52 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B






PAGE 2-A




PAGE 3-A




PAGE 3-B



PAGE 4-A



PAGE 4-B




CM 2

CRN 204335-57-9


CMF C121 H159 N36 O51 P9

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



PAGE 2-B

NH<sub>2</sub>



$$\begin{array}{c} \text{O} \\ \parallel \\ \text{HO} \end{array}$$

The image displays three chemical structures of nucleoside phosphates, arranged vertically. Each structure consists of a phosphate group, a deoxyribose sugar, and a nitrogenous base.


- Top structure (dATP):** The phosphate group is linked to the 5' carbon of the deoxyribose sugar. The sugar is attached to the adenine base at the N9 position. The adenine base is a purine derivative.
- Middle structure (dGTP):** The phosphate group is linked to the 5' carbon of the deoxyribose sugar. The sugar is attached to the guanine base at the N9 position. The guanine base is a purine derivative.
- Bottom structure (dTTP):** The phosphate group is linked to the 5' carbon of the deoxyribose sugar. The sugar is attached to the thymine base at the N3 position. The thymine base is a pyrimidine derivative.

CRN 204335-56-8  
CMF C47 H55 F4 N21 O24 P4


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B




F

PAGE 2-A



PAGE 2-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 204712-08-3 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3β)-cholest-5-en-3-yl]oxy]hydroxyphosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylate inner salt and 3'-(17-oxoestra-1,3,5(10)-trien-3-yl) 5'-O-[[[2-[(4-azido-2,3,5,6-tetrafluorobenzoyl)amino]ethyl]amino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-guanylate (1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 204335-58-0


CMF C120 H159 N34 O52 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B






PAGE 2-A




PAGE 3-A




PAGE 3-B



PAGE 4-A



PAGE 4-B




CM 2

CRN 204335-55-7


CMF C65 H76 F4 N21 O28 P5

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



CM 3

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 204712-30-1 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3 $\beta$ )-cholest-5-en-3-yloxy]hydroxyphosphinyl]-2'-deoxyguanylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-thymidylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-2'-deoxy-3'-guanylate inner salt, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[[[(3 $\beta$ )-cholest-5-en-3-yloxy]hydroxyphosphinyl]thymidylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-2'-deoxyguanylyl-(3' $\rightarrow$ 5')-2'-deoxyguanylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxy-3'-adenylylate inner salt and 3'-(17-oxoestra-1,3,5(10)-trien-3-yl) 5'-O-[[[2-[(4-azido-2,3,5,6-tetrafluorobenzoyl)amino]ethyl]amino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxyadenylyl-(3' $\rightarrow$ 5')-2'-deoxycytidylyl-(3' $\rightarrow$ 5')-2'-deoxy-3'-guanylate (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 204335-58-0


CMF C120 H159 N34 O52 P9

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B









PAGE 2-A




PAGE 3-A




PAGE 3-B



PAGE 4-A



PAGE 4-B




CM 2

CRN 204335-57-9


CMF C121 H159 N36 O51 P9

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B

NH<sub>2</sub>

PAGE 3-A



PAGE 3-B




CM 3

CRN 204335-55-7


CMF C65 H76 F4 N21 O28 P5

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



CM 4

CRN 150227-65-9  
 CMF Unspecified  
 CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 204712-84-5 CAPLUS


CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[2-[(4-azido-2,3,5,6-tetrafluorobenzoyl)amino]ethyl]amino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanosine, 2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanosine inner salt and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 204335-59-1  
 CMF C95 H117 N37 O47 P8

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




HO




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 2

CRN 204335-56-8


CMF C47 H55 F4 N21 O24 P4

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9

CMF Unspecified

CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 204803-23-6 CAPLUS

CN DNA, d(T-G-C-C-T-G-G-A-G-C-T-G-C-T-T-G-A-T-G-C), 5'-(dihydrogen phosphate), complex with 5'-O-[[[2-[(4-azido-2,3,5,6-tetrafluorobenzoyl)amino]ethyl]amino]hydroxyphosphinyl]-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanosine, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 2'-deoxy-5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]guanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-3'-guanylate bis(inner salt) and 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] 5'-O-[hydroxy[[3-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]propyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-3'-adenylylate bis(inner salt) (1:1:1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 204335-56-8


CMF C47 H55 F4 N21 O24 P4

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




F

PAGE 2-A



PAGE 2-B




CM 2

CRN 177079-72-0

CMF C111 H133 N40 O51 P9

Absolute stereochemistry.

PAGE 1-A







PAGE 1-B

NH<sub>2</sub>


PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B




CM 3

CRN 177079-71-9


CMF C110 H133 N38 O52 P9

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 3-B



CM 4

CRN 150227-65-9  
CMF Unspecified  
CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L46 ANSWER 15 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1997:168528 CAPLUS  
DOCUMENT NUMBER: 126:153644  
TITLE: Treatment of hemoglobinopathies by  
third-strand-targeted mutagenesis or homologous  
recombination method  
INVENTOR(S): Glazer, Peter M.  
PATENT ASSIGNEE(S): Yale University, USA

SOURCE: PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640271	A1	19961219	WO 1996-US9430	19960606
W: AU, BR, CA, CN, CZ, FI, HU, IL, JP, KP, KR, MX, NO, NZ, SG, SK, UA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9663286	A1	19961230	AU 1996-63286	19960606
PRIORITY APPLN. INFO.:			US 1995-473845	A 19950607
			WO 1996-US9430	W 19960606

ED Entered STN: 13 Mar 1997

AB The present invention relates to management and treatment of hemoglobinopathies, such as sickle cell anemia and  $\beta$ -thalassemia. The invention also relates to developing research animals and cell lines for the study of hemoglobinopathies and their therapies. The invention utilizes third strand oligonucleotides to target double-stranded nucleic acid sequences in or near the globin genes, or in or near sequences controlling expression of those genes to cause either a desired mutation (third-strand-targeted mutagenesis method) or nucleic acid damage to stimulate homologous recombination (third-strand-targeted homologous recombination method) with a supplied donor nucleic acid.

IT **186707-85-7P 186707-86-8P 186707-88-0P**

RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)


(nucleotide sequence of third-strand-oligonucleotide for targeting nature  $\beta$ -globin gene; treatment of hemoglobinopathies by third-strand-targeted mutagenesis or homologous recombination method)

RN 186707-85-7 CAPLUS


CN Guanosine, 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B






PAGE 3-A



PAGE 3-B




RN 186707-86-8 CAPLUS


CN Guanosine, 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-  
 thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 4-A




PAGE 4-B



—NH<sub>2</sub>



RN 186707-88-0 CAPLUS  
 CN Guanosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-  
 thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)

PAGE 1-A




PAGE 1-B





PAGE 3-A



L46 ANSWER 16 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:124382 CAPLUS

DOCUMENT NUMBER: 126:126887

TITLE: Hepatitis C virus-complementary oligonucleotides and analogs and their use in prophylaxis, treatment and diagnosis of viral infection

INVENTOR(S): Frank, Bruce L.; Goodchild, John; Hamlin, Henry A., Jr.; Kilkuskie, Robert E.; Roberts, Noel A.; Roberts, Peter C.; Walther, Debra M.; Wolfe, Jia L.

PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.; Hybridon Inc.

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9639500	A2	19961212	WO 1996-EP2427	19960604
WO 9639500	A3	19970313		
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9604446	A	19961206	ZA 1996-4446	19960530
CA 2226438	AA	19961212	CA 1996-2226438	19960604
AU 9662219	A1	19961224	AU 1996-62219	19960604
EP 833902	A2	19980408	EP 1996-920788	19960604
EP 833902	B1	20030514		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 240392	E	20030515	AT 1996-920788	19960604
EP 1331267	A2	20030730	EP 2003-5364	19960604
EP 1331267	A3	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PT 833902	T	20030930	PT 1996-920788	19960604
ES 2196157	T3	20031216	ES 1996-920788	19960604
PRIORITY APPLN. INFO.:			US 1995-471968	A 19950606
			EP 1996-920788	A3 19960604
			WO 1996-EP2427	W 19960604

ED Entered STN: 24 Feb 1997

AB The present invention discloses synthetic oligonucleotides and oligonucleotide analogs complementary to contiguous and non-contiguous

regions of the hepatitis C virus (HCV) RNA. Also disclosed are methods and 'kits for inhibiting the replication of HCV, inhibiting the expression of HCV nucleic acid and protein, and for treating HCV infections. Numerous oligodeoxyribonucleotides, hybrid oligodeoxy- and deoxyribonucleotides, and analogs of these oligonucleotides containing modified linkages, modified bases, modified sugar residues, etc. were prepared. These oligonucleotides were tested in RNase H cleavage assays as well as in inhibition of HCV luciferase fusion protein expression in stably transfected cells, inhibition of HCV RNA expression in stably transfected cells, and inhibition of HCV protein expression in Semliki Forest virus/HCV recombinant virus infected cells. Sequence-specific inhibition was observed.

IT 185946-81-0P

RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)


(hepatitis C virus-complementary oligonucleotides and analogs and their use in prophylaxis, treatment and diagnosis of viral infection)

RN 185946-81-0 CAPLUS

CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A







PAGE 1-B



PAGE 2-A



PAGE 2-B



ACCESSION NUMBER: 1996:621459 CAPLUS  
 DOCUMENT NUMBER: 125:273628  
 TITLE: Anti-DNA antibody detection involving telomeric DNA  
 sequence recognition and binding  
 INVENTOR(S): Salonen, Eeva-Marjatta  
 PATENT ASSIGNEE(S): Finland  
 SOURCE: PCT Int. Appl., 48 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9627131	A1	19960906	WO 1996-FI117	19960229
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
FI 9500962	A	19960902	FI 1995-962	19950301
FI 100556	B1	19971231		
US 5700641	A	19971223	US 1995-396238	19950301
ZA 9601628	A	19960808	ZA 1996-1628	19960229
AU 9647215	A1	19960918	AU 1996-47215	19960229
AU 720912	B2	20000615		
EP 812421	A1	19971217	EP 1996-903036	19960229
EP 812421	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
NZ 301725	A	20010223	NZ 1996-301725	19960229
AT 219580	E	20020715	AT 1996-903036	19960229
ES 2175069	T3	20021116	ES 1996-903036	19960229
PRIORITY APPLN. INFO.:			FI 1995-962	A 19950301
			WO 1996-FI117	W 19960229

ED Entered STN: 19 Oct 1996

AB The invention relates to a diagnostic method for detection of anti-DNA antibodies in patients with lupus erythematosus, particularly SLE, test kit, solid phase means and a therapeutic method and a drug. All these applications are characterized by the use of telomeric DNA sequences able to bind specifically to anti-DNA-antibodies. Preferred antibody-binding telomeric sequences comprise 5'-TTAGGG-3', 5'-CCCTAA-3', repeats thereof or double stranded vertebrate telomere. Solid phase removal of anti-DNA antibodies with solid phase bound telomeric sequences and use of the telomeric sequences as a drug for treatment of patients with autoimmune disorders are revealed.

IT 117490-04-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(telomeric DNA sequence for determination of anti-DNA antibody and for diagnosis and treatment of autoimmune disease)

RN 117490-04-7 CAPLUS


CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



L46 ANSWER 18 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:458116 CAPLUS

DOCUMENT NUMBER: 125:110182

TITLE: The ahpCF operon of Mycobacterium and its role in isoniazid resistance and the treatment of infection

INVENTOR(S): Collins, Desmond Michael; Wilson, Theresa

PATENT ASSIGNEE(S): New Zealand Pastoral Agriculture Research Institute Limited, N. Z.

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9619578	A2	19960627	WO 1995-NZ133	19951220
WO 9619578	A3	19960829		
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF				
CA 2210378	AA	19960627	CA 1995-2210378	19951220
EP 805863	A2	19971112	EP 1995-941938	19951220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AU 708456	B2	19990805	AU 1996-43185	19951220
PRIORITY APPLN. INFO.:			NZ 1994-270222	A 19941220
			WO 1995-NZ133	W 19951220

ED Entered STN: 03 Aug 1996

AB Methods for identifying and characterizing an operon that detcs. mycobacterial resistance to the antibiotic isoniazid (INH) and its analogs is described. This operon, termed ahpCF, encodes polypeptides, AhpC and AhpF, which likely combine to form an active alkyl hydroperoxide reductase enzyme that may either be a direct target for INH or act to confer INH resistance. The sequence of the mutant ahpCF operon is provided, showing that INH resistance can be conferred by a mutation in the promoter and polypeptides that are useful in diagnosis and treatment. Cloning of the isoniazid resistance factor of Mycobacterium bovis by expression in M.

smegmatis is described. The factor was identified as the *ahpCF* operon and sequences of wild-type and mutant operons were compared to identify the mutations responsible for resistance. Antisense oligonucleotides capable of inhibiting expression of the *ahpCF* operon may be used to overcome isoniazid resistance.

IT 179127-92-5


RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)  
(for detection of mutation in *ahpCF* operon; *ahpCF* operon of *Mycobacterium* and its role in isoniazid resistance and treatment of infection)

RN 179127-92-5 CAPLUS


CN Cytidine, thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



L46 ANSWER 19 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1996:288256 CAPLUS  
 DOCUMENT NUMBER: 124:333058  
 TITLE: Antiviral phosphorothioate oligodeoxyribonucleotides  
 for clinical application  
 INVENTOR(S): Shoji, Yoko; Shimada, Jingoro; Mizushima, Yutaka;  
 Iwatani, Wakao; Tamura, Nobuya  
 PATENT ASSIGNEE(S): Ltt Institute Co., Ltd., Japan; Kaken Pharmaceutical  
 Co., Ltd.  
 SOURCE: PCT Int. Appl., 163 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603500	A1	19960208	WO 1995-JP1472	19950725
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9529912	A1	19960222	AU 1995-29912	19950725
PRIORITY APPLN. INFO.:			JP 1994-173862	A 19940726
			JP 1994-268603	A 19941101
			WO 1995-JP1472	W 19950725

ED Entered STN: 15 May 1996

AB Synthetic phosphorothioate oligodeoxyribonucleotides having 5-30 base units and contain  $\geq 1$  base sequence 5'-GXGGG-3' (X= adenine, thymine, guanine or cytosine), its salt, and derivs. are provided for antiviral agents. The oligodeoxyribonucleotides have a high antiviral activity against herpes simplex virus (HSV), varicella zoster virus (VZV), and human immunodeficiency virus (HIV) and are useful for treating or preventing various viral infections. Some of the oligodeoxyribonucleotides are complementary to the splicing acceptor of immediate early precursor mRNA4 or mRNA5 of HIV I and show effective viral growth-inhibiting activities.

IT 126208-94-4P 176328-94-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and clin. application of antiviral phosphorothioate oligodeoxyribonucleotides)

RN 126208-94-4 CAPLUS


CN Thymidine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A







PAGE 2-B



PAGE 3-A



PAGE 3-B




RN 176328-94-2 CAPLUS


CN Adenosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



L46 ANSWER 20 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1996:392130 CAPLUS  
 DOCUMENT NUMBER: 125:76345  
 TITLE: Inhibition of human immunodeficiency virus by  
 tetramer-forming d(GGGG)-containing oligonucleotides  
 Ecker, David J.; Wyatt, Jacqueline R.; Imbach, Jean L.  
 INVENTOR(S):  
 PATENT ASSIGNEE(S): ISIS Pharmaceuticals, Inc., USA  
 SOURCE: U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 954, 185,  
 abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5523389	A	19960604	US 1993-128011	19930928
HU 70965	A2	19951128	HU 1995-911	19930929
EP 1016715	A1	20000705	EP 1999-203835	19930929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
PRIORITY APPLN. INFO.:			US 1992-954185	B2 19920929
			EP 1993-922788	A3 19930929

ED Entered STN: 09 Jul 1996

AB The phosphorothioate oligonucleotide T2G4T2 (ISIS 5320) was identified as an inhibitor of HIV infection in vitro by combinatorial screening of a library of phosphorothioate oligonucleotides that contained all possible 8-nucleotide sequences. The oligonucleotide forms a parallel-stranded tetrameric guanosine quartet (G-quartet) structure. Tetramer formation and the phosphorothioate backbone are essential for antiviral activity. The G-quartet structure binds to the HIV envelope protein gp120 at the V3 loop and inhibits both cell-to-cell and virus-to-cell infection.

IT **126208-94-4D**, phosphorothioated at one or more residues  
 RL: **BAC (Biological activity or effector, except adverse)**; **BSU**  
 (Biological study, unclassified); **THU (Therapeutic use)**; **BIOL**  
 (Biological study); **USES (Uses)**  
 (inhibition of human immunodeficiency virus by tetramer-forming  
 d(GGGG)-containing oligonucleotides)

RN 126208-94-4 CAPLUS


CN Thymidine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-

PAGE 2-B

NH<sub>2</sub>

NH<sub>2</sub>


PAGE 3-A




deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-  
(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



=> fil capl; d que nos l35; s (l35 and l23) not l44  
FILE 'CAPLUS' ENTERED AT 14:18:57 ON 30 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Sep 2005 VOL 143 ISS 15  
FILE LAST UPDATED: 29 Sep 2005 (20050929/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L14	6113380	SEA FILE=REGISTRY ABB=ON	SQL<46 AND NS/FS
L15	1667	SEA FILE=REGISTRY ABB=ON	RRI[IG]YY/SQSN
L16	1612	SEA FILE=REGISTRY ABB=ON	L14 AND L15
L20		STR	
L22	2568	SEA FILE=REGISTRY SSS FUL	L20
L23	166	SEA FILE=CAPLUS ABB=ON	L16
L24	1716	SEA FILE=CAPLUS ABB=ON	L22
L25	1073	SEA FILE=CAPLUS ABB=ON	(L23 OR L24) NOT P/DT
L26	834	SEA FILE=CAPLUS ABB=ON	L25 NOT PY>1997
L27	802	SEA FILE=CAPLUS ABB=ON	(L23 OR L24) NOT L25
L28	173	SEA FILE=CAPLUS ABB=ON	L27 NOT AY>1997
L29	1007	SEA FILE=CAPLUS ABB=ON	L26 OR L28
L30	146	SEA FILE=CAPLUS ABB=ON	(L23 OR L24) (L) (THU OR BAC OR PAC OR PKT OR DMA)/RL
L31	383	SEA FILE=CAPLUS ABB=ON	(L23 OR L24) AND PHARMAC?/SC,SX
L33	55668	SEA FILE=CAPLUS ABB=ON	(IMMUNOSTIM? OR IMMUNOMOD? OR IMMUNOSUP PRES?)/CW
L34	50	SEA FILE=CAPLUS ABB=ON	L31 AND L33
L35	51	SEA FILE=CAPLUS ABB=ON	(L30 OR L34) AND L29


L47 14 (L35 AND L23) NOT L44

=> fil uspatf; d que nos l42; s (l42 and l16) not l45  
FILE 'USPATFULL' ENTERED AT 14:19:24 ON 30 SEP 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


FILE COVERS 1971 TO PATENT PUBLICATION DATE: 29 Sep 2005 (20050929/PD)  
FILE LAST UPDATED: 29 Sep 2005 (20050929/ED)  
HIGHEST GRANTED PATENT NUMBER: US6951031  
HIGHEST APPLICATION PUBLICATION NUMBER: US2005217002

*sequence search answers not included  
in structure  
search  
answer set*

PAGE 2-A




PAGE 2-B







PAGE 1-A




PAGE 1-B



PAGE 1-B



PAGE 2-B



CM 2

CRN 89802-96-0

CMF C57 H74 N21 O33 P5

CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-2'-deoxy-, double-stranded complementary  
(9CI) (CA INDEX NAME)

CM 1


CRN 117490-04-7

CMF C60 H75 N24 O35 P5


CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

PAGE 1-A



PAGE 2-B



L46 ANSWER 53 OF 53 USPATFULL on STN

ACCESSION NUMBER: 1998:33758 USPATFULL

TITLE: Telomere repeat binding factor and diagnostic and therapeutic use thereof

INVENTOR(S): De Lange, Titia, New York, NY, United States

PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5733730		19980331
APPLICATION INFO.:	US 1995-519103		19950825 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Campbell, Eggerton A.		
LEGAL REPRESENTATIVE:	Klauber & Jackson		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	1919		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel nucleotide sequence encoding a telomeric protein which binds a repeat region of telomeric sequences, and to the protein encoded thereby. Also included within the invention are expression vectors for the production of the telomeric protein and host cells transformed with the nucleotide sequence. In addition, antibodies, probes and antagonists specific for the telomeric protein are contemplated. Methods of identifying antagonists of the telomeric protein, diagnostic methods of identifying the telomeric protein in a sample, and therapeutic uses of the telomeric protein, particularly in the treatment of aging and cancer, are also contemplated.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 157961-44-9D, oligomers


(as affinity ligand for human telomere repeat factor; mammalian telomere repeat binding factor and gene encoding it and their diagnostic and therapeutic uses)

RN 157961-44-9 USPATFULL


PAGE 1-B



PAGE 2-A



PAGE 2-B



CM 2


CRN 177792-81-3

CMF C70 H88 N26 O41 P6


CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 959

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 177792-83-5

(CHR element of cdc25C gene; genetic **therapy** of diseases caused by immune system using genetic construct regulated in cell- or virus-specific, cell cycle-dependent manner)

RN 177792-83-5 USPATFULL

CN Adenosine, 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-, double-stranded complementary (9CI) (CA INDEX NAME)

CM 1


CRN 177792-82-4

CMF C68 H87 N25 O39 P6

CDES 5:ALL,B-D-ERYTHRO


Absolute stereochemistry.

PAGE 1-A






PAGE 2-A



PAGE 2-B




L46 ANSWER 52 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 1998:135027 USPATFULL  
 TITLE: Gene therapy of tumors with an endothelial  
 cell-specific, cell cycle-dependent active compound  
 INVENTOR(S): Sedlacek, Hans-Harald, Marburg, Germany, Federal  
 Republic of  
 Bosslet, Klaus, Marburg, Germany, Federal Republic of  
 Muller, Rolf, Marburg, Germany, Federal Republic of  
 PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany,  
 Federal Republic of (non-U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830880		19981103
	WO 9606940		19960307
APPLICATION INFO.:	US 1997-793107		19970418 (8)
	WO 1995-EP3370		19950825
			19970418 PCT 371 date
			19970418 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-17366	19940826
	GB 1995-6466	19950329
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Campbell, Bruce R.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	


PAGE 1-A




PAGE 1-B



PAGE 1-B



PAGE 2-B



CM 2

CRN 89802-96-0

CMF C57 H74 N21 O33 P5

CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

EXEMPLARY CLAIM: 1

LINE COUNT: 1904

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 157961-44-9

(mammalian telomerase RNA component sequences, regulation by oligonucleotides, and uses in gene **therapy** and cancer diagnosis)

RN 157961-44-9 USPATFULL

CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy-, double-stranded complementary (9CI) (CA INDEX NAME)

CM 1


CRN 117490-04-7

CMF C60 H75 N24 O35 P5


CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




PAGE 2-B




L46 ANSWER 51 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 1998:144253 USPATFULL  
 TITLE: Mammalian telomerase  
 INVENTOR(S): Villeponteau, Bryant, San Carlos, CA, United States  
 Feng, Junli, San Carlos, CA, United States  
 Funk, Walter, Union City, CA, United States  
 Andrews, William H., Richmond, CA, United States  
 PATENT ASSIGNEE(S): Geron Corporation, Menlo Park, CA, United States (U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837857		19981117
APPLICATION INFO.:	US 1996-660678		19960605 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-330123, filed on 27 Oct 1994, now patented, Pat. No. US 5583016, issued on 10 Dec 1996 which is a continuation-in-part of Ser. No. US 1994-272102, filed on 7 Jul 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Houtteman, Scott W.		
LEGAL REPRESENTATIVE:	Kaster, Esq., Kevin R., Storella, Esq., John		
NUMBER OF CLAIMS:	48		

PAGE 1-A



PAGE 1-B






PAGE 2-A



PAGE 2-B




CM 2


CRN 177792-81-3  
CMF C70 H88 N26 O41 P6  
CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5854019		19981229
APPLICATION INFO.:	US 1996-679217		19960712 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1995-19524720	19950712
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Nguyen, Dave Trong	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	529	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to promoter sequences for a gene comprising a tissue inhibitor of metalloproteinase-3 (TIMP-3). This inhibitor is found in particular in macrophages, synovial cells, and connective tissue cells. The invention also relates to cell-specific gene therapy of a subject, wherein expression of a gene in a tissue is regulated by the aforementioned promoter sequence operationally coupled to said gene. The promoter may also be used in diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 177792-83-5

(CHR element of cdc25C gene; genetic **therapy** of diseases caused by immune system using genetic construct regulated in cell- or virus-specific, cell cycle-dependent manner)

RN 177792-83-5 USPATFULL

CN Adenosine, 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-, double-stranded complementary (9CI) (CA INDEX NAME)

CM 1


CRN 177792-82-4

CMF C68 H87 N25 O39 P6


CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

PAGE 1-B



PAGE 2-B



L46 ANSWER 50 OF 53 USPATFULL on STN

ACCESSION NUMBER: 1998:162290 USPATFULL

TITLE: Cell-specific gene therapy using as promoter novel promoters for tissue inhibitors of metalloproteinase-3


INVENTOR(S): Sedlacek, Hans-Harald, Marburg, Germany, Federal Republic of

Wick, Marisa, Deutschland, Germany, Federal Republic of


Muller, Rolf, Marburg, Germany, Federal Republic of

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt, Germany, Federal Republic of (non-U.S. corporation)

PAGE 2-A




PAGE 2-B




RN 249277-07-4 USPATFULL  
 CN Guanosine, thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-A




PAGE 1-B



PAGE 1-B



PAGE 2-B




RN 249277-06-3 USPATFULL

CN Guanosine, thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-  
 thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-B




RN 249277-01-8 USPTFULL  
CN Guanosine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-A




PAGE 1-B



PAGE 1-B



PAGE 2-B




RN 249276-98-0 USPATFULL  
 CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 249276-96-8 USPATFULL

CN Guanosine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 166325-99-1 249276-96-8 249276-98-0

249277-01-8 249277-06-3 249277-07-4


(unclaimed sequence; nucleic acid sequences controlling lung  
cell-specific gene expression with **therapeutic** applications)

RN 166325-99-1 USPTAFULL


CN Guanosine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-C




L46 ANSWER 49 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 1999:137022 USPATFULL  
 TITLE: Nucleic acid sequences controlling lung cell-specific gene expression  
 INVENTOR(S): Bohinski, Robert J., Cincinnati, OH, United States  
 Whitsett, Jeffrey A., Cincinnati, OH, United States  
 PATENT ASSIGNEE(S): Children's Hospital Medical Center, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5976873		19991102
APPLICATION INFO.:	US 1995-442809		19950517 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-245356, filed on 18 May 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	Olstein, Elliot M., Lillie, Raymond J.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	3		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 50 Drawing Page(s)		
LINE COUNT:	3815		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oligonucleotide which includes at least one nucleic acid sequence which binds to at least one nuclear protein found in lung cells, such as TTF-1 protein. The oligonucleotide may be contained in a vector. The at least one nuclear protein provides for lung cell-specific expression of the vector upon binding of the at least one nucleic acid sequence to the at least one nuclear protein. Such vector may also include genes encoding therapeutic agents, and may be employed for delivering genes encoding therapeutic agents to lung cells.


PAGE 2-A




PAGE 2-B



PAGE 1-A



PAGE 1-B



ACCESSION NUMBER: 1999:155722 USPATFULL  
TITLE: Oxidant scavengers  
INVENTOR(S): Crapo, James D., Durham, NC, United States  
Fridovich, Irwin, Durham, NC, United States  
Oury, Tim, Durham, NC, United States  
Day, Brian J., Durham, NC, United States  
Folz, Rodney J., Durham, NC, United States  
Freeman, Bruce A., Birmingham, AL, United States  
PATENT ASSIGNEE(S): University of Alabama at Birmingham Research  
Foundation, Birmingham, AL, United States (U.S.  
corporation)  
Duke University, Durham, NC, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994339		19991130
APPLICATION INFO.:	US 1995-476866		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-322766, filed on 13 Oct 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-136207, filed on 15 Oct 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Saidha, Tekchand		
LEGAL REPRESENTATIVE:	Nixon & Vanderhye		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	53 Drawing Figure(s); 38 Drawing Page(s)		
LINE COUNT:	2910		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating intra- and extracellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 143305-02-6


(unclaimed nucleotide sequence; human extracellular superoxide  
dismutase for antioxidant **therapy**)

RN 143305-02-6 USPATFULL


CN DNA, d(C-A-G-C-T-G-T-G-G) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-B



PAGE 2-A




PAGE 2-B



L46 ANSWER 48 OF 53 USPATFULL on STN

Searched by Barb O'Bryen, STIC 2-2518

PAGE 2-B



CM 2


CRN 89802-96-0

CMF C57 H74 N21 O33 P5

CDES 5:ALL,B-D-ERYTHRO


Absolute stereochemistry.

PAGE 1-A






PAGE 1-A



PAGE 1-B



ACCESSION NUMBER: 2000:4631 USPATFULL  
 TITLE: RNA component of telomerase  
 INVENTOR(S): Andrews, William H., Richmond, CA, United States  
 Avilion, Ariel Athena, Shoreham, NY, United States  
 Feng, Junli, San Carlos, CA, United States  
 Funk, Walter, Union City, CA, United States  
 Greider, Carol, Huntington, NY, United States  
 Marhuenda, Maria Antonia Blasco, Mill Neck, NY, United States  
 Villeponteau, Bryant, San Carlos, CA, United States  
 PATENT ASSIGNEE(S): Cold Spring Harbor Laboratory, Cold Spring Harbor, NY,  
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013468		20000111
APPLICATION INFO.:	US 1995-520550		19950829 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-387524, filed on 13 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-330123, filed on 27 Oct 1994, now patented, Pat. No. US 5583016 which is a continuation-in-part of Ser. No. US 1994-272102, filed on 7 Jul 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Horlick, Kenneth R.		
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds, P.C.		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	18		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2464		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 157961-44-9

(mammalian telomerase RNA component sequences, regulation by oligonucleotides, and uses in gene **therapy** and cancer diagnosis)

RN 157961-44-9 USPATFULL

CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy-, double-stranded complementary (9CI) (CA INDEX NAME)

CM 1


CRN 117490-04-7

CMF C60 H75 N24 O35 P5


CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.


PAGE 1-B



PAGE 2-A




PAGE 2-B



L46 ANSWER 47 OF 53 USPATFULL on STN

Searched by Barb O'Bryen, STIC 2-2518

PAGE 2-B



CM 2


CRN 89802-96-0

CMF C57 H74 N21 O33 P5

CDES 5:ALL,B-D-ERYTHRO


Absolute stereochemistry.

PAGE 1-A




Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



PAGE 3-A



L46 ANSWER 46 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 2000:50825 USPATFULL  
 TITLE: Mammalian telomerase RNA gene promoter  
 INVENTOR(S): Villeponteau, Bryant, San Carlos, CA, United States  
 Feng, Junli, San Carlos, CA, United States  
 Funk, Walter, Union City, CA, United States  
 Andrews, William H., Richmond, CA, United States  
 PATENT ASSIGNEE(S): Geron Corporation, Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054575		20000425
APPLICATION INFO.:	US 1997-998443		19971224 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-660678, filed on 5 Jun 1996, now patented, Pat. No. US 5837857 which is a continuation of Ser. No. US 1994-330123, filed on 27 Oct 1994, now patented, Pat. No. US 5583016 which is a continuation-in-part of Ser. No. US 1994-272102, filed on 7 Jul 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Houteman, Scott W.		
LEGAL REPRESENTATIVE:	Kaster, Kevin R., Collins, Amy L., Parent, Annette S.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1575		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 157961-44-9

(mammalian telomerase RNA component sequences, regulation by oligonucleotides, and uses in gene therapy and cancer diagnosis)

RN 157961-44-9 USPATFULL

CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy-, double-stranded complementary (9CI) (CA INDEX NAME)


CM 1

CRN 117490-04-7


CMF C60 H75 N24 O35 P5

CDES 5:ALL,B-D-ERYTHRO

PAGE 2-A



PAGE 2-B



or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen. Proteins and peptides described herein can be administered to subjects to enhance or suppress T cell-mediated immune responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **257280-30-1**


(unclaimed sequence; cTLA4/CD28 ligands and uses therefor)

RN 257280-30-1 USPATFULL


CN Guanosine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B




PAGE 1-C





PAGE 3-B



L46 ANSWER 45 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 2000:84403 USPATFULL  
 TITLE: CTLA4/CD28 ligands and uses therefor  
 INVENTOR(S): Freeman, Gordon J., Brookline, MA, United States  
 Nadler, Lee M., Newton, MA, United States  
 Gray, Gary S., Brookline, MA, United States  
 PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Boston, MA, United States  
 (U.S. corporation)  
 Genetics Institute, Inc., Cambridge, MA, United States  
 (U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6084067		20000704
APPLICATION INFO.:	US 1995-479744		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-147773, filed on 3 Nov 1993, now abandoned And Ser. No. US 1994-280757, filed on 26 Jul 1994 which is a continuation-in-part of Ser. No. US 1993-109393, filed on 19 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-101624, filed on 26 Jul 1993		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-US8423	19940726
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Benzion, Gary	
ASSISTANT EXAMINER:	Nelson, Amy J.	
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP, Mandragouras, Amy E., Williams, Megan E.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1,2	
NUMBER OF DRAWINGS:	47 Drawing Figure(s); 33 Drawing Page(s)	
LINE COUNT:	5133	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in FIG. 8, SEQ ID NO:1 or FIG. 14, SEQ ID NO:23. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins


PAGE 2-A



PAGE 2-B



PAGE 1-B



PAGE 1-C

NH<sub>2</sub>

NH<sub>2</sub>

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 96492-36-3


(unclaimed nucleotide sequence; cloning of, **therapeutic** use in nerve related diseases, and antibodies to glial cell line-derived neurotrophic factor)

RN 96492-36-3 USPATFULL


CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 2-B




PAGE 3-A




L46 ANSWER 44 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 2000:95101 USPATFULL  
 TITLE: Glial cell line-derived neurotrophic factor  
 INVENTOR(S): Lin, Leu-Fen H., Boulder, CO, United States  
 Collins, Franklin D., Agoura Hills, CA, United States  
 Doherty, Daniel H., Boulder, CO, United States  
 Lile, Jack, Nederland, CO, United States  
 Bektesh, Susan, Boulder, CO, United States  
 PATENT ASSIGNEE(S): Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6093802		20000725
APPLICATION INFO.:	US 1995-451374		19950526 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 182183		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schain, Howard E.		
LEGAL REPRESENTATIVE:	Curry, Daniel R., Levy, Ron K., Odre, Steven M.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 31 Drawing Page(s)		
LINE COUNT:	3240		

PAGE 1-C



PAGE 2-A



NO:23. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen. Proteins and peptides described herein can be administered to subjects to enhance or suppress T cell-mediated immune responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 257280-30-1


(unclaimed sequence; fusion proteins of novel CTLA4/CD28 ligands and uses therefore)

RN 257280-30-1 USPTAFULL


CN Guanosine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B



PAGE 2-B



L46 ANSWER 43 OF 53 USPATFULL on STN

ACCESSION NUMBER: 2000:134983 USPATFULL

TITLE: Fusion proteins of novel CTLA4/CD28 ligands and uses therefore

INVENTOR(S): Freeman, Gordon J., Brookline, MA, United States

Nadler, Lee M., Newton, MA, United States

Gray, Gary S., Brookline, MA, United States

Greenfield, Edward, Randolph, MA, United States

PATENT ASSIGNEE(S): Dana Farber Cancer Institute, Boston, MA, United States  
(U.S. corporation)  
Repligen Corporation, Cambridge, MA, United States  
(U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6130316		20001010
APPLICATION INFO.:	US 1994-280757		19940726 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-109393, filed on 19 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-101624, filed on 26 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-147773, filed on 3 Nov 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spector, Lorraine		
LEGAL REPRESENTATIVE:	Lahive & Cockfield LLP, Mandragouras, Amy E., Williams, Megan E.		
NUMBER OF CLAIMS:	69		
EXEMPLARY CLAIM:	1,23		
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 26 Drawing Page(s)		
LINE COUNT:	4973		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in FIG. 8, SEQ ID NO:1 or FIG. 14, SEQ ID




PAGE 1-B



PAGE 2-A



PAGE 2-B



CM 2


CRN 177792-81-3

CMF C70 H88 N26 O41 P6


CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 177792-83-5

(CHR element of cdc25C gene; genetic **therapy** of diseases caused by immune system using genetic construct regulated in cell- or virus-specific, cell cycle-dependent manner)

RN 177792-83-5 USPATFULL

CN Adenosine, 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-, double-stranded complementary (9CI) (CA INDEX NAME)

CM 1


CRN 177792-82-4

CMF C68 H87 N25 O39 P6


CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

PAGE 1-A



PAGE 2-B



L46 ANSWER 42 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 2001:51838 USPATFULL  
 TITLE: Cell cycle regulated repressor and DNA element  
 INVENTOR(S): Muller, Rolf, Marburg, Germany, Federal Republic of  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany, Federal Republic of (non-U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6214614	B1	20010410
	WO 9606943		19960307
APPLICATION INFO.:	US 1997-793660		19970909 (8)
	WO 1995-GB2000		19950823
			19970909 PCT 371 date
			19970909 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-17366	19940826
	GB 1995-6466	19950329
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schwartzman, Robert A.	
LEGAL REPRESENTATIVE:	Dike, Bronstein, Roberts & Cushman, LLP, Conlin, David G., Lowen, Cara Z.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 16 Drawing Page(s)	
LINE COUNT:	1113	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a cell cycle regulated repressor protein which binds to a DNA element present in the control sequences of the human cdc25C gene and other cell cycle regulated genes, as well as the use thereof in cell cycle regulated expression systems.

PAGE 1-B



PAGE 2-A



NUMBER OF CLAIMS: 49  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)  
LINE COUNT: 3249

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful a synthetic adjuvant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 207496-45-5


(unclaimed sequence; **immunostimulatory** nucleic acid mols.)

RN 207496-45-5 USPATFULL


CN Adenosine, thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A



PAGE 2-B




L46 ANSWER 41 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 2001:79141 USPATFULL  
 TITLE: Immunostimulatory nucleic acid molecules  
 INVENTOR(S): Krieg, Arthur M., Iowa City, IA, United States  
 Kline, Joel N., Iowa City, IA, United States  
 PATENT ASSIGNEE(S): University of Iowa Research Foundation, Iowa City, IA,  
 United States (U.S. corporation)  
 Coley Pharmaceutical Group, Inc., Wellesley, MA, United  
 States (U.S. corporation)  
 The United States of America as represented by the  
 Department of Health and Human Services, Washington,  
 DC, United States (U.S. government)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6239116	B1	20010529
APPLICATION INFO.:	US 1997-960774		19971030 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-738652, filed on 30 Oct 1996		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Martinell, James		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		




PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




CM 2


CRN 177792-81-3  
CMF C70 H88 N26 O41 P6  
CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Priebe, Scott D.  
LEGAL REPRESENTATIVE: Heller Ehrman White & McAuliffe  
NUMBER OF CLAIMS: 16  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)  
LINE COUNT: 779

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A DNA sequence is disclosed for the genetic therapy of diseases of the central nervous system. The essential components for the DNA sequence are the activator sequence, the promoter module, and the active substance coding gene. The activator sequence is specifically activated in activated endothelial or glial cells. Activation is cell cycle-regulated by the promoter module. The active substance represents an inhibitor of the nerve growth factor, a dopanine metabolism enzyme, and/or a nerve cell protection factor. The disclosed DNA sequence is inserted into a viral or non-viral vector, supplemented with a ligand with affinity for the target cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 177792-83-5

(CHR element of cdc25C gene; genetic **therapy** of diseases caused by immune system using genetic construct regulated in cell- or virus-specific, cell cycle-dependent manner)

RN 177792-83-5 USPATFULL

CN Adenosine, 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-, double-stranded complementary (9CI) (CA INDEX NAME)

CM 1


CRN 177792-82-4

CMF C68 H87 N25 O39 P6


CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

PAGE 2-A



PAGE 2-B




L46 ANSWER 40 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 2002:57592 USPATFULL  
 TITLE: DNA for expression under control of a cell  
 cycle-dependent promoter  
 INVENTOR(S): Sedlacek, Hans-Harald, Marburg, GERMANY, FEDERAL  
 REPUBLIC OF  
 PATENT ASSIGNEE(S): Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF  
 Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY,  
 FEDERAL REPUBLIC OF (non-U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358732	B1	20020319
	WO 9606939		19960307
APPLICATION INFO.:	US 1997-793110		19970425 (8)
	WO 1995-EP3369		19950825
			19970425 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-17366	19940826
	GB 1995-6466	19950329
DOCUMENT TYPE:	Utility	


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




CM 2


CRN 177792-81-3  
CMF C70 H88 N26 O41 P6  
CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-17366	19940826
	GB 1995-6466	19950329
	DE 1995-19524720	19950712
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Clark, Deborah J. R.	
ASSISTANT EXAMINER:	Baker, Anne-Marie	
LEGAL REPRESENTATIVE:	Heller Ehrman White and McAuliffe	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 15 Drawing Page(s)	
LINE COUNT:	2654	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A DNA sequence is described for the gene therapy of diseases associated with the immune system. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated in a cell-specific or virus-specific manner and this activation is regulated by the promoter module in a cell cycle-specific manner. The choice of activator sequence and active substance depends on the indication area. The DNA sequence is inserted into a viral or non-viral vector which is supplemented by a ligand having affinity for the target cell. Depending on the choice of activator sequence and active substance, the following can be treated by administering the DNA sequence: defective formation of blood cells; autoimmune diseases and allergies and, in addition, rejection reactions against transplanted organs; chronic arthritis; viral and parasitic infections and, in addition, prophylaxis of viral, bacterial and parasitic infections; and leukemias.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 177792-83-5

(CHR element of cdc25C gene; genetic **therapy** of diseases caused by immune system using genetic construct regulated in cell- or virus-specific, cell cycle-dependent manner)

RN 177792-83-5 USPATFULL

CN Adenosine, 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-, double-stranded complementary (9CI) (CA INDEX NAME)

CM 1


CRN 177792-82-4

CMF C68 H87 N25 O39 P6


CDES 5:ALL,B-D-ERYTHRO

Absolute stereochemistry.

PAGE 1-B



PAGE 2-B



L46 ANSWER 39 OF 53 USPATFULL on STN

ACCESSION NUMBER: 2002:102621 USPATFULL

TITLE: Cell-specific active compounds regulated by the cell cycle

INVENTOR(S): Sedlacek, Hans-Harald, Marburg, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF  
Hoechst Aktiengesellschaft, Frankfurt am Main, GERMANY,  
FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6384202	B1	20020507
	WO 9606941		19960307
APPLICATION INFO.:	US 1997-793109		19970425 (8)
	WO 1995-EP3371		19950825
			19970425 PCT 371 date

ASSISTANT EXAMINER: Walicka, Malgorzata A  
 LEGAL REPRESENTATIVE: Clark & Elbing LLP  
 NUMBER OF CLAIMS: 4  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
 LINE COUNT: 429

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An artificial mammalian chromosome, more specifically, a clone containing a mammalian centromere sequence and a DNA replication origin with mammalian telomere sequences added to both ends of the clone, is provided by preparing a CEPH artificial yeast chromosome library containing a human genome, identifying clones having a repetitive human alphoid sequence from this library, and further preparing a yeast strain in which mammalian telomere sequences are added to the ends of its chromosome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204643-99-2P


(human telomere; preparation of mammalian artificial chromosomes for gene therapy containing)

RN 204643-99-2 USPATFULL


CN Adenosine, cytidylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-(3'→5')- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 3-A



PAGE 4-A



NH<sub>2</sub>

L46 ANSWER 38 OF 53 USPATFULL on STN  
 ACCESSION NUMBER: 2004:85164 USPATFULL  
 TITLE: Artificial chromosome  
 INVENTOR(S): Ishikawa, Fuyuki, Kanagawa, JAPAN  
 Hasegawa, Mamoru, Ibaraki, JAPAN  
 PATENT ASSIGNEE(S): DNAMEC Research, Inc., Ibaraki, JAPAN (non-U.S. corporation)



	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6716608	B1	20040406
	WO 9812336		19980326
APPLICATION INFO.:	US 2000-254947		20000313 (9)
	WO 1997-JP3305		19970918

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-246749	19960918
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Prouty, Rebecca E.	


PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 126346-76-7 CAPLUS


CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01196296	A2	19890808	JP 1988-20174	19880129
PRIORITY APPLN. INFO.:			JP 1988-20174	19880129

ED Entered STN: 12 May 1990

AB A number of pentanucleotides inserted immediately upstream of the translation initiation codon (ATG), e.g. CAAAGATG, CCATAATG, CAAACATG, and CCAAGATG, improve the efficiency of gene expression in animal cells. These sequences are used for expression of gene, e.g., for human interferon  $\beta$  (IFN  $\beta$ ). The sequence CAAAG was inserted into plasmid pSV2IFN $\beta$  so that it was linked to ATG of the IFN  $\beta$  gene to give plasmid pSV2IFN( $\gamma$ ) $\beta$ . CHO cells transformed with pSV2IFN( $\gamma$ ) $\beta$  produced 11.2-fold more IFN  $\beta$  than those transformed with pSV2IFN $\beta$ .

IT 126346-75-6 126346-76-7


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (in plasmid for improved expression of heterologous genes in animal cells, effect of)

RN 126346-75-6 CAPLUS

CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 3-A




PAGE 3-B



L46 ANSWER 37 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1990:177016 CAPLUS  
DOCUMENT NUMBER: 112:177016  
TITLE: Animal cell expression vectors for improved gene  
expression  
INVENTOR(S): Sakurai, Toru; Naruto, Masanobu; Ozawa, Hitoshi  
PATENT ASSIGNEE(S): Toray Industries, Inc., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
CODEN: JKXXAF


PAGE 2-B




PAGE 2-C



PAGE 1-B




PAGE 2-A



H<sub>2</sub>N

PAGE 4-A



IT 125676-84-8

RL: RCT (Reactant); RACT (Reactant or reagent)


(reaction of, with undecylcyanoethyldiisopropylamidophosphine)

RN 125676-84-8 CAPLUS



CN Guanosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-  
 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 3-A




PAGE 3-B



PAGE 2-A



PAGE 2-B




AB To enhance the penetration of oligonucleotides (oligo) into cells, the oligo was combined with the hydrophobic undecyl residue. The oligo complementary to the loop-forming site of the RNA and encoding polymerase 3 of the influenza A virus was synthesized with the undecyl residue added to the 5'-terminal phosphate group. The modified oligo effectively suppressed the influenza A/PR8/34 (H1N1) virus reproduction and the synthesis of virus-specific proteins in MDCK cells. Under the same conditions, the non-modified antisense oligo and modified nonsense oligo did not affect the virus development.

RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
(preparation of and influenza virus response to)


5'-Guanylic acid, 2'-deoxyguanylyl-(5'→3')-2'-deoxyadenylyl-(5'→3')-2'-deoxyguanylyl-(5'→3')-2'-deoxyadenylyl-(5'→3')-thymidylyl-(5'→3')-thymidylyl-(5'→3')-2'-deoxyguanylyl-(5'→3')-thymidylyl-(5'→3')-2'-deoxyguanylyl-(5'→3')-2'-deoxyguanylyl-(5'→3')-2'-deoxy-, 5'-undecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 3-A




PAGE 3-B




L46 ANSWER 36 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1990:111551 CAPLUS  
 DOCUMENT NUMBER: 112:111551  
 TITLE: A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells  
 AUTHOR(S): Kabanov, A. V.; Vinogradov, S. V.; Ovcharenko, A. V.; Krivonos, A. V.; Melik-Nubarov, N. S.; Kiselev, V. I.; Severin, E. S.  
 CORPORATE SOURCE: Res. Cent. Mol. Diagn., USSR Ministry of Health, Moscow, 113149, USSR




PAGE 2-A




PAGE 2-B



PAGE 1-B



PAGE 1-C



PAGE 3-A

HO

L46 ANSWER 35 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:17089 CAPLUS

DOCUMENT NUMBER: 114:17089

TITLE: Inhibition of reproduction of the human immunodeficiency virus in a cell culture by the derivatives of antisense oligonucleotides

AUTHOR(S): Abramova, T. V.; Blinov, V. M.; Vlasov, V. V.; Gorn, V. V.; Zarytova, V. F.; Ivanova, E. M.; Konevets, D. A.; Plyasunova, O. A.; Pokrovskii, A. G.; et al.

CORPORATE SOURCE: Novosib. Inst. Bioorg. Khim. Sib. Otd., Novosibirsk, USSR

SOURCE: Doklady Akademii Nauk SSSR (1990), 312(5), 1259-62 [Biochem.]

CODEN: DANKAS; ISSN: 0002-3264

DOCUMENT TYPE: Journal

LANGUAGE: Russian

ED Entered STN: 26 Jan 1991

AB The inhibition of HIV-1 reproduction by 13 antisense oligonucleotides and their derivs. were tested in lymphoid cell line MT-4. The antiviral activity of antisense oligonucleotides might be improved by introducing of hydrophobic and high-reactive groups (e.g. residues of aromatic 2-chloroethylamine) into their mols.

IT 131242-84-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(antiviral activity of, against HIV-1, structure in relation to)

RN 131242-84-7 CAPLUS


CN Guanosine, 2'-deoxyadenylyl-(5'→3')-2'-deoxyguanylyl-(5'→3')-2'-deoxyadenylyl-(5'→3')-2'-deoxyguanylyl-(5'→3')-2'-deoxycytidylyl-(5'→3')-2'-deoxycytidylyl-(5'→3')-2'-deoxyadenylyl-(5'→3')-2'-deoxyguanylyl-(5'→3')-2'-deoxyadenylyl-(5'→3')-2'-deoxy-, 5'-[hydrogen (2-aminopropyl)phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-A




PAGE 2-B




PAGE 1-A




PAGE 1-B



PAGE 4-A



PAGE 4-B




RN 134784-45-5 CAPLUS


CN Guanosine, thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-  
 2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 3-A




PAGE 3-B



PAGE 2-B




PAGE 2-C





PAGE 1-C



PAGE 2-A

O

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02237930	A2	19900920	JP 1989-56196	19890310
PRIORITY APPLN. INFO.:			JP 1989-56196	19890310

OTHER SOURCE(S): MARPAT 115:41979

ED Entered STN: 10 Aug 1991

AB Oligodeoxynucleotides RTGGGTGG (R = G, CG, TCG, etc.) are antitumor agents. Thus, an oligodeoxynucleotide, CGGTGGGCTGTCGTGGGTGG, was synthesized by using the DNA synthesizer Model 430A and bonding sequentially monomers with protective groups. The tumor inhibitory activity of the oligodeoxynucleotide against sarcoma formation in chicken was demonstrated.

IT 134766-66-8P 134784-45-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as antitumor agent)


RN 134766-66-8 CAPLUS

CN Guanosine, 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


PAGE 1-B



PAGE 3-B



PAGE 4-B




L46 ANSWER 34 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1991:441979 CAPLUS  
DOCUMENT NUMBER: 115:41979  
TITLE: Oligodeoxynucleotides as antitumor agents  
INVENTOR(S): Mori, Kazuya; Tsukii, Yuji; Uchida, Kumiko  
PATENT ASSIGNEE(S): Tsumura and Co., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese


PAGE 2-B

NH<sub>2</sub>


PAGE 3-A



PAGE 1-A




PAGE 2-A



L46 ANSWER 33 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1993:573624 CAPLUS  
DOCUMENT NUMBER: 119:173624  
TITLE: Comparative evaluation of seven oligonucleotide  
analogs as potential antisense agents  
AUTHOR(S): Morvan, F.; Porumb, H.; Degols, G.; Lefebvre, I.;  
Pompon, A.; Sproat, B. S.; Rayner, B.; Malvy, C.;  
Lebleu, B.; Imbach, J. L.  
CORPORATE SOURCE: Lab. Chim. Bio-Org., Univ. Montpellier II,  
Montpellier, 34095, Fr.  
SOURCE: Journal of Medicinal Chemistry (1993), 36(2), 280-7  
CODEN: JMCMAR; ISSN: 0022-2623  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
ED Entered STN: 30 Oct 1993  
AB The 12-mer analogs, representative of seven different classes of  
structurally modified oligonucleotides and complementary to the same  
target, have been compared for their binding affinity for both  
single-stranded DNA and RNA, resistance to hydrolysis by nucleases in  
culture medium (RPMI 1640 + 10% inactivated fetal calf serum), and  
inhibition of HIV-1 replication in de novo infected MT4 T lymphocytes.  
The viral target was the splice acceptor site of the premessenger coding  
for the regulatory protein tat. The oligo(2'-O-alkyl)ribonucleotides  
( $\beta$ -2'-O-allyl-RNA and  $\beta$ -2'-O-Me-RNA) were shown to form the most  
stable hybrids with complementary RNA strands whereas the  $\alpha$ -anomeric  
oligodeoxynucleoside phosphorothioate analog displayed the highest  
stability in the culture medium. All the modified oligonucleotides examined  
at the present study exhibited a sequence-nonspecific inhibitory effect on  
HIV-1 replication, the phosphorothioate analogs being the most active ones  
(ED50 < 1  $\mu$ M).  
IT 141888-05-3  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); BIOL (Biological study)  
(as antisense agent, to tat gene, HIV-1 inhibition by, in human cells)  
RN 141888-05-3 CAPLUS  
CN  $\alpha$ -Adenosine,  $\alpha$ -uridylyl-(3' $\rightarrow$ 5')- $\alpha$ -cytidylyl-  
(3' $\rightarrow$ 5')- $\alpha$ -uridylyl-(3' $\rightarrow$ 5')- $\alpha$ -uridylyl-  
(3' $\rightarrow$ 5')- $\alpha$ -adenylyl-(3' $\rightarrow$ 5')- $\alpha$ -adenylyl-  
(3' $\rightarrow$ 5')- $\alpha$ -cytidylyl-(3' $\rightarrow$ 5')- $\alpha$ -cytidylyl-  
(3' $\rightarrow$ 5')- $\alpha$ -cytidylyl-(3' $\rightarrow$ 5')- $\alpha$ -adenylyl-  
(3' $\rightarrow$ 5')- $\alpha$ -cytidylyl-(3' $\rightarrow$ 5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-B




PAGE 3-A




PAGE 3-B



PAGE 1-B



PAGE 2-A





50-55% efficiency (fraction of covalent adducts reagent-target), whereas the derivs. with a terminal reactive group were more effective (70%). The main point of the modification was the guanosine residue to the target which located near to the photoactive group and was not involved in the duplex formation. Tandems of reagents which are complementary to neighboring sites of the target modify predominantly the same guanosine residue up to 80%.

IT 158479-10-8


RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(site-specific photomodification of oligonucleotides by arylazide and perfluoro arylazide derivs. of oligonucleotides with terminal or internal photoactive group)

RN 158479-10-8 CAPLUS


CN Guanosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy-, 3'-[hydrogen [3-[(4-azido-2,3,5,6-tetrafluorobenzoyl)amino]propyl]phosphoramidate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 3-A



PAGE 3-B



L46 ANSWER 32 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:675333 CAPLUS

DOCUMENT NUMBER: 121:275333

TITLE: Site-specific photomodification of nucleic acids by arylazide and perfluoro arylazide derivatives of oligonucleotides. III. Oligonucleotide reagents with a terminal or internal photoactive group

AUTHOR(S): Levina, A. S.; Tabatadze, D. R.; Zarytova, V. F.; Dobrikov, M. I.; Gorn, V. V.; Khalimskaya, L. M.

CORPORATE SOURCE: Novosibirsk Institute Bioorganic Chemistry, Novosibirsk, Russia

SOURCE: Bioorganicheskaya Khimiya (1994), 20(1), 21-9  
CODEN: BIKHD7; ISSN: 0132-3423


DOCUMENT TYPE: Journal

LANGUAGE: Russian

ED Entered STN: 10 Dec 1994

AB Photomodification of target oligonucleotides with reagents bearing p-azidotetrafluorobenzamide group at various positions of the oligonucleotide address was investigated. The photoactive group was attached to the 5'- or 3'-terminal phosphate or at the C5-position of a deoxyuridine residue at the 5'-end or inside the oligonucleotide chain. The reagents with the internal photoactive group modified the target with

PAGE 2-A



PAGE 2-B


NH<sub>2</sub>

NH<sub>2</sub>


CN Thymidine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-  
(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 3-A



PAGE 3-B



RN 155902-32-2 CAPLUS

CN DNA, d(G-T-T-G-G-A-G-A-C-C-G-G-I-G-T-T-G-G-I-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L46 ANSWER 31 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:217625 CAPLUS

DOCUMENT NUMBER: 122:133642

TITLE: 2-Diphenylmethylsilylethyl (DPSE): a versatile protecting group for oligodeoxyribonucleotide synthesis

AUTHOR(S): Ravikumar, Vasulinga T.; Cole, Douglas L.

CORPORATE SOURCE: Isis Pharmaceuticals, Carlsbad, CA, 92008, USA

SOURCE: Gene (1994), 149(1), 157-61

CODEN: GENED6; ISSN: 0378-1119

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 30 Nov 1994

AB 2-Diphenylmethylsilylethyl (DPSE) is a new protecting group for the internucleotidic bonds in the solid-support and solution-phase synthesis of oligodeoxyribonucleotides by the phosphoramidite approach. This group is stable under acidic conditions and can be removed by a  $\beta$ -fragmentation mechanism under mild conditions using aqueous  $\text{NH}_4\text{OH}$ . Alternatively, this group can also be removed using tetrafluorosilane in acetonitrile. Antiviral activity of oligodeoxyribonucleotide is reported (no data).

IT 126208-94-4P

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); SPN (Synthetic preparation); BIOL

(Biological study); PREP (Preparation)


(diphenylmethylsilylethyl protective group for Merrifield synthesis of oligodeoxyribonucleotides)

RN 126208-94-4 CAPLUS

PAGE 2-A



PAGE 2-B




RN 126596-01-8 CAPLUS



CN DNA, d(G-G-G-G-T-T-G-G-G-G) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




PAGE 1-C




PAGE 2-B



PAGE 3-A




PAGE 3-B






PAGE 1-A



PAGE 2-A



```

-----
WO 9419945      A1      19940915      WO 1994-US2471      19940307
W:  AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV,
    MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
    BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
US 5514577      A      19960507      US 1993-31147      19930312
AU 9463619      A1      19940926      AU 1994-63619      19940307
EP 692930       A1      19960124      EP 1994-910879      19940307
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 08503959     T2      19960430      JP 1994-520254      19940307
PRIORITY APPLN. INFO.:
                                US 1993-31147      A 19930312
                                US 1990-485297      A2 19900226
                                US 1992-852132      A2 19920428
                                US 1992-954185      B2 19920929
                                WO 1994-US2471      W 19940307

```

ED Entered STN: 10 Dec 1994

AB Compns. and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52, and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

IT 126208-94-4P 126596-01-8P 155902-32-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(oligonucleotides for treatment or diagnosis of infection by herpes simplex virus type 1 or herpes simplex virus type 2 or cytomegalovirus or human herpes virus 6 or Epstein Barr virus or varicella zoster virus)

RN 126208-94-4 CAPLUS


CN Thymidine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 3-B



PAGE 4-B



L46 -ANSWER 30 OF 53 -CAPLUS -COPYRIGHT 2005 ACS-on STN

ACCESSION NUMBER: 1994:672152 CAPLUS

DOCUMENT NUMBER: 121:272152

TITLE: Oligonucleotide therapies for modulating the effects of herpesviruses

INVENTOR(S): Draper, Kenneth G.; Crooke, Stanley T.; Mirabelli, Christopher K.; Ecker, David J.; Hanecak, Ronnie C.; Anderson, Kevin P.; Brown-Driver, Vickie L.; Wyatt, Jacqueline R.

PATENT ASSIGNEE(S): ISIS Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 71

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.

KIND


DATE

APPLICATION NO.


DATE

Searched by Barb O'Bryen, STIC 2-2518

PAGE 2-A




PAGE 2-B




(9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A




PAGE 1-B




PAGE 3-B



PAGE 4-A



PAGE 4-B



IT 197095-70-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of short oligonucleotide alkylating derivs. and effect of various effectors on alkylation of target DNA)


RN 197095-70-8 CAPLUS

CN 3'-Adenylic acid, 5'-O-phosphonothymidyl-(3'→5')-2'-  
 deoxycytidyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-  
 deoxyadenyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-deoxy-,  
 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] ester, inner salt


PAGE 2-A




PAGE 3-A



PAGE 1-A




PAGE 1-B





PAGE 3-B



IT 197095-64-0P



RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (effector; preparation of short oligonucleotide alkylating derivs. and effect of various effectors on alkylation of target DNA)

RN 197095-64-0 CAPLUS


CN 3'-Adenylic acid, 5'-O-[[[3-[[[(3 $\beta$ )-cholest-5-en-3-yl]oxy]-3-oxopropyl]amino]hydroxyphosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-, 3'-[2-[[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] ester, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-B




PAGE 3-A



PAGE 1-A




PAGE 2-A



PAGE 3-A




PAGE 3-B





RN 197095-62-8 CAPLUS  
 CN 3'-Adenylic acid, 5'-O-[hydroxy[[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl]amino]phosphinyl]thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-, 3'-[2-[[10-(2-hydroxyethyl)phenazinium-2-yl]amino]ethyl] ester, bis(inner salt) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-A



PAGE 2-B



PAGE 1-A



PAGE 1-B




LANGUAGE: Russian  
OTHER SOURCE(S): CASREACT 127:304361  
ED Entered STN: 15 Sep 1997  
AB It was shown that the tandem of the derivs. of short oligonucleotides efficiently and site specifically interacts with target 20 base deoxyribonucleotide (M). The very low hybridization ability of tetranucleotide (D) and its 3'-cholesterol and 3'-estrone esters (D-ChS and D-EsS, resp.) increases significantly in the presence of the effectors octanucleotides (E1 and E2), and their 5',3'-diphenazinium (Phn-E1-Phn and Phn-E2-Phn) and 5'-cholesteryl-3'-phenazinium (ChS-E1-Phn and ChS-E2-Phn) derivs., which flank them on the target strand. The influence of the effectors on the interaction of the target M with tetranucleotide D or its alkylating derivs. (RCl-D) increases in a series  $E1 + E2 < ChS-E1-Phn + ChS-E2-Phn < Phn-E1-Phn + Phn-E2-Phn$ . For the steroid derivs., D-ChS and D-EsS, and the reagents based on them (RCl-D-ChS and RCl-D-EsS), this series is  $E1 + E2 < Phn-E1-Phn + Phn-E2-Phn < ChS-E1-Phn + ChS-E2-Phn$ . The modification level of the target M with derivative RCl-D-EsS in the presence of ChS-E1-Phn and ChS-E2-Phn reaches 40% even at 37°C under conditions close to physiol. The possibility of using 5'-cholesteryl-3'-phenazinium-containing oligonucleotides as effectors of the interaction of target DNA with the derivs. of short oligonucleotides was demonstrated.

IT 197095-57-1 197095-62-8  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(effector; interaction of short oligonucleotide derivs. with nucleic acids and effect of various effectors on alkylation of target DNA)


RN 197095-57-1 CAPLUS  
CN Adenosine, 5'-O-phosphonothymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-B




PAGE 3-A




L46 ANSWER 29 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1997:588415 CAPLUS  
 DOCUMENT NUMBER: 127:304361  
 TITLE: Interaction of short oligonucleotide derivatives with  
 nucleic acids. Part 1. Effect of various types of  
 effectors on alkylation of target DNA  
 AUTHOR(S): Pushnyi, D. V.; Pyshnaya, I. A.; Lokhov, S. G.;  
 Ivanova, E. M.; Zarytova, V. F.  
 CORPORATE SOURCE: Novosib. Inst. Bioorg. Khim., SO RAN, Novosibirsk,  
 Russia  
 SOURCE: Bioorganicheskaya Khimiya (1995), 21(09), 709-716  
 CODEN: BIKHD7; ISSN: 0132-3423  
 PUBLISHER: MAIK Nauka  
 DOCUMENT TYPE: Journal




PAGE 1-A




PAGE 2-A



PAGE 3-A




PAGE 3-B



RN 155661-28-2 CAPLUS  
 CN  $\alpha$ -Thymidine,  $\alpha$ -thymidylyl-(3'→5')- $\alpha$ -thymidylyl-  
 (3'→5')-2'-deoxy- $\alpha$ -guanylyl-(3'→5')-2'-deoxy- $\alpha$ -  
 guanylyl-(3'→5')-2'-deoxy- $\alpha$ -guanylyl-(3'→5')-2'-deoxy-  
 $\alpha$ -guanylyl-(3'→5')- $\alpha$ -thymidylyl-(3'→5')- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A



PAGE 2-B

NH<sub>2</sub>

NH<sub>2</sub>

infectious virus and virus-infected cells to uninfected target cells by binding to the cationic V3 loop of the envelope glycoprotein. The G-quartet structure is a potential candidate for use in anti-HIV chemotherapy.

IT 126208-94-4, ISIS 5671 155661-28-2, ISIS 7283

RL: **BAC** (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); **THU** (Therapeutic use); BIOL (Biological study); USES (Uses)


(novel guanosine quartet structure binds to HIV envelope and inhibits envelope mediated cell fusion)

RN 126208-94-4 CAPLUS

CN Thymidine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A







PAGE 1-A




PAGE 1-B



PAGE 1-B



PAGE 2-B



CM 2

CRN 89802-96-0

CMF C57 H74 N21 O33 P5

Absolute stereochemistry.

go through from .apprx.50 to .apprx.60. Cells incubated with the oligonucleotide TTAGGGTTAGGG 1.0  $\mu$ M stopped dividing with the maximum number of doublings <10. The lengths of telomeres were shown to be a function of the proliferative history of a cell and so they could be used as markers in the assessment of senescence, e.g. in atherogenesis. Telomere loss was more rapid in cultured cells derived from Down's syndrome patients ( $133 \pm 15$  bp/y) than from age-matched controls ( $41 \pm 7.7$  bp/y).

IT 157961-44-9D, oligomers

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(as primer for telomerase assay; determination of telomere length and telomerase activity and their use in diagnosis and treatment of disease)

RN 157961-44-9 CAPLUS

CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy-, double-stranded complementary (9CI) (CA INDEX NAME)


CM 1

CRN 117490-04-7

CMF C60 H75 N24 O35 P5


Absolute stereochemistry.

PAGE 1-A





PAGE 4-A




L46 ANSWER 27 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1995:780399 CAPLUS  
 DOCUMENT NUMBER: 123:190561  
 TITLE: Determination of telomere length and telomerase activity and their use in the diagnosis and treatment of disease  
 INVENTOR(S): West, Michael David; Shay, Jerry; Blackburn, Elizabeth H.; Kim, Nam Woo; Wright, Woodring E.; Harley, Calvin B.; Weinrich, Scott L.; Strahl, Catherine M.; McEachern, Michael J.; Vaziri, Homayoun  
 PATENT ASSIGNEE(S): Geron Corp., USA; Board of Regents, University of Texas System; Regents of the University of California  
 SOURCE: PCT Int. Appl., 228 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 21  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9513382	A1	19950518	WO 1994-US13122	19941114
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5830644	A	19981103	US 1993-151477	19931112
AU 9511781	A1	19950529	AU 1995-11781	19941114
PRIORITY APPLN. INFO.:			US 1993-151477	A 19931112
			US 1992-882438	B2 19920513
			US 1993-38766	A2 19930324
			US 1993-60952	A2 19930513
			WO 1994-US13122	W 19941114


ED Entered STN: 08 Sep 1995

AB Methods and reagents for the determination of telomere length and telomerase activity, as well as the ability to increase or decrease telomerase activity in the treatment of proliferative diseases are described. A primer extension method used under conditions that minimize interference from other genomic sequences is used to obtain accurate detns. of telomeric length or telomerase activity. In addition, compns. are provided for intracellular inhibition of telomerase activity and means are shown for slowing or reversing the loss of telomeric repeats in aging cells. Primers hybridizing to the single-stranded region of the telomere were shown to increase the number of divisions that non-immortalized cells could


PAGE 2-B




PAGE 3-A




PAGE 1-A




PAGE 2-A



PAGE 1-B



PAGE 2-B



RN 125443-46-1 CAPLUS

CN Adenosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-  
 (3'→5')-thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
 US 5645986 A 19970708 US 1993-153051 19931112  
 US 5830644 A 19981103 US 1993-151477 19931112  
 AU 9513307 A1 19950529 AU 1995-13307 19941110  
 PRIORITY APPLN. INFO.: US 1993-151477 A 19931112  
 US 1993-153051 A 19931112  
 US 1992-882438 B2 19920513  
 US 1993-38766 A2 19930324  
 US 1993-60952 A2 19930513  
 WO 1994-US13130 W 19941110

ED Entered STN: 20 Sep 1995

AB Method and compns. for increasing telomere length in normal cells can be used to increase the proliferative capacity of cells and to delay the onset of cellular senescence. The method comprises culturing the cells in the presence of an oligonucleotide substrate for telomerase. The substrate contains a telomeric repeat sequence. A human fibroblast cell line treated as above displayed increased telomere length. A correlation between telomere length and cell lifespan was demonstrated using hybrid cells.

IT 117490-04-7 125443-46-1


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (telomerase substrate; methods and reagents for lengthening telomeres in normal cells and delaying onset of cellular senescence)

RN 117490-04-7 CAPLUS


CN Guanosine, thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-B




PAGE 3-A




L46 ANSWER 26 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1995:801573 CAPLUS  
 DOCUMENT NUMBER: 123:220261  
 TITLE: Methods and reagents for lengthening telomeres in normal cells and delaying onset of cellular senescence  
 INVENTOR(S): Shay, Jerry; West, Michael David; Wright, Woodring E.  
 PATENT ASSIGNEE(S): Geron Corp., USA; Board of Regents, University of Texas System  
 SOURCE: PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 21  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9513383	A1	19950518	WO 1994-US13130	19941110
W: AU, CA, JP				


PAGE 1-B



PAGE 2-A



PAGE 3-B




RN 173264-68-1 CAPLUS

CN Adenosine, thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-  
 thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A







PAGE 2-A




PAGE 2-B




PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 173264-67-0 CAPLUS  
 CN Cytidine, thymidyl- (3'→5')-2'-deoxycytidyl- (3'→5')-2'-  
 deoxycytidyl- (3'→5')-thymidyl- (3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxyguanylyl- (3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 173264-66-9 CAPLUS


CN Adenosine, thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 173264-63-6 CAPLUS


CN Guanosine, thymidyl- (3'→5')-2'-deoxycytidyl- (3'→5')-2'-  
 deoxyadenyl- (3'→5')-2'-deoxyadenyl- (3'→5')-2'-  
 deoxyguanylyl- (3'→5')-2'-deoxyguanylyl- (3'→5')-2'-  
 deoxyadenyl- (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 2-B



PAGE 3-A




PAGE 3-B





RN 173264-61-4 CAPLUS  
 CN Adenosine, thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B




PAGE 2-A




RN 173264-56-7 CAPLUS  
CN Adenosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-  
2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A




PAGE 2-B




PAGE 2-C




PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 2-C


—NH<sub>2</sub>

RN 173264-47-6 CAPLUS


CN Cytidine, 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B



PAGE 2-A



PAGE 2-C


—NH<sub>2</sub>

RN 173264-46-5 CAPLUS

CN Adenosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-  
(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-  
(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-  
(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 2-A




PAGE 2-B




Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-B



PAGE 3-A




PAGE 3-B




RN 173264-45-4 CAPLUS  
 CN Adenosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)


PAGE 1-A




PAGE 2-A



PAGE 2-A



PAGE 2-B




RN 173264-41-0 CAPLUS


CN Guanosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-B



PAGE 3-A




PAGE 3-B




RN 173264-34-1 CAPLUS  
 CN Adenosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-  
 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-  
 thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A






PAGE 2-A

H<sub>2</sub>N—

PAGE 2-B




RN 173264-32-9 CAPLUS

CN Adenosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-  
 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

The diagram illustrates a dinucleotide structure, specifically a 2-aminopurine-2'-phosphate-3'-phosphate-5'-ribose-2-aminopyrimidine derivative. The structure shows two nucleosides linked by a pyrophosphate bridge. The nucleosides are 2-aminopurine and 2-aminopyrimidine. The pyrophosphate bridge is shown with two phosphate groups, each with a hydroxyl group and a hydroxymethyl group. The sugar rings are labeled with R and S configurations, indicating their stereochemistry. The structure is drawn in a perspective view, showing the spatial arrangement of the atoms and the orientation of the phosphate groups.

PAGE 3-A





PAGE 3-B




RN 173264-31-8 CAPLUS  
 CN Adenosine, 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-  
 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 3-A




RN 173264-23-8 CAPLUS

CN Guanosine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-  
(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-  
(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 3-B




RN 173264-22-7 CAPLUS


CN Cytidine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-B





PAGE 3-A






PAGE 1-B



\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

PAGE 4-A




RN 173264-21-6 CAPLUS


CN Adenosine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-A




PAGE 2-A



PAGE 2-A



PAGE 2-B




RN 173264-18-1 CAPLUS


CN Cytidine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 173264-10-3 CAPLUS


CN Adenosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 173264-09-0 CAPLUS

CN Adenosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-  
 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-A




PAGE 1-B



PAGE 2-B



PAGE 3-B





RN 173264-08-9 CAPLUS


CN Adenosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-  
 2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-B



PAGE 2-A



PAGE 2-B





RN 173264-07-8 CAPLUS


CN    Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI)    (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 3-B



PAGE 3-C




RN 173264-05-6 CAPLUS


CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-  
 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-B



PAGE 2-B




RN 173264-04-5 CAPLUS

CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-  
 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A







PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 173264-01-2 CAPLUS


CN Adenosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 173264-00-1 CAPLUS


CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 3-B




RN 173263-97-3 CAPLUS



CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-B




PAGE 3-A



PAGE 1-A




PAGE 2-A







PAGE 2-B



PAGE 3-B




PAGE 3-C




RN 173263-95-1 CAPLUS  
 CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-  
 2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-B



PAGE 3-B



PAGE 3 - C




RN	173263-94-0	CAPLUS
CN	Guanosine, 2'-deoxycytidyl- (3'→5')-2'-deoxyadenyl- (3'→5')-thymidyl- (3'→5')-2'-deoxycytidyl- (3'→5')-2'-deoxyadenyl- (3'→5')-2'-deoxyadenyl- (3'→5')-2'-deoxyguanyl- (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)	


Absolute stereochemistry.

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 3-B




RN 173263-91-7 CAPLUS  
 CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)


(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-B



PAGE 3-A




PAGE 3-B




RN 173263-90-6 CAPLUS  
 CN Adenosine, 2'-deoxycytidyl-(3'→5')-2'-deoxyadenyl-  
 (3'→5')-2'-deoxycytidyl-(3'→5')-2'-deoxycytidyl-  
 (3'→5')-2'-deoxyadenyl-(3'→5')-2'-deoxyadenyl-

PAGE 1-A




PAGE 2-A






PAGE 2-A



PAGE 2-B




RN 173263-74-6 CAPLUS


CN Adenosine, 2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



PAGE 2-B



PAGE 3-A




RN 173263-69-9 CAPLUS


CN Adenosine, 2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-  
 2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-  
 thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-  
 (3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A



PAGE 3-A



PAGE 3-B




RN 173263-58-6 CAPLUS


CN Guanosine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-  
 2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-A




PAGE 2-B




PAGE 1-A




PAGE 1-B



PAGE 2-B



PAGE 3-A




RN 173263-57-5 CAPLUS

CN Cytidine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-  
 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-  
 deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-A




PAGE 2-A



PAGE 2-A



PAGE 2-B




RN 173263-56-4 CAPLUS


CN Adenosine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-B



PAGE 3-A



PAGE 3-B




RN 173263-54-2 CAPLUS  
 CN Guanosine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-  
 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-  
 deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

Me  
|


PAGE 2-A




RN 173263-53-1 CAPLUS  
CN Adenosine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-  
(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-  
2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A




PAGE 2-B




PAGE 3-A




PAGE 1-A




PAGE 1-B







PAGE 2-B




RN 173263-52-0 CAPLUS


CN Guanosine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 173263-51-9 CAPLUS


CN Guanosine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-  
 (3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-  
 (3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.

PAGE 1-B



PAGE 2-A



purpose, such as identification of cancerous cells. The target nucleic acid may be DNA or mRNA. A set of 151 5'-primers and 30 3'-primers is described.

IT 173263-41-7 173263-51-9 173263-52-0  
 173263-53-1 173263-54-2 173263-56-4  
 173263-57-5 173263-58-6 173263-69-9  
 173263-74-6 173263-90-6 173263-91-7  
 173263-94-0 173263-95-1 173263-97-3  
 173264-00-1 173264-01-2 173264-04-5  
 173264-05-6 173264-07-8 173264-08-9  
 173264-09-0 173264-10-3 173264-18-1  
 173264-21-6 173264-22-7 173264-23-8  
 173264-31-8 173264-32-9 173264-34-1  
 173264-41-0 173264-45-4 173264-46-5  
 173264-47-6 173264-56-7 173264-61-4  
 173264-63-6 173264-66-9 173264-67-0  
 173264-68-1


RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (nucleotide sequence, 5'-primer for anal. amplification of nucleic acids; panels of short oligonucleotide primers for use in characterizing DNA sequences and methods for their anal. use)

RN 173263-41-7 CAPLUS


CN Adenosine, 2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 3-B



PAGE 3-C



L46 ANSWER 25 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:91933 CAPLUS

DOCUMENT NUMBER: 124:137787

TITLE: Panels of short oligonucleotide primers for use in characterizing DNA sequences and methods for their analytical use

INVENTOR(S): Lopez-Nieto, Carlos Eduardo; Nigam, Sanjay Kumar

PATENT ASSIGNEE(S): Brigham and Women's Hospital, USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9531574	A1	19951123	WO 1995-US6032	19950512
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2190471	AA	19951123	CA 1995-2190471	19950512
AU 9525499	A1	19951205	AU 1995-25499	19950512
EP 760009	A1	19970305	EP 1995-919826	19950512
R: CH, DE, FR, GB, LI				
JP 10510981	T2	19981027	JP 1995-529819	19950512
US 6110667	A	20000829	US 1996-522384	19961115
PRIORITY APPLN. INFO.:			US 1994-242887	A 19940516
			WO 1995-US6032	W 19950512


ED Entered STN: 14 Feb 1996

AB A fingerprinting method for nucleic acid acid characterization that uses pairs of short oligonucleotides taken from a large panel as primers in an amplification reactions is described. The fingerprint is defined by the amplification products from different pairs of products. The process may be automated and the panel of primers can be supplied in a kit form with specific subsets having a particular utility being supplied for a defined

PAGE 1-B



PAGE 2-B



PUBLISHER: Academic  
DOCUMENT TYPE: Journal  
LANGUAGE: English

ED Entered STN: 09 May 1996

AB Base substitution mutation frequency is influenced by the sequence context surrounding lesions in the DNA. We have been studying UV mutagenesis in human repair-deficient cells in the supF marker gene carried in a shuttle vector plasmid. There are prominent hotspots, on opposite strands, at the 5' TC sites in the eight base palindrome 5' CTTCGAAG. Recently, we developed a reporter system which permits sequence manipulation in the vicinity of mutational hotspots. We have used the system to characterize the influence of individual positions in the palindrome on the frequency of mutagenesis at the two UV hotspots. In this paper we have determined the contribution of bases at the second and third positions in the palindrome. Changes in bases that were in the primer template duplex when the replication complex encountered the photoproducts at one of the hotspot sites significantly increased or decreased the probability of mutations at the site. We also observed modulation of hotspot activity at other sites as a function of single base changes as much as 80 bases away from the hotspots. In these instances, the site of the changed base was in the unreplicated template ahead of the primer terminus when the polymerase encountered the relevant photoproduct. Our results indicate that sequence context has both proximal and distal consequences for mutagenesis.

IT 149181-78-2

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)


(single nucleotide positions have proximal and distal influence on UV mutation hotspots and coldspots)

RN 149181-78-2 CAPLUS

CN Guanosine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-B



PAGE 2-B



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 24 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1996:272042 CAPLUS  
DOCUMENT NUMBER: 124:334799  
TITLE: Single nucleotide positions have proximal and distal influence on UV mutation hotspots and coldspots  
AUTHOR(S): Levy, Dan D.; Magee, Ashalla D.; Seidman, Michael M.  
CORPORATE SOURCE: Laboratory Molecular Carcinogenesis, NCI, NIH, Bethesda, MD, 20892, USA  
SOURCE: Journal of Molecular Biology (1996), 258(2), 251-60  
CODEN: JMOBAK; ISSN: 0022-2836

in relation to the initiator ATG abolished glucose repression. Mutation of a single hexanucleotide sequence 5'GTGGGG at nucleotide -720 was sufficient for derepression. This site is similar to the binding sites of the glucose repressors MIG1 of *Saccharomyces cerevisiae* and CREA/CRE1 of filamentous fungi. Removal of the glucose repressor site did not affect sophorose induction. Sophorose induction of the promoter was retained even in deletion derivs. lacking sequences upstream of position -161, which retained about 70 bp upstream of the transcription start point and only 30 bp upstream of the TATA box.

IT 186416-80-8


RL: **BAC (Biological activity or effector, except adverse)**; BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)  
(nucleotide sequence; identification of two glucose repressor-binding sites (-1001 and -720) in the cellobiohydrolase I gene promoter of *Trichoderma reesei*)

RN 186416-80-8 CAPLUS


CN Guanosine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 3-A




PAGE 3-B




L46 ANSWER 23 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1997:70076 CAPLUS  
 DOCUMENT NUMBER: 126:127753  
 TITLE: Functional analysis of the cellobiohydrolase I promoter of the filamentous fungus *Trichoderma reesei*  
 AUTHOR(S): Ilmen, M.; Onnela, M.-L.; Klemsdal, S.; Penttila, M.  
 CORPORATE SOURCE: VTT Biotechnology Food Research, Espoo, FIN-02044, Finland  
 SOURCE: Molecular & General Genetics (1996), 253(3), 303-314  
 CODEN: MGGEAE; ISSN: 0026-8925  
 PUBLISHER: Springer  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 ED Entered STN: 31 Jan 1997  
 AB Functional anal. of the cellulase promoter *cbh1* of the filamentous fungus *Trichoderma reesei* was carried out using the *Escherichia coli* *lacZ* gene as a reporter. An assay based on cultivation on solid medium in microtiter plates was developed that allows rapid and reliable semiquant. anal. of  $\beta$ -galactosidase expression of a large number of transformants. A series of deletions and specifically designed alterations were made covering 2.2 kb of the *cbh1* promoter. Removal of sequences upstream of nucleotide -500

PAGE 2-A



PAGE 2-B

NH<sub>2</sub>



IT 135625-40-0

RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); BUU (Biological use, unclassified); BIOL  
(Biological study); USES (Uses)


(role of the gonococcal uptake sequence (GCUS) and piliation phenotype  
in transformation of different concns. of DNA in *Neisseria gonorrhoeae*)

RN 135625-40-0 CAPLUS


CN Guanosine, 2'-deoxyadenylyl-(5'→3')-2'-deoxyadenylyl-(5'→3')-  
2'-deoxyguanylyl-(5'→3')-thymidylyl-(5'→3')-2'-  
deoxycytidylyl-(5'→3')-thymidylyl-(5'→3')-2'-deoxyguanylyl-  
(5'→3')-2'-deoxycytidylyl-(5'→3')-2'-deoxycytidylyl-  
(5'→3')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 3-A



PAGE 3-B



RN 155902-32-2 CAPLUS  
 CN DNA, d(G-T-T-G-G-A-G-A-C-C-G-G-I-G-T-T-G-G-I-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L46 ANSWER 22 OF 53 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:676294 CAPLUS

DOCUMENT NUMBER: 125:319714

TITLE: Uptake-sequence-independent DNA transformation exists in *Neisseria gonorrhoeae*

AUTHOR(S): Boyle-Vavra, Susan; Seifert, H. Steven

CORPORATE SOURCE: Dep. Microbiol.-Immunology, Northwestern Univ. Medical School, Chicago, IL, 60611, USA

SOURCE: Microbiology (Reading, United Kingdom) (1996), 142(10), 2839-2845

CODEN: MROBEO; ISSN: 1350-0872

PUBLISHER: Society for General Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 16 Nov 1996

AB A DNA transformation dose-response curve of piliated (P+) gonococci with the use of cloned DNA containing a pile2-cat fusion showed saturation at high and

low levels of transforming DNA. At low DNA concns., transformation of the P+ strain MS11-A was effectively inhibited by a 1000-fold molar excess of the gonococcal transformation uptake sequence (GCUS). The same molar excess of the GCUS did not inhibit transformation of MS11-A at high DNA concns. In MS11-B2, a nonpiliated (P-), pilin-nonproducing, isogenic variant of MS11-A, the GCUS did not inhibit transformation at any level of transforming DNA. These data suggest that two mechanisms of transformation exist in P+ cells: one which utilizes the GCUS and one which does not. In MS11-B2 P- cells, no evidence was found for the presence of the GCUS-dependent mechanism, suggesting that transformation in this background occurs solely by the GCUS-independent mechanism.

CA INDEXING IS CURRENT THROUGH 29 Sep 2005 (20050929/UPCA)  
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 29 Sep 2005 (20050929/PD)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

```
>>> USPAT2 is now available.  USPATFULL contains full text of the  <<<
>>> original, i.e., the earliest published granted patents or  <<<
>>> applications.  USPAT2 contains full text of the latest US  <<<
>>> publications, starting in 2001, for the inventions covered in  <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent  <<<
>>> publications.  The publication number, patent kind code, and  <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.  <<<

>>> USPATFULL and USPAT2 can be accessed and searched together  <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to  <<<
>>> enter this cluster.  <<<
>>>  <<<
>>> Use USPATALL when searching terms such as patent assignees,  <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.  <<<
```

This file contains CAS Registry Numbers for easy and accurate  
 substance identification.

```
L14      6113380 SEA FILE=REGISTRY ABB=ON  SQL<46 AND NS/FS
L15      1667 SEA FILE=REGISTRY ABB=ON  RRI[IG]YY/SQSN
L16      1612 SEA FILE=REGISTRY ABB=ON  L14 AND L15
L20      STR
L22      2568 SEA FILE=REGISTRY SSS FUL L20
L36      639 SEA FILE=USPATFULL ABB=ON  L16 OR L22
L37      185 SEA FILE=USPATFULL ABB=ON  L36 NOT AY>1997
L38      10501 SEA FILE=USPATFULL ABB=ON  (IMMUNOSTIM? OR IMMUNOMOD? OR
      IMMUNOSUPPRES?)/IT
L39      8 SEA FILE=USPATFULL ABB=ON  L37 AND L38
L40      64 SEA FILE=USPATFULL ABB=ON  L36(L) (PHARMAC? OR THERAP?)/IT
L41      13 SEA FILE=USPATFULL ABB=ON  L37 AND L40
L42      16 SEA FILE=USPATFULL ABB=ON  L39 OR L41
```

```
73 L16
L48      0 (L42 AND L16) NOT L45
```

*seq. search answers not included  
 in structure search  
 answer set*

```
=> fil capl;d ibib ed abs hitseq l47 1
FILE 'CAPLUS' ENTERED AT 14:19:56 ON 30 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is  
 held by the publishers listed in the PUBLISHER (PB) field (available  
 for records published or updated in Chemical Abstracts after December  
 26, 1996), unless otherwise indicated in the original publications.  
 The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Sep 2005 VOL 143 ISS 15  
FILE LAST UPDATED: 29 Sep 2005 (20050929/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L47 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:716750 CAPLUS

DOCUMENT NUMBER: 136:243732

TITLE: Nucleic acid-based ribozyme and DNAzyme modulators of gene expression

INVENTOR(S): Mcswiggen, James; Usman, Nassim; Blatt, Lawrence; Beigelman, Leonid; Burgin, Alex; Karpeisky, Alexander; Matulic-Adamic, Jasenka; Sweedler, David; Draper, Kenneth; Chowrira, Bharat; Stinchcomb, Dan; Beaudry, Amber; Zinnen, Shawn; Ludwig, Janos; Sproat, Brian S.

PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 717 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016312 A3		20010809	WO 2000-US23998	20000830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-PV151713	19990831
			US 1999-406643	19990927
			US 1999-PV156467	19990927
			US 1999-PV156236	19990927
			US 1999-436430	19991108
			US 1999-PV169100	19991206
			US 1999-PV173612	19991229
			US 1999-474432	19991229
			US 1999-476387	19991230
			US 2000-498824	20000204
			US 2000-531025	20000320
			US 2000-PV197769	20000414
			US 2000-578223	20000523

ED Entered STN: 02 Oct 2001

AB Novel nucleic acid mols. useful as inhibitors of gene expression, compns., and methods for their use are provided. The invention features novel nucleic acid-based techniques (e.g., enzymic nucleic acid mols. (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex



DNA, and antisense nucleic acids containing RNA-cleaving chemical groups) and their use to modulate the expression of mol. targets impacting the development and progression of cancers, diabetes, obesity, Alzheimer's disease diseases, age-related diseases, and/or hepatitis B infections and related conditions. Catalytic nucleic acids were designed for site-specific cleavage of human mRNA targets encoding protein tyrosine phosphatase 1b, methionine aminopeptidase,  $\beta$ -secretase, presenilin-1, epidermal growth factor receptor-2 (HER2/c-erb2/neu), phospholamban, telomerase, and hepatitis B virus genes. Methods for chemical synthesis of modified nucleoside triphosphates (NTPs) and RNA polymerase-catalyzed incorporation of modified NTPs into catalytic oligonucleotides are also provided. [This abstract record is the fifth of six records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 402796-95-6 402796-98-9 402797-02-8  
402797-14-2 402797-21-1 402797-48-2  
402797-57-3 402797-94-8 402798-13-4  
402798-28-1 402798-44-1 402798-67-8  
402798-79-2 402798-85-0 402798-90-7  
402798-98-5 402799-15-9 402799-28-4  
402799-45-5 402799-56-8 402799-72-8  
402799-82-0 402799-90-0 402800-01-5  
402800-48-0 402800-56-0 402800-77-5  
402800-83-3 402800-86-6 402800-98-0  
402801-16-5 402801-20-1 402801-26-7 40280  
1-36-9 402801-52-9 402801-73-4  
402801-77-8 402801-92-7 402801-94-9  
402801-96-1 402802-09-9 402802-18-0  
402802-22-6 402802-43-1 402802-49-7  
402802-53-3 402802-55-5 402802-61-3  
402802-68-0 402802-75-9 402802-77-1  
402802-92-0 402803-07-0 402803-16-1  
402803-18-3 402803-52-5 402803-72-9  
402803-82-1 402804-18-6 402804-28-8  
402804-49-3 402804-83-5 402804-85-7  
402804-90-4 402804-95-9 402805-03-2  
402805-19-0 402805-27-0 402805-29-2  
402805-39-4 402805-42-9 402805-58-7  
402805-72-5 402805-93-0 402805-98-5  
402806-02-4 402806-19-3 402806-22-8  
402806-26-2 402806-34-2 402806-38-6  
402806-44-4 402806-65-9 402806-68-2  
402806-73-9 402806-75-1 402806-77-3  
402806-79-5 402806-83-1 402806-91-1  
402807-00-5 402807-07-2 402807-21-0  
402807-36-7 402807-50-5 402807-53-8  
402807-56-1 402807-60-7 402807-62-9  
402807-81-2 402807-89-0 402807-91-4  
402807-95-8 402808-02-0 402808-09-7  
402808-13-3 402808-18-8 402808-24-6  
402808-28-0 402808-41-7 402808-48-4  
402808-61-1 402808-65-5 402808-75-7  
402808-78-0 402808-80-4 402808-85-9  
402808-93-9 402809-12-5

RL: BSU (Biological study, unclassified); PRP (Properties); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(NCH ribozyme specific for human HER2/neu mRNA; nucleic acid-based  
ribozyme and DNazyme modulators of gene expression)

RN 402796-95-6 CAPLUS  
CN RNA, (G-G-G-G-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-A-

C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402796-98-9 CAPLUS

CN RNA, (A-C-C-A-A-A-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402797-02-8 CAPLUS

CN RNA, (C-U-G-C-C-C-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402797-14-2 CAPLUS

CN RNA, (C-A-G-U-A-A-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402797-21-1 CAPLUS

CN RNA, (G-G-G-G-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402797-48-2 CAPLUS

CN RNA, (G-G-C-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-C-C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402797-57-3 CAPLUS

CN RNA, (C-G-G-C-A-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-G-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402797-94-8 CAPLUS

CN RNA, (U-C-C-A-G-G-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-U-C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402798-13-4 CAPLUS

CN RNA, (G-A-G-U-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402798-28-1 CAPLUS

CN RNA, (G-A-A-G-G-A-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402798-44-1 CAPLUS

CN RNA, (C-C-U-C-A-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-G-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402798-67-8 CAPLUS

CN RNA, (G-U-U-C-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402798-79-2 CAPLUS

CN RNA, (C-C-U-G-G-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-C

C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402798-85-0 CAPLUS

CN RNA, (C-U-C-C-C-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402798-90-7 CAPLUS

CN RNA, (C-U-C-U-G-U-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-U-C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402798-98-5 CAPLUS

CN RNA, (G-A-G-C-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402799-15-9 CAPLUS

CN RNA, (A-G-C-C-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-G-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402799-28-4 CAPLUS

CN RNA, (G-G-G-U-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-G-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402799-45-5 CAPLUS

CN RNA, (G-C-G-C-G-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-C-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402799-56-8 CAPLUS

CN RNA, (U-G-G-G-C-A-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402799-72-8 CAPLUS

CN RNA, (G-U-G-C-U-U-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-G-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402799-82-0 CAPLUS

CN RNA, (U-G-G-A-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402799-90-0 CAPLUS

CN RNA, (G-C-C-A-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-G-A-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402800-01-5 CAPLUS

CN RNA, (G-U-G-A-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402800-48-0 CAPLUS

CN RNA, (C-A-C-C-U-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-G-

U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402800-56-0 CAPLUS

CN RNA, (G-G-G-C-A-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-U-G-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402800-77-5 CAPLUS

CN RNA, (A-A-A-U-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-C-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402800-83-3 CAPLUS

CN RNA, (G-G-A-G-G-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402800-86-6 CAPLUS

CN RNA, (G-U-G-U-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402800-98-0 CAPLUS

CN RNA, (G-C-U-G-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-16-5 CAPLUS

CN RNA, (G-U-C-A-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-20-1 CAPLUS

CN RNA, (G-A-C-G-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-A-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-26-7 CAPLUS

CN RNA, (U-A-C-U-U-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-36-9 CAPLUS

CN RNA, (C-C-U-U-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-A-G-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-52-9 CAPLUS

CN RNA, (U-G-G-A-U-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-G-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-73-4 CAPLUS

CN RNA, (A-A-A-G-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-77-8 CAPLUS

CN RNA, (U-U-G-G-U-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-

C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-92-7 CAPLUS

CN RNA, (C-G-U-C-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-G-G-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-94-9 CAPLUS

CN RNA, (G-C-A-G-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402801-96-1 CAPLUS

CN RNA, (U-G-G-U-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-09-9 CAPLUS

CN RNA, (A-C-U-G-G-G-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-18-0 CAPLUS

CN RNA, (A-A-G-G-A-A-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-22-6 CAPLUS

CN RNA, (G-C-A-C-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-43-1 CAPLUS

CN RNA, (C-A-U-U-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-A-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-49-7 CAPLUS

CN RNA, (C-C-A-A-A-A-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-A-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-53-3 CAPLUS

CN RNA, (C-A-C-A-C-A-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-A-G-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-55-5 CAPLUS

CN RNA, (U-G-G-G-C-A-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-61-3 CAPLUS

CN RNA, (G-A-A-G-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-68-0 CAPLUS

CN RNA, (G-G-G-C-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-

C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-75-9 CAPLUS

CN RNA, (A-G-A-G-G-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-U-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-77-1 CAPLUS

CN RNA, (G-U-A-G-G-A-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-A-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402802-92-0 CAPLUS

CN RNA, (U-G-G-G-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402803-07-0 CAPLUS

CN RNA, (G-U-C-A-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-A-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402803-16-1 CAPLUS

CN RNA, (A-G-A-G-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-C-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402803-18-3 CAPLUS

CN RNA, (C-G-U-C-A-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402803-52-5 CAPLUS

CN RNA, (C-U-G-C-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402803-72-9 CAPLUS

CN RNA, (A-C-U-U-U-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402803-82-1 CAPLUS

CN RNA, (U-C-U-U-U-G-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-U-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402804-18-6 CAPLUS

CN RNA, (C-C-G-G-A-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-U-A-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402804-28-8 CAPLUS

CN RNA, (G-U-U-C-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402804-49-3 CAPLUS

CN RNA, (U-U-U-G-A-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-G-

G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402804-83-5 CAPLUS

CN RNA, (U-A-A-G-G-U-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402804-85-7 CAPLUS

CN RNA, (C-A-U-C-G-U-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-U-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402804-90-4 CAPLUS

CN RNA, (A-U-C-U-C-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402804-95-9 CAPLUS

CN RNA, (U-U-C-C-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-A-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-03-2 CAPLUS

CN RNA, (A-G-A-U-G-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-19-0 CAPLUS

CN RNA, (G-G-A-A-U-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-G-A-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-27-0 CAPLUS

CN RNA, (G-G-G-U-C-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-29-2 CAPLUS

CN RNA, (G-C-G-C-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-39-4 CAPLUS

CN RNA, (A-C-U-G-G-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-A-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-42-9 CAPLUS

CN RNA, (A-A-G-G-G-A-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-58-7 CAPLUS

CN RNA, (A-U-C-C-A-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-72-5 CAPLUS

CN RNA, (C-G-G-G-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-U-

G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-93-0 CAPLUS

CN RNA, (U-A-G-U-G-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402805-98-5 CAPLUS

CN RNA, (C-U-U-C-A-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-C-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-02-4 CAPLUS

CN RNA, (G-A-C-C-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-19-3 CAPLUS

CN RNA, (C-A-U-U-C-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-A-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-22-8 CAPLUS

CN RNA, (A-G-C-C-C-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-26-2 CAPLUS

CN RNA, (U-G-U-G-G-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-U-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-34-2 CAPLUS

CN RNA, (A-G-G-G-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-A-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-38-6 CAPLUS

CN RNA, (C-U-G-U-A-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-44-4 CAPLUS

CN RNA, (U-A-C-U-G-U-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-65-9 CAPLUS

CN RNA, (G-G-G-C-U-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-A-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-68-2 CAPLUS

CN RNA, (A-G-G-C-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-73-9 CAPLUS

CN RNA, (C-A-U-A-U-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-



G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-75-1 CAPLUS

CN RNA, (A-U-C-U-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-A-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-77-3 CAPLUS

CN RNA, (G-A-A-C-A-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-79-5 CAPLUS

CN RNA, (G-G-G-G-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-G-A-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-83-1 CAPLUS

CN RNA, (G-C-G-A-A-G-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402806-91-1 CAPLUS

CN RNA, (A-G-G-C-A-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-00-5 CAPLUS

CN RNA, (C-A-C-C-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-07-2 CAPLUS

CN RNA, (G-A-G-U-C-U-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-U-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-21-0 CAPLUS

CN RNA, (G-U-A-C-U-C-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-36-7 CAPLUS

CN RNA, (G-A-G-G-G-U-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-A-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-50-5 CAPLUS

CN RNA, (G-A-A-G-G-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-A-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-53-8 CAPLUS

CN RNA, (U-U-G-U-C-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-56-1 CAPLUS

CN RNA, (G-U-A-A-U-A-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-G-

U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-60-7 CAPLUS

CN RNA, (U-G-G-G-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-62-9 CAPLUS

CN RNA, (C-U-C-U-G-G-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-C-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-81-2 CAPLUS

CN RNA, (G-U-A-C-U-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-89-0 CAPLUS

CN RNA, (G-G-C-C-U-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-A-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-91-4 CAPLUS

CN RNA, (G-C-G-G-A-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-U-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402807-95-8 CAPLUS

CN RNA, (C-A-C-A-U-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-U-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-02-0 CAPLUS

CN RNA, (A-G-A-A-G-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-U-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-09-7 CAPLUS

CN RNA, (G-G-U-C-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-C-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-13-3 CAPLUS

CN RNA, (C-U-G-G-A-A-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-G-G-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-18-8 CAPLUS

CN RNA, (G-C-A-U-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-24-6 CAPLUS

CN RNA, (U-U-A-G-G-A-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-28-0 CAPLUS

CN RNA, (G-G-A-A-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-C-

C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-41-7 CAPLUS

CN RNA, (U-C-C-A-A-C-G-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-G-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-48-4 CAPLUS

CN RNA, (U-U-G-G-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-U-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-61-1 CAPLUS

CN RNA, (C-C-A-A-G-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-G-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-65-5 CAPLUS

CN RNA, (A-A-G-G-A-A-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-A-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-75-7 CAPLUS

CN RNA, (U-U-C-C-C-U-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-U-U-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-78-0 CAPLUS

CN RNA, (C-C-C-U-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-A-G-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-80-4 CAPLUS

CN RNA, (U-C-C-C-U-U-A-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-C-C-G-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-85-9 CAPLUS

CN RNA, (U-C-U-G-A-A-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-G-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402808-93-9 CAPLUS

CN RNA, (C-A-G-U-A-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-U-U-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 402809-12-5 CAPLUS

CN RNA, (U-C-C-C-C-C-U-C-U-G-A-U-G-A-G-G-C-C-G-A-A-A-G-G-C-C-G-A-A-I-G-U-C-U-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 401962-96-7 401963-17-5 401963-20-0

401963-47-1 401963-67-5 401964-51-0

401964-92-9 401965-02-4 401965-21-7

401965-29-5 401965-41-1 401965-44-4

401965-46-6

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NCH ribozyme specific for human phospholamban mRNA; nucleic acid-based ribozyme and DNazyme modulators of gene expression)

RN 401962-96-7 CAPLUS  
CN RNA, (U-G-A-A-G-U-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-G-A-G-A) (9CI) (CA INDEX NAME)

SEQ 1 ugaaguuuu guagaggccg uuaggccgaa igucgaga

RN 401963-17-5 CAPLUS  
CN RNA, (U-U-U-C-A-A-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-U-U-C) (9CI) (CA INDEX NAME)

SEQ 1 uuucaaugcu gaugaggccg uuaggccgaa igcucuuc

RN 401963-20-0 CAPLUS  
CN RNA, (G-A-G-G-C-A-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-A-G-G) (9CI) (CA INDEX NAME)

SEQ 1 gaggcauucu gaugaggccg uuaggccgaa iguugagg

RN 401963-47-1 CAPLUS  
CN RNA, (C-U-G-C-A-G-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-U-A-G) (9CI) (CA INDEX NAME)

SEQ 1 cugcagaucu gaugaggccg uuaggccgaa iguuguag

RN 401963-67-5 CAPLUS  
CN RNA, (C-U-A-C-U-C-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-G-U-U) (9CI) (CA INDEX NAME)

SEQ 1 cuacucagcu gaugaggccg uuaggccgaa igucuguu

RN 401964-51-0 CAPLUS  
CN RNA, (U-A-U-G-U-A-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-U-A-C) (9CI) (CA INDEX NAME)

SEQ 1 uauguaagcu gaugaggccg uuaggccgaa igccuuac

RN 401964-92-9 CAPLUS  
CN RNA, (U-C-U-G-A-A-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-C-A-U) (9CI) (CA INDEX NAME)

SEQ 1 ucugaagucu gaugaggccg uuaggccgaa iguuuau

RN 401965-02-4 CAPLUS

CN RNA, (G-C-A-U-U-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-A-A) (9CI) (CA INDEX NAME)

SEQ 1 gcuuuggacu gaugaggccg uuaggccgaa igcuggaa

RN 401965-21-7 CAPLUS

CN RNA, (G-A-U-G-U-A-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-A-C-A) (9CI) (CA INDEX NAME)

SEQ 1 gauguaaucu gaugaggccg uuaggccgaa igccaaca

RN 401965-29-5 CAPLUS

CN RNA, (C-C-C-C-A-U-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-A-G-C-U) (9CI) (CA INDEX NAME)

SEQ 1 ccccaugucu gaugaggccg uuaggccgaa igucagcu

RN 401965-41-1 CAPLUS

CN RNA, (A-U-G-G-U-C-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-A-U-U-A) (9CI) (CA INDEX NAME)

SEQ 1 auggucaacu gaugaggccg uuaggccgaa igcuauua

RN 401965-44-4 CAPLUS

CN RNA, (C-A-G-U-A-A-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-A-A-U-A) (9CI) (CA INDEX NAME)

SEQ 1 caguaaggcu gaugaggccg uuaggccgaa igucaaua

RN 401965-46-6 CAPLUS

CN RNA, (A-U-G-U-U-A-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-A-U-G) (9CI) (CA INDEX NAME)

SEQ 1 auguuauccu gaugaggccg uuaggccgaa iguuuau

=> d ibib ed abs hitseq l47 2-14; fil hom

L47 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:598168 CAPLUS

DOCUMENT NUMBER: 135:192168

TITLE: Enzymic nucleic acids for the modulation and diagnosis of human CD20 and NOGO gene expression

INVENTOR(S): Blatt, Lawrence; Mcswiggen, James; Chowrira, Bharat M.

PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 200 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2001059103 A2		20010816	WO 2001-US4273	20010209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR,				
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,				
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				
MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,				
BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB,				
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR				
PRIORITY APPLN. INFO.:			US 2000-PV181797	20000211
			US 2000-PV185516	20000228
			US 2000-PV187128	20000306

ED Entered STN: 17 Aug 2001

AB The present invention relates to nucleic acid mols., including antisense and enzymic nucleic acid mols., such as hammerhead ribozymes, DNazymes, and antisense oligonucleotides, which modulate the expression of the human CD20 and/or NOGO genes. The known sequences of human CD20 and NOGO mRNAs are screened for accessible sites using a computer-folding algorithm for regions that do not form secondary folding structures and thus may act as binding/cleaving sites. Thousands of target site and enzymic nucleic acid sequences are provided (hammerhead, Inozymes G-cleaver, Zinzymes Amberzymes, and DNazymes). Several oncol. models in rodent, rabbit, and non-human primates are utilized to evaluate the therapeutic potential of anti-CD20 enzymic nucleic acids. Diagnostic systems and methods for detecting the presence of nucleic acids are further disclosed, using a ribozyme effector mol. and nucleic acid inhibitors complementary to the ribozyme and nucleic acid-based reporter mols. [This abstract record is the first of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 355872-41-2P 355872-44-5P 355872-59-2P  
 355872-61-6P 355872-69-4P 355872-77-4P  
 355873-29-9P 355873-54-0P 355873-92-6P  
 355874-11-2P 355874-22-5P 355874-65-6P  
 355874-68-9P 355874-77-0P 355874-96-3P  
 355875-07-9P 355875-34-2P 355875-56-8P

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Inozyme specific for human CD20 mRNA; enzymic nucleic acids for the modulation and diagnosis of human CD20 and NOGO gene expression)

RN 355872-41-2 CAPLUS  
CN RNA, (A-A-U-C-U-C-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-A-U-U) (9CI) (CA INDEX NAME)

SEQ 1 aaucucaacu gaugaggccg uuaggccgaa igcugauu

RN 355872-44-5 CAPLUS  
CN RNA, (A-G-U-C-U-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-A-A) (9CI) (CA INDEX NAME)

SEQ 1 agucuccacu gaugaggccg uuaggccgaa igccucaa

RN 355872-59-2 CAPLUS  
CN RNA, (C-C-U-U-U-C-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-U-G-C) (9CI) (CA INDEX NAME)

SEQ 1 ccuuucaucu gaugaggccg uuaggccgaa igcucugc

RN 355872-61-6 CAPLUS  
CN RNA, (U-A-G-C-A-A-U-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-U-U-C) (9CI) (CA INDEX NAME)

SEQ 1 uagcaauacu gaugaggccg uuaggccgaa igccuuuc

RN 355872-69-4 CAPLUS  
CN RNA, (C-U-G-A-A-G-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 cugaagagcu gaugaggccg uuaggccgaa iguuuugg

RN 355872-77-4 CAPLUS  
CN RNA, (U-U-U-G-C-G-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-A-C-C) (9CI) (CA INDEX NAME)

SEQ 1 uuugcgugcu gaugaggccg uuaggccgaa igcccacc

RN 355873-29-9 CAPLUS  
CN RNA, (C-A-G-C-A-A-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-A-A-U) (9CI) (CA INDEX NAME)

SEQ 1 cagcaaagcu gaugaggccg uuaggccgaa igcucaau

RN 355873-54-0 CAPLUS  
CN RNA, (G-G-A-U-U-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-A-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ggauuagccu gaugaggccg uuaggccgaa iguucaca

RN 355873-92-6 CAPLUS  
CN RNA, (U-U-A-G-A-U-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-G-G-A) (9CI) (CA INDEX NAME)

SEQ 1 uuagauuucu gaugaggccg uuaggccgaa igucugga

RN 355874-11-2 CAPLUS  
CN RNA, (U-C-A-U-U-C-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-G-G-A) (9CI) (CA INDEX NAME)

SEQ 1 ucauucuucu gaugaggccg uuaggccgaa iguuggga

RN 355874-22-5 CAPLUS  
CN RNA, (U-C-U-U-G-G-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ucuuggggcu gaugaggccg uuaggccgaa iguucugg

RN 355874-65-6 CAPLUS  
CN RNA, (C-C-A-U-G-C-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-G-A-U) (9CI) (CA INDEX NAME)

SEQ 1 ccaugcaacu gaugaggccg uuaggccgaa igccagau

RN 355874-68-9 CAPLUS  
CN RNA, (A-G-G-A-G-C-U-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-A-C-U-C) (9CI) (CA INDEX NAME)

SEQ 1 aggagcuacu gaugaggccg uuaggccgaa igucacuc

RN 355874-77-0 CAPLUS  
CN RNA, (U-G-C-U-A-C-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-A-C-A-U) (9CI) (CA INDEX NAME)



SEQ 1 ugcuaacaacu gaugaggccg uuaggccgaa igcuacau

RN 355874-96-3 CAPLUS

CN RNA, (C-A-A-G-G-A-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-A-G-U-A) (9CI) (CA INDEX NAME)

SEQ 1 caaggaaccu gaugaggccg uuaggccgaa iguuagua

RN 355875-07-9 CAPLUS

CN RNA, (A-G-U-C-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-C-U-G) (9CI) (CA INDEX NAME)

SEQ 1 agucuccccu gaugaggccg uuaggccgaa iguugcug

RN 355875-34-2 CAPLUS

CN RNA, (A-A-U-G-G-A-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-U-G-U) (9CI) (CA INDEX NAME)

SEQ 1 aauggaauuc gaugaggccg uuaggccgaa iguucugu

RN 355875-56-8 CAPLUS

CN RNA, (A-U-G-G-G-U-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-A-U-U-U) (9CI) (CA INDEX NAME)

SEQ 1 augggugucu gaugaggccg uuaggccgaa igcuauuu

L47 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:475327 CAPLUS

DOCUMENT NUMBER: 135:207449

TITLE: Nucleic acid-based ribozyme and DNzyme modulators of gene expression

INVENTOR(S): McSwiggen, James; Usman, Nassim; Blatt, Lawrence; Beigelman, Leonid; Burgin, Alex; Karpeisky, Alexander; Matulic-Adamic, Jasenka; Sweedler, David; Draper, Kenneth; Chowrira, Bharat; Stinchcomb, Dan; Beaudry, Amber; Zinnen, Shawn; Lugwig, Janos; Sproat, Brian S.

PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 717 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016312 A2		20010308	WO 2000-US23998	20000830
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1999-PV151713	19990831
			US 1999-406643	19990927
			US 1999-PV156467	19990927
			US 1999-PV156236	19990927
			US 1999-436430	19991108
			US 1999-PV169100	19991206
			US 1999-PV173612	19991229
			US 1999-474432	19991229
			US 1999-476387	19991230
			US 2000-498824	20000204
			US 2000-531025	20000320
			US 2000-PV197769	20000414
			US 2000-578223	20000523

ED Entered STN: 03 Jul 2001

AB Novel nucleic acid mols. useful as inhibitors of gene expression, compns., and methods for their use are provided. The invention features novel nucleic acid-based techniques (e.g., enzymic nucleic acid mols. (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, and antisense nucleic acids containing RNA-cleaving chemical groups) and their use to modulate the expression of mol. targets impacting the development and progression of cancers, diabetes, obesity, Alzheimer's disease diseases, age-related diseases, and/or hepatitis B infections and related conditions. Catalytic nucleic acids were designed for site-specific cleavage of human mRNA targets encoding protein tyrosine phosphatase 1b, methionine aminopeptidase,  $\beta$ -secretase, presenilin-1, epidermal growth factor receptor-2 (HER2/c-erb2/neu), phospholamban, telomerase, and hepatitis B virus genes. Methods for chemical synthesis of modified nucleoside triphosphates (NTPs) and RNA polymerase-catalyzed incorporation of modified NTPs into catalytic oligonucleotides are also provided. [This abstract record os one of 6 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 358419-67-7 358419-74-6 358419-77-9  
 358419-82-6 358419-84-8 358419-98-4  
 358420-04-9 358420-17-4 358420-21-0  
 358420-39-0 358420-62-9 358420-64-1  
 358420-67-4 358420-70-9 358420-74-3  
 358420-91-4 358421-05-3 358421-07-5  
 358421-10-0 358421-13-3 358421-18-8  
 358421-21-3 358421-50-8 358421-64-4  
 358421-66-6 358421-72-4 358421-80-4  
 358422-21-6 358422-35-2 358422-43-2  
 358422-70-5 358422-75-0 358422-81-8 35842  
 2-88-5 358422-94-3 358423-11-7  
 358423-15-1 358423-20-8 358423-50-4  
 358423-62-8 358423-98-0 358424-14-3  
 358424-16-5 358424-38-1 358424-48-3  
 358424-64-3 358424-68-7 358424-70-1  
 358425-10-2 358425-18-0 358425-33-9  
 358425-39-5 358425-79-3 358425-82-8  
 358425-93-1 358426-14-9 358426-21-8

358426-31-0

RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); PRP (Properties); THU (Therapeutic  
use); BIOL (Biological study); USES (Uses)  
(NCH ribozyme specific for human BACE; nucleic acid-based ribozyme and  
DNAzyme modulators of gene expression)

RN 358419-67-7 CAPLUS

CN RNA, (U-C-C-C-G-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-  
G-C-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ucccgggccu gaugaggccg uuaggccgaa igcugcgg

RN 358419-74-6 CAPLUS

CN RNA, (G-G-C-U-G-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-  
A-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ggcugcuccu gaugaggccg uuaggccgaa igccacca

RN 358419-77-9 CAPLUS

CN RNA, (G-G-C-U-G-C-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-  
G-C-U-C) (9CI) (CA INDEX NAME)

SEQ 1 ggcugcgucu gaugaggccg uuaggccgaa igcugcuc

RN 358419-82-6 CAPLUS

CN RNA, (A-G-G-G-C-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-  
C-C-U-G) (9CI) (CA INDEX NAME)

SEQ 1 agggcucccu gaugaggccg uuaggccgaa igcuccug

RN 358419-84-8 CAPLUS

CN RNA, (A-G-G-G-G-C-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-  
C-C-G-G) (9CI) (CA INDEX NAME)

SEQ 1 aggggcaacu gaugaggccg uuaggccgaa igcuccgg

RN 358419-98-4 CAPLUS

CN RNA, (G-G-C-U-U-C-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-  
C-C-C-C) (9CI) (CA INDEX NAME)

SEQ 1 ggcucccccu gaugaggccg uuaggccgaa iguccccc

RN 358420-04-9 CAPLUS  
CN RNA, (G-G-C-A-U-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-G-U-G) (9CI) (CA INDEX NAME)

SEQ 1 ggcauggccu gaugaggccg uuaggccgaa igccggug

RN 358420-17-4 CAPLUS  
CN RNA, (U-C-C-C-G-G-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G-A) (9CI) (CA INDEX NAME)

SEQ 1 ucccggcgc u gaugaggccg uuaggccgaa igcuggga

RN 358420-21-0 CAPLUS  
CN RNA, (G-C-G-G-G-C-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-C-C-G) (9CI) (CA INDEX NAME)

SEQ 1 gcggggcgc u gaugaggccg uuaggccgaa igcucccg

RN 358420-39-0 CAPLUS  
CN RNA, (C-A-G-G-G-G-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G-A) (9CI) (CA INDEX NAME)

SEQ 1 caggggagc u gaugaggccg uuaggccgaa igcuggga

RN 358420-62-9 CAPLUS  
CN RNA, (C-C-G-G-G-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ccggguccu gaugaggccg uuaggccgaa igcugugg

RN 358420-64-1 CAPLUS  
CN RNA, (C-A-G-C-C-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 cagcccccu gaugaggccg uuaggccgaa iguccggg

RN 358420-67-4 CAPLUS  
CN RNA, (A-G-G-G-C-C-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-G-C-C) (9CI) (CA INDEX NAME)

SEQ 1 agggcccuc u gaugaggccg uuaggccgaa igccagcc

RN 358420-70-9 CAPLUS  
CN RNA, (G-G-C-C-U-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ggccugcacu gaugaggccg uuaggccgaa igcccugg

RN 358420-74-3 CAPLUS  
CN RNA, (G-G-A-C-G-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ggacgccacu gaugaggccg uuaggccgaa igccugca

RN 358420-91-4 CAPLUS  
CN RNA, (G-G-U-G-C-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-C-U-C) (9CI) (CA INDEX NAME)

SEQ 1 ggugcuggcu gaugaggccg uuaggccgaa igcuucuc

RN 358421-05-3 CAPLUS  
CN RNA, (G-C-U-C-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-A-C-G) (9CI) (CA INDEX NAME)

SEQ 1 gcucgcaccu gaugaggccg uuaggccgaa igcccacg

RN 358421-07-5 CAPLUS  
CN RNA, (G-G-C-C-C-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ggcccucucu gaugaggccg uuaggccgaa igcucgca

RN 358421-10-0 CAPLUS  
CN RNA, (C-G-G-C-C-U-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-U-C-U) (9CI) (CA INDEX NAME)

SEQ 1 cggccuuccu gaugaggccg uuaggccgaa igcccucu

RN 358421-13-3 CAPLUS  
CN RNA, (G-C-C-A-U-G-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-C-G-G) (9CI) (CA INDEX NAME)

SEQ 1 gccauggucu gaugaggccg uuaggccgaa igccccgg

RN 358421-18-8 CAPLUS  
CN RNA, (C-A-G-G-G-C-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 cagggcuucu gaugaggccg uuaggccgaa igccaugg

RN 358421-21-3 CAPLUS  
CN RNA, (C-C-A-G-G-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ccagggcacu gaugaggccg uuaggccgaa igcuuggg

RN 358421-50-8 CAPLUS  
CN RNA, (C-G-C-C-C-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-C-U-G) (9CI) (CA INDEX NAME)

SEQ 1 cgcccccccu gaugaggccg uuaggccgaa igccgcug

RN 358421-64-4 CAPLUS  
CN RNA, (G-G-C-U-C-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-U-U-C) (9CI) (CA INDEX NAME)

SEQ 1 ggcuccuccu gaugaggccg uuaggccgaa igcucuuc

RN 358421-66-6 CAPLUS  
CN RNA, (C-U-C-C-G-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-C-U-C) (9CI) (CA INDEX NAME)

SEQ 1 cuccggcccu gaugaggccg uuaggccgaa igcuccuc

RN 358421-72-4 CAPLUS  
CN RNA, (U-G-C-C-C-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-U-C-C) (9CI) (CA INDEX NAME)

SEQ 1 ugccccuccu gaugaggccg uuaggccgaa iguugucc

RN 358421-80-4 CAPLUS  
CN RNA, (U-C-U-G-C-G-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-C-C) (9CI) (CA INDEX NAME)

SEQ 1 ucugcgggcu gaugaggccg uuaggccgaa igcugccc

RN 358422-21-6 CAPLUS  
CN RNA, (C-C-U-U-C-C-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-C-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ccuuccggcu gaugaggccg uuaggccgaa igucccg

RN 358422-35-2 CAPLUS  
CN RNA, (U-G-C-U-U-A-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-G-G-U-G) (9CI) (CA INDEX NAME)

SEQ 1 ugcuuacccu gaugaggccg uuaggccgaa igucggug

RN 358422-43-2 CAPLUS  
CN RNA, (U-G-A-C-G-U-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ugacguugcu gaugaggccg uuaggccgaa igccaugg

RN 358422-70-5 CAPLUS  
CN RNA, (C-U-C-A-G-C-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-G-C-C) (9CI) (CA INDEX NAME)

SEQ 1 cucagcaucu gaugaggccg uuaggccgaa igccagcc

RN 358422-75-0 CAPLUS  
CN RNA, (G-A-G-U-C-G-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-G-G-C) (9CI) (CA INDEX NAME)

SEQ 1 gagucguccu gaugaggccg uuaggccgaa igccuggc

RN 358422-81-8 CAPLUS  
CN RNA, (U-C-A-A-A-G-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 ucaaagaacu gaugaggccg uuaggccgaa igcuccag

RN 358422-88-5 CAPLUS  
CN RNA, (G-G-G-A-A-C-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-G-C-U) (9CI) (CA INDEX NAME)

SEQ 1 gggaacgucu gaugaggccg uuaggccgaa igucugcu

RN 358422-94-3 CAPLUS  
CN RNA, (G-G-G-A-G-A-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-G-G-A) (9CI) (CA INDEX NAME)

SEQ 1 gggagaagcu gaugaggccg uuaggccgaa iguuggga

RN 358423-11-7 CAPLUS  
CN RNA, (C-U-U-C-A-G-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-A-G-G) (9CI) (CA INDEX NAME)

SEQ 1 cuucagaccu gaugaggccg uuaggccgaa iguugagg

RN 358423-15-1 CAPLUS  
CN RNA, (U-C-C-G-A-C-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 uccgacagcu gaugaggccg uuaggccgaa igccagca

RN 358423-20-8 CAPLUS  
CN RNA, (A-C-A-G-C-G-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-G-A-U-A) (9CI) (CA INDEX NAME)

SEQ 1 acagcgagcu gaugaggccg uuaggccgaa igucgaua

RN 358423-50-4 CAPLUS  
CN RNA, (G-C-A-A-A-C-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-G-U-G) (9CI) (CA INDEX NAME)

SEQ 1 gcaaacgacu gaugaggccg uuaggccgaa iguuggug

RN 358423-62-8 CAPLUS  
CN RNA, (C-G-U-G-G-A-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-C-U) (9CI) (CA INDEX NAME)



SEQ 1 cguggaggcu gaugaggccg uuaggccgaa igcugccu

RN 358423-98-0 CAPLUS

CN RNA, (G-G-A-A-G-G-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-G-U-A) (9CI) (CA INDEX NAME)

SEQ 1 ggaaggaccu gaugaggccg uuaggccgaa iguuggua

RN 358424-14-3 CAPLUS

CN RNA, (U-C-U-U-C-C-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 ucuuccaccu gaugaggccg uuaggccgaa igccgcag

RN 358424-16-5 CAPLUS

CN RNA, (U-U-G-G-G-A-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-C-A-U) (9CI) (CA INDEX NAME)

SEQ 1 uugggacgcu gaugaggccg uuaggccgaa igccacau

RN 358424-38-1 CAPLUS

CN RNA, (U-C-G-U-U-U-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-G-A-U) (9CI) (CA INDEX NAME)

SEQ 1 ucguuuuccu gaugaggccg uuaggccgaa igcccgau

RN 358424-48-3 CAPLUS

CN RNA, (U-G-A-C-A-A-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-U-C-C) (9CI) (CA INDEX NAME)

SEQ 1 ugacaaaacu gaugaggccg uuaggccgaa igccuucc

RN 358424-64-3 CAPLUS

CN RNA, (G-G-U-C-A-U-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-A-C-U) (9CI) (CA INDEX NAME)

SEQ 1 ggucaugacu gaugaggccg uuaggccgaa iguugacu

RN 358424-68-7 CAPLUS  
CN RNA, (A-U-A-G-G-C-U-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-A-U-G-A) (9CI) (CA INDEX NAME)

SEQ 1 auaggcuacu gaugaggccg uuaggccgaa igucauga

RN 358424-70-1 CAPLUS  
CN RNA, (C-A-U-G-A-C-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-A-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 caugacauacu gaugaggccg uuaggccgaa igcuaugg

RN 358425-10-2 CAPLUS  
CN RNA, (C-U-G-C-C-C-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-C-U) (9CI) (CA INDEX NAME)

SEQ 1 cugcccaucu gaugaggccg uuaggccgaa igccuccu

RN 358425-18-0 CAPLUS  
CN RNA, (C-G-G-A-G-G-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-A-G-G) (9CI) (CA INDEX NAME)

SEQ 1 cggaggugcu gaugaggccg uuaggccgaa iguccagg

RN 358425-33-9 CAPLUS  
CN RNA, (A-G-G-U-G-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 agguguccu gaugaggccg uuaggccgaa igccacag

RN 358425-39-5 CAPLUS  
CN RNA, (G-G-U-G-G-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-U-G-A) (9CI) (CA INDEX NAME)

SEQ 1 gguggggacu gaugaggccg uuaggccgaa iguccuga

RN 358425-79-3 CAPLUS  
CN RNA, (A-A-G-G-U-U-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-A-A-G) (9CI) (CA INDEX NAME)

SEQ 1 aagguucacu gaugaggccg uuaggccgaa igcugaag

RN 358425-82-8 CAPLUS  
CN RNA, (G-U-G-G-A-C-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-A-G-G) (9CI) (CA INDEX NAME)

SEQ 1 guggacaacu gaugaggccg uuaggccgaa iguucagg

RN 358425-93-1 CAPLUS  
CN RNA, (A-A-U-A-C-U-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-G-A-G) (9CI) (CA INDEX NAME)

SEQ 1 aaauacuucu gaugaggccg uuaggccgaa iguuggag

RN 358426-14-9 CAPLUS  
CN RNA, (C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-C-U-U) (9CI) (CA INDEX NAME)

SEQ 1 cugaugaggc cguuaggccg aaigucucuu

RN 358426-21-8 CAPLUS  
CN RNA, (A-C-U-G-A-C-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 acugacuucu gaugaggccg uuaggccgaa igccagca

RN 358426-31-0 CAPLUS  
CN RNA, (C-C-A-A-U-G-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-G-U-U) (9CI) (CA INDEX NAME)

SEQ 1 ccaauguucu gaugaggccg uuaggccgaa igcuuguu

L47 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:400023 CAPLUS  
Correction of: 2001:294219

DOCUMENT NUMBER: 135:16022  
Correction of: 134:337614

TITLE: Nucleic acid-based ribozyme and DNzyme modulators of gene expression

INVENTOR(S): McSwiggen, James; Usman, Nassim; Blatt, Lawrence; Beigelman, Leonid; Burgin, Alex; Karpeisky, Alexander; Matulic-adamic, Jasenka; Sweedler, David; Draper, Kenneth; Chowrira, Bharat; Stinchcomb, Dan; Beaudry,

PATENT ASSIGNEE(S): Amber; Zinnen, Shawn; Lugwig, Janos; Sproat, Brian S.  
 SOURCE: Ribozyme Pharmaceuticals, Inc., USA  
 PCT Int. Appl., 717 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016312 A2		20010308	WO 2000-US23998	20000830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-PV151713	19990831
			US 1999-406643	19990927
			US 1999-PV156467	19990927
			US 1999-PV156236	19990927
			US 1999-436430	19991108
			US 1999-PV169100	19991206
			US 1999-PV173612	19991229
			US 1999-474432	19991229
			US 1999-476387	19991230
			US 2000-498824	20000204
			US 2000-531025	20000320
			US 2000-PV197769	20000414
			US 2000-578223	20000523

ED Entered STN: 05 Jun 2001

AB Novel nucleic acid mols. useful as inhibitors of gene expression, compns., and methods for their use are provided. The invention features novel nucleic acid-based techniques (e.g., enzymic nucleic acid mols. (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, and antisense nucleic acids containing RNA-cleaving chemical groups) and their use to modulate the expression of mol. targets impacting the development and progression of cancers, diabetes, obesity, Alzheimer's disease diseases, age-related diseases, and/or hepatitis B infections and related conditions. Catalytic nucleic acids were designed for site-specific cleavage of human mRNA targets encoding protein tyrosine phosphatase 1b, methionine aminopeptidase,  $\beta$ -secretase, presenilin-1, epidermal growth factor receptor-2 (HER2/c-erb2/neu), phospholamban, telomerase, and hepatitis B virus genes. Methods for chemical synthesis of modified nucleoside triphosphates (NTPs) and RNA polymerase-catalyzed incorporation of modified NTPs into catalytic oligonucleotides are also provided. [This abstract record os one of 6 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 341558-79-0 341558-82-5 341558-86-9  
 341558-97-2 341559-00-0 341559-06-6  
 341559-09-9 341559-18-0 341559-22-6  
 341559-31-7 341559-61-3 341559-69-1  
 341560-10-9 341560-18-7 341560-32-5  
 341560-50-7 341560-90-5 341561-08-8  
 341561-18-0 341561-57-7 341561-79-3  
 341561-94-2 341561-97-5 341562-06-9  
 341562-14-9 341562-25-2 341562-91-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)  
(NCH ribozyme specific for human methionine aminopeptidase type 2;  
nucleic acid-based ribozyme and DNAzyme modulators of gene expression)

RN 341558-79-0 CAPLUS  
CN RNA, (G-C-U-C-C-C-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-C-U-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341558-82-5 CAPLUS  
CN RNA, (C-A-U-U-C-A-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-C-C-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341558-86-9 CAPLUS  
CN RNA, (C-U-G-G-A-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-G-C-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341558-97-2 CAPLUS  
CN RNA, (U-U-U-U-U-U-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341559-00-0 CAPLUS  
CN RNA, (G-C-U-G-C-A-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-U-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341559-06-6 CAPLUS  
CN RNA, (U-C-U-U-U-A-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-C-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341559-09-9 CAPLUS  
CN RNA, (A-U-C-C-A-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-C-U-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341559-18-0 CAPLUS  
CN RNA, (U-G-A-A-C-U-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-U-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341559-22-6 CAPLUS  
CN RNA, (C-U-G-A-G-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-G-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341559-31-7 CAPLUS  
CN RNA, (U-A-G-G-A-U-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-A-C-A-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341559-61-3 CAPLUS  
CN RNA, (G-U-C-A-U-C-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-G-A-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341559-69-1 CAPLUS  
CN RNA, (G-A-A-A-U-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-

U-G-C-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341560-10-9 CAPLUS

CN RNA, (U-U-C-U-U-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-A-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341560-18-7 CAPLUS

CN RNA, (U-U-A-C-G-G-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-C-A-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341560-32-5 CAPLUS

CN RNA, (A-C-U-A-C-C-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-C-A-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341560-50-7 CAPLUS

CN RNA, (G-A-A-G-G-C-A-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-C-A-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341560-90-5 CAPLUS

CN RNA, (U-G-U-U-G-A-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-U-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341561-08-8 CAPLUS

CN RNA, (U-A-U-U-A-C-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-A-C-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341561-18-0 CAPLUS

CN RNA, (U-U-U-U-U-C-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-A-A-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341561-57-7 CAPLUS

CN RNA, (U-U-C-C-A-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-A-A-A-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341561-79-3 CAPLUS

CN RNA, (C-A-A-A-U-A-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-G-A-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341561-94-2 CAPLUS

CN RNA, (U-U-A-U-A-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-G-A-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341561-97-5 CAPLUS

CN RNA, (U-U-C-U-A-G-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-A-U-A-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341562-06-9 CAPLUS

CN RNA, (U-A-G-U-U-G-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-

U-U-G-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341562-14-9 CAPLUS

CN RNA, (U-C-A-G-G-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-U-U-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341562-25-2 CAPLUS

CN RNA, (G-U-U-C-U-C-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-U-A-A) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 341562-91-2 CAPLUS

CN RNA, (U-C-U-G-A-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-A-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 342825-90-5 342825-93-8 342825-96-1

342826-16-8 342826-23-7 342826-27-1

342826-34-0 342826-39-5 342826-70-4

342826-76-0 342826-81-7 342826-83-9

342826-89-5 342827-41-2 342827-43-4

342827-51-4 342827-55-8 342827-57-0

342827-66-1 342827-70-7 342827-82-1

342827-96-7 342828-10-8 342828-13-1

342828-38-0 342828-47-1 342828-62-0

342828-76-6 342828-88-0 342828-91-5

342828-96-0 342829-02-1 342829-24-7

342829-31-6 342829-58-7 342829-64-5

342829-70-3 342829-85-0 342829-91-8

342830-02-8 342830-35-7 342830-47-1

342830-60-8 342830-83-5 342830-85-7

342831-01-0 342831-07-6 342831-25-8

342831-33-8 342831-38-3 342831-44-1

342831-47-4 342831-72-5 342831-88-3

342831-91-8 342831-98-5 342832-10-4

342832-12-6 342832-24-0 342832-27-3

342832-64-8 342832-85-3 342832-90-0

342833-04-9 342833-11-8 342833-14-1

342833-20-9 342833-26-5 342833-37-8

342833-42-5 342833-61-8 342833-66-3

342833-94-7 342834-05-3 342834-17-7

342834-21-3 342834-25-7 342834-61-1

342834-76-8 342834-78-0 342834-88-2

342834-93-9 342835-01-2 342835-09-0

342835-19-2 342835-26-1 342835-32-9

342835-35-2 342835-43-2 342835-47-6

342835-74-9 342835-82-9 342836-27-5

342836-30-0 342836-35-5 342836-42-4

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); PRP (Properties); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(NCH ribozyme specific for human telomerase reverse transcriptase;

nucleic acid-based ribozyme and DNAzyme modulators of gene expression)

RN 342825-90-5 CAPLUS

CN RNA, (C-G-G-G-G-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-C-C-C) (9CI) (CA INDEX NAME)

SEQ 1 cggggccacu gaugaggccg uuaggccgaa igcuuccc

RN 342825-93-8 CAPLUS

CN RNA, (G-G-U-G-G-C-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 gguggccgcu gaugaggccg uuaggccgaa igccaggg

RN 342825-96-1 CAPLUS

CN RNA, (C-G-C-G-G-G-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 cgcgggggcu gaugaggccg uuaggccgaa igccgggg

RN 342826-16-8 CAPLUS

CN RNA, (C-G-C-G-G-U-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-G-C) (9CI) (CA INDEX NAME)

SEQ 1 cgcgguagcu gaugaggccg uuaggccgaa igcugcgc

RN 342826-23-7 CAPLUS

CN RNA, (C-A-C-G-A-A-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-G-C-G) (9CI) (CA INDEX NAME)

SEQ 1 cacgaacgcu gaugaggccg uuaggccgaa igccagcg

RN 342826-27-1 CAPLUS

CN RNA, (C-A-G-C-C-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 cagcccugcu gaugaggccg uuaggccgaa igccccag

RN 342826-34-0 CAPLUS

CN RNA, (A-A-G-C-C-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-C-C-G) (9CI) (CA INDEX NAME)

SEQ 1 aagccgcccu gaugaggccg uuaggccgaa iguccccg

RN 342826-39-5 CAPLUS

CN RNA, (C-A-G-G-C-A-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-



A-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 caggcacucu gaugaggccg uuaggccgaa igccacca

RN 342826-70-4 CAPLUS

CN RNA, (C-A-G-C-A-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 cagcacuccu gaugaggccg uuaggccgaa igccacca

RN 342826-76-0 CAPLUS

CN RNA, (G-A-A-G-C-C-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 gaagccgacu gaugaggccg uuaggccgaa igccagca

RN 342826-81-7 CAPLUS

CN RNA, (G-C-C-C-C-C-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-C-G-U) (9CI) (CA INDEX NAME)

SEQ 1 gcccccgccu gaugaggccg uuaggccgaa igccccgu

RN 342826-83-9 CAPLUS

CN RNA, (C-C-U-C-G-G-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-C-C-G) (9CI) (CA INDEX NAME)

SEQ 1 ccucggggcu gaugaggccg uuaggccgaa igcccccg

RN 342826-89-5 CAPLUS

CN RNA, (G-G-U-G-G-U-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-G-G) (9CI) (CA INDEX NAME)

SEQ 1 gguggugacu gaugaggccg uuaggccgaa igccucgg

RN 342827-41-2 CAPLUS

CN RNA, (C-G-G-G-G-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-G-A-G) (9CI) (CA INDEX NAME)

SEQ 1 cgggggcccu gaugaggccg uuaggccgaa igccugag

RN 342827-43-4 CAPLUS  
CN RNA, (U-G-U-G-G-C-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-G-G-C) (9CI) (CA INDEX NAME)

SEQ 1 uguggcgccu gaugaggccg uuaggccgaa igccgggc

RN 342827-51-4 CAPLUS  
CN RNA, (C-G-C-C-U-U-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-A-C-U) (9CI) (CA INDEX NAME)

SEQ 1 cgccuucgcu gaugaggccg uuaggccgaa iguccacu

RN 342827-55-8 CAPLUS  
CN RNA, (A-U-G-G-U-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-G-U-U) (9CI) (CA INDEX NAME)

SEQ 1 augguucccu gaugaggccg uuaggccgaa igcccguu

RN 342827-57-0 CAPLUS  
CN RNA, (U-G-A-C-G-C-U-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 ugacgcuacu gaugaggccg uuaggccgaa iguuccag

RN 342827-66-1 CAPLUS  
CN RNA, (G-G-G-C-U-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-A-G-G) (9CI) (CA INDEX NAME)

SEQ 1 gggcuggccu gaugaggccg uuaggccgaa igcccagg

RN 342827-70-7 CAPLUS  
CN RNA, (C-G-C-A-C-C-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 cgcacccgcu gaugaggccg uuaggccgaa igcuggca

RN 342827-82-1 CAPLUS  
CN RNA, (C-C-A-C-G-C-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-U-U) (9CI) (CA INDEX NAME)

SEQ 1 ccacgccucu gaugaggccg uuaggccgaa igccucuu

RN 342827-96-7 CAPLUS

CN RNA, (G-C-C-C-G-G-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-A-G-G) (9CI) (CA INDEX NAME)

SEQ 1 gcccgggucu gaugaggccg uuaggccgaa igcccagg

RN 342828-10-8 CAPLUS

CN RNA, (U-C-U-U-C-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-G-G-C) (9CI) (CA INDEX NAME)

SEQ 1 ucuucggccu gaugaggccg uuaggccgaa igucuggc

RN 342828-13-1 CAPLUS

CN RNA, (C-A-A-A-G-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-C-U-U) (9CI) (CA INDEX NAME)

SEQ 1 caaagaggcu gaugaggccg uuaggccgaa igcuucuu

RN 342828-38-0 CAPLUS

CN RNA, (U-G-G-A-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-G-C-G) (9CI) (CA INDEX NAME)

SEQ 1 uggaugggcu gaugaggccg uuaggccgaa igcccgcg

RN 342828-47-1 CAPLUS

CN RNA, (G-G-A-C-G-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-C-G-A) (9CI) (CA INDEX NAME)

SEQ 1 ggacguggcu gaugaggccg uuaggccgaa igccgcga

RN 342828-62-0 CAPLUS

CN RNA, (G-A-A-G-U-G-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-C-G-G) (9CI) (CA INDEX NAME)

SEQ 1 gaagugcucu gaugaggccg uuaggccgaa igucucgg

RN 342828-76-6 CAPLUS

CN RNA, (A-G-G-A-A-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-

G-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 aggaaggacu gaugaggccg uuaggccgaa igccgcag

RN 342828-88-0 CAPLUS

CN RNA, (G-U-C-A-G-G-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 gucaggcucu gaugaggccg uuaggccgaa igccucag

RN 342828-91-5 CAPLUS

CN RNA, (C-G-C-C-A-G-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G-C) (9CI) (CA INDEX NAME)

SEQ 1 cgccaguccu gaugaggccg uuaggccgaa igcugggc

RN 342828-96-0 CAPLUS

CN RNA, (C-A-G-A-A-A-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 cagaaagacu gaugaggccg uuaggccgaa igucucca

RN 342829-02-1 CAPLUS

CN RNA, (G-G-C-A-U-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-G-G-A) (9CI) (CA INDEX NAME)

SEQ 1 ggcauccacu gaugaggccg uuaggccgaa igccugga

RN 342829-24-7 CAPLUS

CN RNA, (A-G-A-A-A-C-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-C-A-U) (9CI) (CA INDEX NAME)

SEQ 1 agaaacagcu gaugaggccg uuaggccgaa igccgcac

RN 342829-31-6 CAPLUS

CN RNA, (A-C-U-G-C-G-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 acugcgcgcu gaugaggccg uuaggccgaa iguuccca

RN 342829-58-7 CAPLUS  
CN RNA, (G-A-G-C-C-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-C-U-C) (9CI) (CA INDEX NAME)

SEQ 1 gagcccugcu gaugaggccg uuaggccgaa igcuucuc

RN 342829-64-5 CAPLUS  
CN RNA, (C-U-C-C-U-C-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 cuccucggcu gaugaggccg uuaggccgaa igccgcca

RN 342829-70-3 CAPLUS  
CN RNA, (G-G-C-G-A-C-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-G-U-G) (9CI) (CA INDEX NAME)

SEQ 1 ggcgacggcu gaugaggccg uuaggccgaa igucugug

RN 342829-85-0 CAPLUS  
CN RNA, (C-C-U-G-C-C-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-U-G) (9CI) (CA INDEX NAME)

SEQ 1 ccugccagcu gaugaggccg uuaggccgaa igcugcug

RN 342829-91-8 CAPLUS  
CN RNA, (G-C-G-C-A-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ggcgaggccu gaugaggccg uuaggccgaa igcccgca

RN 342830-02-8 CAPLUS  
CN RNA, (A-G-C-C-C-C-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 agccccagcu gaugaggccg uuaggccgaa igccuggg

RN 342830-35-7 CAPLUS  
CN RNA, (C-A-A-C-C-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-C-U-G) (9CI) (CA INDEX NAME)

SEQ 1 caacccucuc gaugaggccg uuaggccgaa igcuccug

RN 342830-47-1 CAPLUS

CN RNA, (C-A-G-G-A-A-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-G-G-A) (9CI) (CA INDEX NAME)

SEQ 1 caggaacucu gaugaggccg uuaggccgaa igccagga

RN 342830-60-8 CAPLUS

CN RNA, (U-U-G-A-A-A-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-C-C-G) (9CI) (CA INDEX NAME)

SEQ 1 uugaaacgcu gaugaggccg uuaggccgaa igucuccg

RN 342830-83-5 CAPLUS

CN RNA, (G-G-C-G-G-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-C-C-C) (9CI) (CA INDEX NAME)

SEQ 1 ggcggggccu gaugaggccg uuaggccgaa igcuuccc

RN 342830-85-7 CAPLUS

CN RNA, (A-G-C-A-G-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-G-G-C) (9CI) (CA INDEX NAME)

SEQ 1 agcagggccu gaugaggccg uuaggccgaa igccuggc

RN 342831-01-0 CAPLUS

CN RNA, (A-G-C-C-C-G-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 agcccguccu gaugaggccg uuaggccgaa igcuuggg

RN 342831-07-6 CAPLUS

CN RNA, (G-A-A-C-G-U-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 gaacguuccu gaugaggccg uuaggccgaa igcuccca

RN 342831-25-8 CAPLUS

CN RNA, (C-G-C-C-C-A-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-

G-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 cgcccaggcu gaugaggccg uuaggccgaa igccgggg

RN 342831-33-8 CAPLUS

CN RNA, (U-A-U-C-G-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-A-G-C) (9CI) (CA INDEX NAME)

SEQ 1 uaucgucccu gaugaggccg uuaggccgaa igcccagc

RN 342831-38-3 CAPLUS

CN RNA, (G-G-U-G-C-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-U-G-U) (9CI) (CA INDEX NAME)

SEQ 1 ggugcgcccu gaugaggccg uuaggccgaa igcccugu

RN 342831-44-1 CAPLUS

CN RNA, (C-G-G-G-U-C-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 cggguccucu gaugaggccg uuaggccgaa igcccgca

RN 342831-47-4 CAPLUS

CN RNA, (C-A-G-G-C-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 caggcgcccu gaugaggccg uuaggccgaa iguccugg

RN 342831-72-5 CAPLUS

CN RNA, (G-U-G-U-U-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-G-A-U) (9CI) (CA INDEX NAME)

SEQ 1 guguucugcu gaugaggccg uuaggccgaa iguuugau

RN 342831-88-3 CAPLUS

CN RNA, (G-C-U-C-U-U-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-U-G-C) (9CI) (CA INDEX NAME)

SEQ 1 gcucuugacu gaugaggccg uuaggccgaa igccuugc

RN 342831-91-8 CAPLUS  
CN RNA, (U-A-G-A-G-A-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-U-U-G) (9CI) (CA INDEX NAME)

SEQ 1 uagagacgcu gaugaggccg uuaggccgaa igcucuug

RN 342831-98-5 CAPLUS  
CN RNA, (A-C-G-G-C-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-G-U-C) (9CI) (CA INDEX NAME)

SEQ 1 acggcuggcu gaugaggccg uuaggccgaa igucuguc

RN 342832-10-4 CAPLUS  
CN RNA, (C-A-G-C-G-G-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-C-C-U) (9CI) (CA INDEX NAME)

SEQ 1 cagcgggccu gaugaggccg uuaggccgaa igucuccu

RN 342832-12-6 CAPLUS  
CN RNA, (C-C-C-U-C-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-U-C) (9CI) (CA INDEX NAME)

SEQ 1 cccucagccu gaugaggccg uuaggccgaa igcugguc

RN 342832-24-0 CAPLUS  
CN RNA, (G-C-C-A-C-U-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-A-U) (9CI) (CA INDEX NAME)

SEQ 1 gccacugccu gaugaggccg uuaggccgaa igccucau

RN 342832-27-3 CAPLUS  
CN RNA, (C-G-U-C-G-A-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-C-U-G) (9CI) (CA INDEX NAME)

SEQ 1 cgucgaagcu gaugaggccg uuaggccgaa igccacug

RN 342832-64-8 CAPLUS  
CN RNA, (C-G-U-A-G-C-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-A-G) (9CI) (CA INDEX NAME)



SEQ 1 cguagcaccu gaugaggccg uuaggccgaa igcugcag

RN 342832-85-3 CAPLUS

CN RNA, (C-C-U-G-A-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-U-C-G) (9CI) (CA INDEX NAME)

SEQ 1 ccugaggacu gaugaggccg uuaggccgaa iguuuucg

RN 342832-90-0 CAPLUS

CN RNA, (U-C-G-G-A-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-U-G-A) (9CI) (CA INDEX NAME)

SEQ 1 ucggaccacu gaugaggccg uuaggccgaa iguccuga

RN 342833-04-9 CAPLUS

CN RNA, (G-C-C-A-C-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-G-U) (9CI) (CA INDEX NAME)

SEQ 1 gccacccacu gaugaggccg uuaggccgaa igccucgu

RN 342833-11-8 CAPLUS

CN RNA, (U-A-G-G-C-C-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 uaggccgucu gaugaggccg uuaggccgaa igccggca

RN 342833-14-1 CAPLUS

CN RNA, (A-G-G-G-G-A-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 aggggaaucu gaugaggccg uuaggccgaa igccgugg

RN 342833-20-9 CAPLUS

CN RNA, (C-C-A-G-C-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-C-A-C) (9CI) (CA INDEX NAME)

SEQ 1 ccagcagccu gaugaggccg uuaggccgaa igccgcac

RN 342833-26-5 CAPLUS

CN RNA, (C-A-C-C-U-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-

C-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 caccuccacu gaugaggccg uuaggccgaa iguccggg

RN 342833-37-8 CAPLUS

CN RNA, (U-C-U-G-A-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ucugauggcu gaugaggccg uuaggccgaa iguccggg

RN 342833-42-5 CAPLUS

CN RNA, (G-G-U-G-A-G-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-U-G-A) (9CI) (CA INDEX NAME)

SEQ 1 ggugagaccu gaugaggccg uuaggccgaa igcucuga

RN 342833-61-8 CAPLUS

CN RNA, (C-C-A-G-A-A-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-U-G-A) (9CI) (CA INDEX NAME)

SEQ 1 ccagaaaccu gaugaggccg uuaggccgaa igcuguga

RN 342833-66-3 CAPLUS

CN RNA, (C-C-G-U-C-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-U-U-C) (9CI) (CA INDEX NAME)

SEQ 1 ccgucuggcu gaugaggccg uuaggccgaa igcuguuc

RN 342833-94-7 CAPLUS

CN RNA, (A-A-A-A-U-G-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-U-U-C) (9CI) (CA INDEX NAME)

SEQ 1 aaaaugugcu gaugaggccg uuaggccgaa iguucuuc

RN 342834-05-3 CAPLUS

CN RNA, (G-C-A-G-A-G-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-U-G-U) (9CI) (CA INDEX NAME)

SEQ 1 gcagagggcu gaugaggccg uuaggccgaa igccgugu

RN 342834-17-7 CAPLUS  
CN RNA, (U-G-C-G-U-U-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-U-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ugcguucucu gaugaggccg uuaggccgaa igcuuuca

RN 342834-21-3 CAPLUS  
CN RNA, (G-G-C-G-C-C-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ggcgcccucu gaugaggccg uuaggccgaa igccccc

RN 342834-25-7 CAPLUS  
CN RNA, (A-G-G-G-C-A-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-G-C-G) (9CI) (CA INDEX NAME)

SEQ 1 agggcagacu gaugaggccg uuaggccgaa igccggcg

RN 342834-61-1 CAPLUS  
CN RNA, (C-U-G-C-G-U-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-U-C-C) (9CI) (CA INDEX NAME)

SEQ 1 cugcgucucu gaugaggccg uuaggccgaa igcugucc

RN 342834-76-8 CAPLUS  
CN RNA, (U-G-C-C-G-G-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ugccgggucu gaugaggccg uuaggccgaa igcugcgg

RN 342834-78-0 CAPLUS  
CN RNA, (G-C-A-G-U-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-G-C-U) (9CI) (CA INDEX NAME)

SEQ 1 gcagugcccu gaugaggccg uuaggccgaa iguuggcu

RN 342834-88-2 CAPLUS  
CN RNA, (G-U-C-C-A-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-U-U-G-A) (9CI) (CA INDEX NAME)

SEQ 1 guccaggacu gaugaggccg uuaggccgaa igucuuga

RN 342834-93-9 CAPLUS  
CN RNA, (U-G-G-G-C-G-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-U-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ugggcgggcu gaugaggccg uuaggccgaa igccauca

RN 342835-01-2 CAPLUS  
CN RNA, (U-C-U-C-G-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ucucggcccu gaugaggccg uuaggccgaa igcugugg

RN 342835-09-0 CAPLUS  
CN RNA, (G-C-G-U-G-A-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-U-G) (9CI) (CA INDEX NAME)

SEQ 1 gcgugacacu gaugaggccg uuaggccgaa igcugcug

RN 342835-19-2 CAPLUS  
CN RNA, (C-U-G-G-G-U-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-C-C-C) (9CI) (CA INDEX NAME)

SEQ 1 cugggugucu gaugaggccg uuaggccgaa igccgccc

RN 342835-26-1 CAPLUS  
CN RNA, (A-G-C-G-G-U-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 agcggugccu gaugaggccg uuaggccgaa igccuggg

RN 342835-32-9 CAPLUS  
CN RNA, (A-C-U-C-A-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 acucacuccu gaugaggccg uuaggccgaa igccucag

RN 342835-35-2 CAPLUS  
CN RNA, (G-G-A-C-A-U-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-

U-C-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ggacaugccu gaugaggccg uuaggccgaa igccucgg

RN 342835-43-2 CAPLUS

CN RNA, (A-C-U-C-G-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 acucgcuccu gaugaggccg uuaggccgaa igccucag

RN 342835-47-6 CAPLUS

CN RNA, (U-C-A-G-C-C-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-A-C) (9CI) (CA INDEX NAME)

SEQ 1 ucagcccucu gaugaggccg uuaggccgaa igcuggac

RN 342835-74-9 CAPLUS

CN RNA, (G-G-A-A-A-A-G-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ggaaaagccu gaugaggccg uuaggccgaa igcccugg

RN 342835-82-9 CAPLUS

CN RNA, (U-G-G-A-A-G-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-C-C-U-G) (9CI) (CA INDEX NAME)

SEQ 1 uggaagcccu gaugaggccg uuaggccgaa igcuccug

RN 342836-27-5 CAPLUS

CN RNA, (C-C-U-U-C-U-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ccuucucacu gaugaggccg uuaggccgaa igucucca

RN 342836-30-0 CAPLUS

CN RNA, (A-G-C-U-C-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-U-U-C) (9CI) (CA INDEX NAME)

SEQ 1 agcucccacu gaugaggccg uuaggccgaa iguccuuc

RN 342836-35-5 CAPLUS  
 CN RNA, (C-A-C-A-C-C-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-A-C-U-C) (9CI) (CA INDEX NAME)

SEQ 1 cacaccuucu gaugaggccg uuaggccgaa igucacuc

RN 342836-42-4 CAPLUS  
 CN RNA, (C-A-G-G-U-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-U-C-G) (9CI) (CA INDEX NAME)

SEQ 1 caggugcacu gaugaggccg uuaggccgaa iguccucg

L47 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:294219 CAPLUS  
 Correction of: 2001:168136  
 DOCUMENT NUMBER: 134:337614  
 Correction of: 134:233606  
 TITLE: Nucleic acid-based ribozyme and DNAzyme modulators of gene expression  
 INVENTOR(S): McSwiggen, James; Usman, Nassim; Blatt, Lawrence; Beigelman, Leonid; Burgin, Alex; Karpeisky, Alexander; Matulic-adamic, Jasenka; Sweedler, David; Draper, Kenneth; Chowrira, Bharat; Stinchcomb, Dan; Beaudry, Amber; Zinnen, Shawn; Lugwig, Janos; Sproat, Brian S.  
 PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 717 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 PATENT INFORMATION: .

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016312 A2		20010308	WO 2000-US23998	20000830
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1999-PV151713	19990831
			US 1999-406643	19990927
			US 1999-PV156467	19990927
			US 1999-PV156236	19990927
			US 1999-436430	19991108
			US 1999-PV169100	19991206
			US 1999-PV173612	19991229
			US 1999-474432	19991229
			US 1999-476387	19991230
			US 2000-498824	20000204
			US 2000-531025	20000320
			US 2000-PV197769	20000414

US 2000-578223

20000523

ED Entered STN: 26 Apr 2001

AB Novel nucleic acid mols. useful as inhibitors of gene expression, compns., and methods for their use are provided. The invention features novel nucleic acid-based techniques (e.g., enzymic nucleic acid mols. (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, and antisense nucleic acids containing RNA-cleaving chemical groups) and their use to modulate the expression of mol. targets impacting the development and progression of cancers, diabetes, obesity, Alzheimer's disease diseases, age-related diseases, and/or hepatitis B infections and related conditions. Catalytic nucleic acids were designed for site-specific cleavage of human mRNA targets encoding protein tyrosine phosphatase 1b, methionine aminopeptidase,  $\beta$ -secretase, presenilin-1, epidermal growth factor receptor-2 (HER2/c-erb2/neu), phospholamban, telomerase, and hepatitis B virus genes. Methods for chemical synthesis of modified nucleoside triphosphates (NTPs) and RNA polymerase-catalyzed incorporation of modified NTPs into catalytic oligonucleotides are also provided. [This abstract record os one of 6 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 335673-81-9 335673-92-2 335673-99-9

335674-05-0 335674-11-8 335674-25-4

335674-33-4 335674-41-4 335674-59-4

335674-73-2 335674-76-5 335674-88-9

335674-97-0 335675-11-1 335675-14-4

335675-23-5 335675-37-1 335675-50-8

335675-74-6 335675-76-8 335675-95-1

335676-02-3 335676-14-7 335676-23-8

335676-48-7 335676-55-6 335676-60-3

335676-86-3 335676-88-5 335677-15-1

335677-28-6 335677-34-4 335677-63-9

335677-69-5 335677-97-9 335678-27-8

335678-30-3 335678-44-9 335678-48-3

335679-00-0 335679-05-5 335679-12-4

335679-38-4 335679-42-0 335679-58-8

335679-92-0 335680-17-6 335680-27-8

335680-32-5 335680-60-9 335680-64-3

335680-78-9 335681-11-3 335681-42-0

335681-71-5 335681-81-7 335681-83-9

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NCH ribozyme specific for protein tyrosine phosphatase PTP-1B; nucleic acid-based ribozyme and DNAzyme modulators of gene expression)

RN 335673-81-9 CAPLUS

CN RNA, (G-C-C-G-C-U-C-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-G-C-G-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335673-92-2 CAPLUS

CN RNA, (U-C-C-A-U-G-A-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-A-G-G-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335673-99-9 CAPLUS

CN RNA, (C-U-G-G-U-A-A-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-G-C-C-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-05-0 CAPLUS

CN RNA, (G-A-A-G-U-C-A-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-U-C-A-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-11-8 CAPLUS

CN RNA, (A-G-G-A-A-G-C-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-A-C-U-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-25-4 CAPLUS

CN RNA, (U-C-C-G-A-C-U-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-A-A-A-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-33-4 CAPLUS

CN RNA, (A-C-U-C-C-U-U-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-U-C-U-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-41-4 CAPLUS

CN RNA, (U-A-G-G-C-A-A-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-C-U-G-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-59-4 CAPLUS

CN RNA, (U-C-U-U-U-U-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-A-G-U-A) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-73-2 CAPLUS

CN RNA, (G-G-G-U-U-G-U-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-U-U-C-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-76-5 CAPLUS

CN RNA, (A-G-U-U-U-C-U-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-G-U-A-A) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-88-9 CAPLUS

CN RNA, (C-C-A-A-A-G-U-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-A-U-G-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335674-97-0 CAPLUS

CN RNA, (C-A-A-G-A-A-U-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-G-G-U-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335675-11-1 CAPLUS

CN RNA, (C-G-U-G-C-U-C-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-G-A-G-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335675-14-4 CAPLUS

CN RNA, (A-C-C-A-C-A-A-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-C-G-U-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335675-23-5 CAPLUS



CN RNA, (C-A-G-A-C-A-G-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-C-C-A-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335675-37-1 CAPLUS

CN RNA, (C-G-G-A-A-G-A-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-U-U-U-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335675-50-8 CAPLUS

CN RNA, (A-G-C-G-C-A-G-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-G-G-C-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335675-74-6 CAPLUS

CN RNA, (G-G-G-G-C-U-C-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-C-U-C-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335675-76-8 CAPLUS

CN RNA, (U-C-G-G-G-U-G-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-C-C-A-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335675-95-1 CAPLUS

CN RNA, (C-G-U-U-U-G-G-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-G-G-G-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335676-02-3 CAPLUS

CN RNA, (C-C-A-U-U-G-U-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-C-C-A-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335676-14-7 CAPLUS

CN RNA, (A-U-C-C-U-C-C-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-U-C-U-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335676-23-8 CAPLUS

CN RNA, (C-A-U-U-U-A-A-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-U-C-C-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335676-48-7 CAPLUS

CN RNA, (C-U-C-C-C-C-U-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-G-G-G-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335676-55-6 CAPLUS

CN RNA, (U-C-A-G-U-G-C-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-C-U-C-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335676-60-3 CAPLUS

CN RNA, (A-C-C-A-G-G-A-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-U-C-C-A) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335676-86-3 CAPLUS

CN RNA, (G-G-A-G-G-G-U-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-A-U-G-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335676-88-5 CAPLUS

CN RNA, (G-U-G-G-A-G-G-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-A-G-G-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335677-15-1 CAPLUS

CN RNA, (U-C-G-G-G-C-G-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-C-U-G-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335677-28-6 CAPLUS

CN RNA, (U-C-C-G-U-C-C-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-C-G-G-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335677-34-4 CAPLUS

CN RNA, (G-G-G-A-A-G-A-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-U-U-A-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335677-63-9 CAPLUS

CN RNA, (U-C-A-A-A-A-A-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-U-G-U-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335677-69-5 CAPLUS

CN RNA, (A-C-G-G-G-U-G-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-C-C-U-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335677-97-9 CAPLUS

CN RNA, (C-A-A-G-G-G-G-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-G-U-C-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335678-27-8 CAPLUS

CN RNA, (U-A-C-A-U-U-A-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-C-A-A-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335678-30-3 CAPLUS

CN RNA, (U-U-G-A-U-G-C-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-G-A-C-A) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335678-44-9 CAPLUS

CN RNA, (G-A-C-G-C-A-G-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-C-A-U-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335678-48-3 CAPLUS

CN RNA, (C-C-C-A-G-U-A-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-U-G-A-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335679-00-0 CAPLUS

CN RNA, (G-C-A-C-A-G-G-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-G-G-A-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335679-05-5 CAPLUS

CN RNA, (U-A-A-U-G-A-U-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-A-U-G-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335679-12-4 CAPLUS

CN RNA, (U-C-A-G-C-A-A-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-U-A-G-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335679-38-4 CAPLUS

CN RNA, (G-A-C-A-G-G-C-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-U-C-A-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335679-42-0 CAPLUS

CN RNA, (A-C-C-A-G-G-A-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-G-G-G-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335679-58-8 CAPLUS

CN RNA, (U-G-U-G-A-A-U-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-U-C-C-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335679-92-0 CAPLUS

CN RNA, (A-A-U-G-G-C-G-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-G-A-U-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335680-17-6 CAPLUS

CN RNA, (A-A-G-A-A-G-U-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-U-C-C-A) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335680-27-8 CAPLUS

CN RNA, (C-G-U-C-A-C-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-G-U-U-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335680-32-5 CAPLUS

CN RNA, (A-C-G-G-C-G-G-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-G-C-C-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335680-60-9 CAPLUS

CN RNA, (G-C-C-C-C-A-C-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-U-G-A-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335680-64-3 CAPLUS

CN RNA, (G-C-A-C-C-A-U-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-C-C-A-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335680-78-9 CAPLUS

CN RNA, (U-A-A-U-G-U-G-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-C-U-U-C-A) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335681-11-3 CAPLUS

CN RNA, (C-U-C-U-G-U-A-C-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-U-C-U-A) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335681-42-0 CAPLUS

CN RNA, (A-G-G-A-U-A-G-G-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-A-A-A-C) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335681-71-5 CAPLUS

CN RNA, (G-U-A-A-A-U-A-U-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-U-U-A-A-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335681-81-7 CAPLUS

CN RNA, (U-U-A-U-U-C-C-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-C-C-A-U-U-G) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 335681-83-9 CAPLUS

CN RNA, (U-G-U-A-A-A-A-C-U-G-A-U-G-A-G-N-C-G-A-A-I-G-U-U-U-A-U-U) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 337387-33-4 337387-44-7 337387-54-9  
337387-62-9 337387-69-6 337387-92-5  
337387-96-9 337388-08-6 337388-37-1  
337388-72-4 337388-74-6 337388-88-2  
337389-08-9 337389-12-5 337389-24-9  
337389-27-2 337389-41-0 337389-46-5  
337389-71-6 337389-76-1 337389-95-4  
337390-03-1 337390-26-8 337390-28-0  
337390-43-9 337390-50-8 337390-73-5  
337390-79-1 337390-83-7 337390-95-1  
337391-00-1 337391-11-4 337391-23-8  
337391-28-3 337391-53-4 337391-58-9  
337391-67-0 337391-70-5 337391-76-1  
337391-88-5

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)

(human protein kinase C $\alpha$  NCH ribozyme; nucleic acid-based  
ribozyme and DNzyme modulators of gene expression)

RN 337387-33-4 CAPLUS

CN RNA, (G-U-C-A-G-C-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-  
C-C-C-C) (9CI) (CA INDEX NAME)

SEQ 1 gucagccacu gaugaggccg uuaggccgaa iguccccc

RN 337387-44-7 CAPLUS

CN RNA, (G-A-A-G-C-G-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-  
A-C-G-U) (9CI) (CA INDEX NAME)

SEQ 1 gaagcggucu gaugaggccg uuaggccgaa igccacgu

RN 337387-54-9 CAPLUS

CN RNA, (U-G-A-A-U-U-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-U-U-C) (9CI) (CA INDEX NAME)

SEQ 1 ugaauuugcu gaugaggccg uuaggccgaa iguccuuc

RN 337387-62-9 CAPLUS

CN RNA, (C-A-G-A-A-G-G-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-U-U) (9CI) (CA INDEX NAME)

SEQ 1 cagaaggucu gaugaggccg uuaggccgaa igcugcuu

RN 337387-69-6 CAPLUS

CN RNA, (C-G-G-U-G-C-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-A-G) (9CI) (CA INDEX NAME)

SEQ 1 cggugcagcu gaugaggccg uuaggccgaa igcugcag

RN 337387-92-5 CAPLUS

CN RNA, (U-C-A-G-U-G-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-C-U-U) (9CI) (CA INDEX NAME)

SEQ 1 ucaguguccu gaugaggccg uuaggccgaa igucccuu

RN 337387-96-9 CAPLUS

CN RNA, (U-G-C-U-C-C-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-A-U-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ugcuccugcu gaugaggccg uuaggccgaa igucauca

RN 337388-08-6 CAPLUS

CN RNA, (A-G-A-A-G-G-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-C-C-G) (9CI) (CA INDEX NAME)

SEQ 1 agaaggugcu gaugaggccg uuaggccgaa igcuuccg

RN 337388-37-1 CAPLUS

CN RNA, (U-U-C-C-G-C-A-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 uuccgcagcu gaugaggccg uuaggccgaa igcugggg

RN 337388-72-4 CAPLUS

CN RNA, (G-A-U-G-G-U-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-U-U-U) (9CI) (CA INDEX NAME)

SEQ 1 gaugguuucu gaugaggccg uuaggccgaa iguuuuuu

RN 337388-74-6 CAPLUS

CN RNA, (G-G-A-G-C-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ggagcggacu gaugaggccg uuaggccgaa iguuuugg

RN 337388-88-2 CAPLUS

CN RNA, (U-U-G-U-C-U-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-C-A-A) (9CI) (CA INDEX NAME)

SEQ 1 uugucugacu gaugaggccg uuaggccgaa iguuucaa

RN 337389-08-9 CAPLUS

CN RNA, (C-C-A-U-C-C-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-G-G-C-A) (9CI) (CA INDEX NAME)

SEQ 1 ccauccaccu gaugaggccg uuaggccgaa igccggca

RN 337389-12-5 CAPLUS

CN RNA, (C-U-U-C-U-U-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-A-A-G-C) (9CI) (CA INDEX NAME)

SEQ 1 cuucuucucu gaugaggccg uuaggccgaa iguuaagc

RN 337389-24-9 CAPLUS

CN RNA, (G-C-C-A-A-G-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-U-C-U) (9CI) (CA INDEX NAME)

SEQ 1 gccaaguucu gaugaggccg uuaggccgaa igcuuucu

RN 337389-27-2 CAPLUS  
CN RNA, (U-G-C-C-A-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-A-G-U) (9CI) (CA INDEX NAME)

SEQ 1 ugccagcacu gaugaggccg uuaggccgaa igccaagu

RN 337389-41-0 CAPLUS  
CN RNA, (U-U-G-U-U-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-U-U-U) (9CI) (CA INDEX NAME)

SEQ 1 uuguuggacu gaugaggccg uuaggccgaa iguuguuu

RN 337389-46-5 CAPLUS  
CN RNA, (C-U-C-G-G-U-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-U-U-G) (9CI) (CA INDEX NAME)

SEQ 1 cucggucacu gaugaggccg uuaggccgaa iguuguug

RN 337389-71-6 CAPLUS  
CN RNA, (G-U-C-A-A-G-C-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-A-A-G-A) (9CI) (CA INDEX NAME)

SEQ 1 gucaagcacu gaugaggccg uuaggccgaa igccaaga

RN 337389-76-1 CAPLUS  
CN RNA, (A-A-G-A-A-C-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-U-G-U-U-C) (9CI) (CA INDEX NAME)

SEQ 1 aagaacggcu gaugaggccg uuaggccgaa iguuuguc

RN 337389-95-4 CAPLUS  
CN RNA, (G-G-U-A-C-A-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 gguacaugcu gaugaggccg uuaggccgaa igucccca

RN 337390-03-1 CAPLUS  
CN RNA, (A-C-U-G-C-U-U-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-C-C-U-U) (9CI) (CA INDEX NAME)

SEQ 1 acugcuugcu gaugaggccg uuaggccgaa iguuccuu

RN 337390-26-8 CAPLUS

CN RNA, (G-A-A-G-G-U-C-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-G-U-G-A) (9CI) (CA INDEX NAME)

SEQ 1 gaaggucccu gaugaggccg uuaggccgaa igucguga

RN 337390-28-0 CAPLUS

CN RNA, (C-C-C-A-C-A-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-C-U-G-G) (9CI) (CA INDEX NAME)

SEQ 1 cccacagacu gaugaggccg uuaggccgaa iguccugg

RN 337390-43-9 CAPLUS

CN RNA, (G-A-C-G-C-C-A-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-A-C-C) (9CI) (CA INDEX NAME)

SEQ 1 gacgccaucu gaugaggccg uuaggccgaa igcccacc

RN 337390-50-8 CAPLUS

CN RNA, (U-C-A-A-A-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-C-C-C) (9CI) (CA INDEX NAME)

SEQ 1 ucaaauugcu gaugaggccg uuaggccgaa igcugccc

RN 337390-73-5 CAPLUS

CN RNA, (U-G-G-G-U-G-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-A-U-C-A) (9CI) (CA INDEX NAME)

SEQ 1 uggguguucu gaugaggccg uuaggccgaa igucauca

RN 337390-79-1 CAPLUS

CN RNA, (C-A-G-C-C-G-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G-U) (9CI) (CA INDEX NAME)

SEQ 1 cagccgcucu gaugaggccg uuaggccgaa igcugggu

RN 337390-83-7 CAPLUS



CN RNA, (U-C-C-C-C-C-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-C-A-C-A) (9CI) (CA INDEX NAME)

SEQ 1 uccccuccu gaugaggccg uuaggccgaa igcccaca

RN 337390-95-1 CAPLUS

CN RNA, (U-U-G-A-A-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-A-U) (9CI) (CA INDEX NAME)

SEQ 1 uugaauggcu gaugaggccg uuaggccgaa igcuggau

RN 337391-00-1 CAPLUS

CN RNA, (C-A-C-A-C-U-U-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-U-G-A-A) (9CI) (CA INDEX NAME)

SEQ 1 cacacuuucu gaugaggccg uuaggccgaa igcuugaa

RN 337391-11-4 CAPLUS

CN RNA, (G-U-U-A-A-G-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-U-C-C) (9CI) (CA INDEX NAME)

SEQ 1 guuaagaccu gaugaggccg uuaggccgaa igcugucc

RN 337391-23-8 CAPLUS

CN RNA, (A-A-U-C-A-G-A-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-C-U-A-U-G) (9CI) (CA INDEX NAME)

SEQ 1 aaucagaccu gaugaggccg uuaggccgaa igucuauug

RN 337391-28-3 CAPLUS

CN RNA, (C-A-A-A-C-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-A-C-A) (9CI) (CA INDEX NAME)

SEQ 1 caaacuggcu gaugaggccg uuaggccgaa iguugaca

RN 337391-53-4 CAPLUS

CN RNA, (A-G-G-G-C-U-G-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 agggcuggcu gaugaggccg uuaggccgaa igcugggg

RN 337391-58-9 CAPLUS  
CN RNA, (U-G-C-G-G-G-G-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-U-G-G-G-G) (9CI) (CA INDEX NAME)

SEQ 1 ugcggggacu gaugaggccg uuaggccgaa igcugggg

RN 337391-67-0 CAPLUS  
CN RNA, (A-A-A-U-U-U-U-A-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-A-A-G-G) (9CI) (CA INDEX NAME)

SEQ 1 aaauuuuacu gaugaggccg uuaggccgaa iguuaagg

RN 337391-70-5 CAPLUS  
CN RNA, (A-C-A-A-G-C-C-G-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-U-A-A) (9CI) (CA INDEX NAME)

SEQ 1 acaagccgcu gaugaggccg uuaggccgaa igccuuaa

RN 337391-76-1 CAPLUS  
CN RNA, (C-A-A-U-U-U-U-C-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-C-C-U-C-C-A) (9CI) (CA INDEX NAME)

SEQ 1 caauuuuccu gaugaggccg uuaggccgaa igccucca

RN 337391-88-5 CAPLUS  
CN RNA, (A-A-U-G-U-U-C-U-C-U-G-A-U-G-A-G-G-C-C-G-U-U-A-G-G-C-C-G-A-A-I-G-U-U-G-U-A-A) (9CI) (CA INDEX NAME)

SEQ 1 aauguucucu gaugaggccg uuaggccgaa iguuguuaa

L47 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:168136 CAPLUS  
DOCUMENT NUMBER: 134:233606  
TITLE: Nucleic acid-based ribozyme and DNzyme modulators of gene expression  
INVENTOR(S): McSwiggen, James; Usman, Nassim; Blatt, Lawrence; Beigelman, Leonid; Burgin, Alex; Karpeisky, Alexander; Matulic-Adamic, Jasenka; Sweedler, David; Draper, Kenneth; Chowrira, Bharat; Stinchcomb, Dan; Beaudry, Amber; Zinnen, Shawn; Lugwig, Janos; Sproat, Brian S.  
PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 717 pp.

CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016312 A2		20010308	WO 2000-US23998	20000830
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1999-PV151713	19990831
			US 1999-406643	19990927
			US 1999-PV156467	19990927
			US 1999-PV156236	19990927
			US 1999-436430	19991108
			US 1999-PV169100	19991206
			US 1999-PV173612	19991229
			US 1999-474432	19991229
			US 1999-476387	19991230
			US 2000-498824	20000204
			US 2000-531025	20000320
			US 2000-PV197769	20000414
			US 2000-578223	20000523

OTHER SOURCE(S): MARPAT 134:233606

ED Entered STN: 09 Mar 2001

AB Novel nucleic acid mols. useful as inhibitors of gene expression, compns., and methods for their use are provided. The invention features novel nucleic acid-based techniques (e.g., enzymic nucleic acid mols. (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, and antisense nucleic acids containing RNA-cleaving chemical groups) and their use to modulate the expression of mol. targets impacting the development and progression of cancers, diabetes, obesity, Alzheimer's disease diseases, age-related diseases, and/or hepatitis B infections and related conditions. Catalytic nucleic acids were designed for site-specific cleavage of human mRNA targets encoding protein tyrosine phosphatase 1b, methionine aminopeptidase,  $\beta$ -secretase, presenilin-1, epidermal growth factor receptor-2 (HER2/c-erb2/neu), phospholamban, telomerase, and hepatitis B virus genes. Methods for chemical synthesis of modified nucleoside triphosphates (NTPs) and RNA polymerase-catalyzed incorporation of modified NTPs into catalytic oligonucleotides are also provided. [This abstract record os one of 6 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 329986-64-3P

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (NCH-Xylo ribozyme specific for Her2; nucleic acid-based ribozyme and DNzyme modulators of gene expression)

RN 329986-64-3 CAPLUS

CN RNA, (Um-Cm-Um-Cm-Cm-Am-Um-Cm-[2'-deoxy-2'-(2-propenyl)]U-G-A-Um-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am- $\beta$ -D-xylo-I-Gm-Um-Cm-Cm-Cm-Um-(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI)  
 (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 329985-95-7P 329986-13-2P 329986-16-5P  
329986-19-8P 329986-20-1P

RL: BAC (Biological activity or effector, except adverse); BPN  
(Biosynthetic preparation); BSU (Biological study, unclassified); PRP  
(Properties); THU (Therapeutic use); BIOL (Biological study);  
PREP (Preparation); USES (Uses)  
(ribozyme specific for Her2; nucleic acid-based ribozyme and DNzyme  
modulators of gene expression)

RN 329985-95-7 CAPLUS

CN RNA, (Gm-sp-Cm-sp-Am-sp-Cm-sp-Um-Cm-Cm-Cm-[2'-deoxy-2'-(2-propenyl)]U-G-A-  
Um-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Cm-Cm-Cm-Cm-Gm-  
(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 329986-13-2 CAPLUS

CN RNA, (Um-sp-Am-sp-Am-sp-Gm-sp-Gm-Um-Um-Cm-[2'-deoxy-2'-(2-propenyl)]U-G-A-  
Um-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Cm-Cm-Cm-Cm-Am-  
(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 329986-16-5 CAPLUS

CN RNA, (Cm-sp-Am-sp-Um-sp-Cm-sp-Gm-Um-Am-Cm-[2'-deoxy-2'-(2-propenyl)]U-G-A-  
Um-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Um-Um-Um-Gm-Gm-  
(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 329986-19-8 CAPLUS

CN RNA, (Am-sp-Gm-sp-Gm-sp-Gm-sp-Cm-Um-Gm-Cm-[2'-deoxy-2'-(2-propenyl)]U-G-A-  
Um-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Um-Cm-Am-Um-Gm-  
(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 329986-20-1 CAPLUS

CN RNA, (Cm-sp-Um-sp-Gm-sp-Um-sp-Am-Gm-Am-Cm-[2'-deoxy-2'-(2-propenyl)]U-G-A-  
Um-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Cm-Um-Gm-Gm-Gm-  
(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 329986-84-7P 329986-90-5P 329987-47-5P  
329987-74-8P 329987-80-6P 329988-41-2P

RL: BAC (Biological activity or effector, except adverse); BPN  
(Biosynthetic preparation); BSU (Biological study, unclassified); PRP  
(Properties); THU (Therapeutic use); BIOL (Biological study);  
PREP (Preparation); USES (Uses)  
(ribozyme specific for hepatitis B virus; nucleic acid-based ribozyme  
and DNzyme modulators of gene expression)

RN 329986-84-7 CAPLUS

CN RNA, (Cm-sp-Am-sp-Gm-sp-Um-sp-Gm-Gm-Cm-[2'-deoxy-2'-(2-propenyl)]U-G-A-Um-  
G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Um-Um-Gm-Cm-  
(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI)  
(CA INDEX NAME)

NTE modified

SEQ 1 caguggcuga ugaggccguu aggccgaaig uugcx

RN 329986-90-5 CAPLUS

CN RNA, (Gm-sp-Cm-sp-Cm-sp-Um-sp-Cm-Am-Cm-[2'-deoxy-2'-(2-propenyl)]U-G-A-Um-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Um-Cm-Gm-Gm-(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI)  
(CA INDEX NAME)

NTE modified

SEQ 1 gccucacuga ugaggccguu aggccgaaig ucggx

RN 329987-47-5 CAPLUS

CN RNA, (Am-sp-Gm-sp-Cm-sp-Um-sp-Um-Gm-Gm-Cm-[2'-deoxy-2'-(2-propenyl)]U-G-A-Um-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Cm-Um-Um-Gm-Am-(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI)  
(CA INDEX NAME)

NTE modified

SEQ 1 agcuuggcug augaggccgu uaggccgaaig gcuugax

RN 329987-74-8 CAPLUS

CN RNA, (Cm-sp-Am-sp-Gm-sp-Um-sp-Gm-Gm-Cm-(2'-amino-2'-deoxy)U-G-A-(2'-amino-2'-deoxy)U-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Um-Um-Gm-Cm-(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 caguggcuga ugaggccguu aggccgaaig uugcx

RN 329987-80-6 CAPLUS

CN RNA, (Gm-sp-Cm-sp-Cm-sp-Um-sp-Cm-Am-Cm-(2'-amino-2'-deoxy)U-G-A-(2'-amino-2'-deoxy)U-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Um-Cm-Gm-Gm-(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 gccucacuga ugaggccguu aggccgaaig ucggx

RN 329988-41-2 CAPLUS

CN RNA, (Am-sp-Gm-sp-Cm-sp-Um-sp-Um-Gm-Gm-Cm-(2'-amino-2'-deoxy)U-G-A-(2'-amino-2'-deoxy)U-G-Am-Gm-Gm-Cm-Cm-Gm-Um-Um-Am-Gm-Gm-Cm-Cm-G-Am-Am-I-Gm-Cm-Um-Um-Gm-Am-(3'→3')-[(1'ξ)-1'-de(6-amino-9H-purin-9-yl)-1'-hydroxy]dA) (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 agcuuggcug augaggccgu uaggccgaai gcuugax

L47 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:38156 CAPLUS

DOCUMENT NUMBER: 128:137156

TITLE: Oligonucleotide primers/probes derived from gene for nonstructural protein NS3 for detecting hepatitis GB virus C

INVENTOR(S): Yamaguchi, Kenjiro; Matsunaga, Yuka; Yagi, Shintaro; Hasegawa, Akira

PATENT ASSIGNEE(S): Tonen Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10004971	A2	19980113	JP 1996-164443	19960625
PRIORITY APPLN. INFO.:			JP 1996-164443	19960625
ED Entered STN: 23 Jan 1998				
AB Five gene fragments encoding nonstructural protein NS3 are isolated from 5 Japanese patients infected with hepatitis GB virus C by using the primers derived from the NS3-encoding genes isolated by Simon et al. From these gene fragments 8 oligonucleotide primers/probes are designed for the detection of GBV-C genes.				
IT <b>202076-35-5P</b>				
RL: SPN (Synthetic preparation); <b>THU (Therapeutic use)</b> ; BIOL (Biological study); PREP (Preparation); USES (Uses) (oligonucleotide primers/probes derived from gene for nonstructural protein NS3 for detecting hepatitis GB virus C)				
RN 202076-35-5 CAPLUS				
CN DNA, d(A-G-G-C-G-G-A-G-T-G-Y-G-A-G-I-G-I-C-T-I-G-C) (9CI) (CA INDEX NAME)				
NTE singlestranded				
SEQ 1 aggcggagtg ygagigicti gc				

L47 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:31321 CAPLUS

DOCUMENT NUMBER: 128:98548

TITLE: Modulation of tetraplex formation by chemical modifications of a G4-containing oligonucleotide

INVENTOR(S): Wolfe, Jia Liu; Goodchild, John

PATENT ASSIGNEE(S): Hybridon, Inc., USA; Wolfe, Jia Liu; Goodchild, John

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9748715	A1	19971224	WO 1997-US9842	19970609
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9733795	A1	19980107	AU 1997-33795	19970609
PRIORITY APPLN. INFO.:			US 1996-20954P	P 19960619
			WO 1997-US9842	W 19970609
ED	Entered STN: 19 Jan 1998			
AB	This invention provides oligonucleotides having a region of four or more G nucleotides at or near their 5' end and in which from one to all of the 5'-most nucleotides bears a 2' substituent, preferably methoxy, the 3'-terminal nucleotide of the oligonucleotide bears a hydrophobic moiety, preferably cholesterol, or both the 3'-terminal nucleotide bears a hydrophobic moiety and the 5'-most nucleotides are 2'-substituted. Both attachment of a hydrophobic moiety to the 3'-terminal nucleotide of the oligonucleotide and 2'-substitution at the 5'-end results in increased tetraplex stability. The presence of these Hoogsteen base-paired G-quartet structures, however, does not hamper their ability to recognize and form Watson-Crick base-paired duplexes with complementary oligonucleotides. Accordingly, the invention also provides methods of using the disclosed oligonucleotides for nucleic acid expression inhibition.			
IT	<b>178967-34-5</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (modulation of tetraplex formation by chemical modifications of G4-containing oligonucleotide)			
RN	178967-34-5 CAPLUS			
CN	DNA, d(P-thio)(rUm-rGm-G-I-G-C-T-T-A-C-C-T-T-G-C-G-rAm-rAm-rCm-rAm) (9CI) (CA INDEX NAME)			
NTE	singlestranded modified			
SEQ	1 uggigcttac cttgcgaaca			

L47 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:1593 CAPLUS  
 DOCUMENT NUMBER: 128:87864  
 TITLE: Oligonucleotide probes for genotyping the HLA DQB1 gene and for HLA typing  
 INVENTOR(S): Mougín, Bruno  
 PATENT ASSIGNEE(S): Bio Merieux, Fr.; Mougín, Bruno  
 SOURCE: PCT Int. Appl., 44 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9746700	A1	19971211	WO 1997-FR980	19970603
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2749308	A1	19971205	FR 1996-6822	19960603
FR 2749308	B1	19980724		
CA 2257182	AA	19971211	CA 1997-2257182	19970603
EP 910667	A1	19990428	EP 1997-927226	19970603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000511430	T2	20000905	JP 1998-500276	19970603
PRIORITY APPLN. INFO.:			FR 1996-6822	A 19960603
			WO 1997-FR980	W 19970603

ED Entered STN: 02 Jan 1998

AB Oligonucleotide probes for determination of genotypes at the HLA-DQB1 locus and so for determination of HLA-DQB1 type are described. All of the probes are designed to be useful at a single hybridization temperature (37°).

IT 200820-25-3  
RL: ARG (Analytical reagent use); PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(probe determination of HLA DQB1 genotype; oligonucleotide probes for genotyping HLA DQB1 gene and for HLA typing)

RN 200820-25-3 CAPLUS

CN DNA, d(G-G-G-G-I-G-I-C-C-T-I-A-C-G-I-C-G-A-G-T-A-C-T) (9CI) (CA INDEX NAME)

NTE singlestranded

SEQ 1 ggggigicct iacgicgagt act

L47 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:772188 CAPLUS

DOCUMENT NUMBER: 128:31091

TITLE: Poliovirus-specific primers and methods of detection utilizing the same

INVENTOR(S): Kilpatrick, David R.

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: U.S., 22 pp., Cont.-in-part of U.S. 5,585,477.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5691134	A	19971125	US 1994-273474	19940711
US 5585477	A	19961217	US 1993-92110	19930713
US 6143494	A	20001107	US 1997-935100	19970925
PRIORITY APPLN. INFO.:			US 1993-92110	A2 19930713
			US 1994-273474	A1 19940711



ED Entered STN: 11 Dec 1997

AB The ability to rapidly detect wild polioviruses in clin. specimens is a major concern for the world-wide eradication of polioviruses. Provided is a method of detecting polioviruses of all 3 serotypes from viral isolates of clin. specimens using a pair of degenerate PCR primers. This primer set, which uses deoxyinosine residues to compensate for third position mismatches at specific positions, recognizes nucleotide sequences near the receptor binding site of polioviruses. These sequences are unique to polioviruses and are absolutely conserved at the amino acid level. As a result, these PCR primers do not recognize nonpoliovirus enteroviruses. All poliovirus serotypes (40 poliovaccine related genotypes and 120 wild poliovirus genotypes from around the world) tested pos. All 14 prototype strains of nonpoliovirus enteroviruses tested neg. Also provided is a series of degenerate PCR primers that differentiates between the 3 wild poliovirus serotypes and a method of detecting the presence of the 3 serotypes utilizing a nucleic acid amplification technique.

IT 163584-34-7  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (PCR primer Sero 3aP3; poliovirus specific primers and methods of detection utilizing the same)

RN 163584-34-7 CAPLUS

CN DNA, d(A-R-I-G-C-I-C-Y-Y-T-G-I-G-C-I-A-C-I-T-C) (9CI) (CA INDEX NAME)

NTE singlestranded

SEQ 1 arigcicyt gigciacitc

L47 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:625604 CAPLUS

DOCUMENT NUMBER: 127:289115

TITLE: Optimized antisense oligonucleotides exhibiting anti-cytomegalovirus activity

INVENTOR(S): Pari, Gregory S.

PATENT ASSIGNEE(S): Hybridon, Inc., USA

SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9733992	A1	19970918	WO 1997-US4235	19970314
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9722150	A1	19971001	AU 1997-22150	19970314
PRIORITY APPLN. INFO.:			US 1996-615801	A 19960314
			WO 1997-US4235	W 19970314

ED Entered STN: 01 Oct 1997

AB Provided are novel, chemical modified antisense oligonucleotides with improved activities against human cytomegalovirus (HCMV). The modified oligonucleotides also possess enhanced stability, bio-availability, and reduced toxicity, which render them particularly suitable for clin. use. Modified oligonucleotides UL36/37 2x4 OMe and UL36/37 4x4 OMe inhibited 100% HCMV at 0.1  $\mu$ M, or >90% at 0.03  $\mu$ M, by targeting gene UL36/37. The present invention further provides therapeutic compns. comprising the novel oligonucleotides of the invention, and method of preparing medicaments comprising them.

IT **178967-34-5P**  
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
(antisense oligonucleotide UL36/37 2x4 OMe(I); optimized antisense oligonucleotides exhibiting anti-cytomegalovirus activity)

RN 178967-34-5 CAPLUS

CN DNA, d(P-thio)(rUm-rGm-G-I-G-C-T-T-A-C-C-T-T-G-C-G-rAm-rAm-rCm-rAm) (9CI) (CA INDEX NAME)

NTE singlestranded  
modified

SEQ 1 uggigcttac cttgcgaaca

L47 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:135093 CAPLUS

DOCUMENT NUMBER: 126:248169

TITLE: Effect of Structural Modifications on the Activity of the Leadzyme

AUTHOR(S): Chartrand, Pascal; Usman, Nassim; Cedergren, Robert

CORPORATE SOURCE: Departement de Biochimie, Universite de Montreal, Montreal, QC, H3C 3J7, Can.

SOURCE: Biochemistry (1997), 36(11), 3145-3150  
CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 01 Mar 1997

AB The structure/function properties of functional groups in the leadzyme have been studied by assaying the activity of analog ribozymes generated by the systematic substitution of modified nucleotides in the internal loop region of the ribozyme. Guanosine analogs introduced at positions 4 and 7 occupied by guanosine in the wild-type mol. severely diminished cleavage. The substitution of deoxycytidine for cytidine at the cleavage site completely eliminated the activity of the leadzyme, as expected if the adjacent 2'-OH were the nucleophile in the cleavage reaction. Substitution of an abasic nucleotide for adenosine at position 8 did not affect the activity of the ribozyme. An anal. of the activity of these analogs gives rise to the proposal of a triple-base pair motif implicating C1, G4, and G7.

IT **188598-25-6**  
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(effect of structural modifications on activity of leadzyme)

RN 188598-25-6 CAPLUS

CN RNA, (A-C-A-G-A-C-U-G-G-G-dI-G-U-C-A-C-G) (9CI) (CA INDEX NAME)

NTE singlestranded  
modified

SEQ 1 acagacuggg igucacg

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:235616 CAPLUS

DOCUMENT NUMBER: 124:308722

TITLE: HSP60 gene sequences as universal targets for  
microbial species identification: Studies with  
coagulase-negative staphylococci

AUTHOR(S): Goh, Swee Han; Potter, Sheila; Wood, Julian O.;  
Hemmingsen, Sean M.; Reynolds, Robert P.; Chow,  
Anthony W.

CORPORATE SOURCE: Departments Medicine, University British Columbia,  
Vancouver, BC, Can.

SOURCE: Journal of Clinical Microbiology (1996), 34(4), 818-23  
CODEN: JCMIDW; ISSN: 0095-1137

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 20 Apr 1996

AB A set of universal degenerate primers which amplified, by PCR, a 600-bp oligomer encoding a portion of the 60-kDa heat shock protein (HSP60) of both *Staphylococcus aureus* and *Staphylococcus epidermidis* were developed. However, when used as a DNA probe, the 600-bp PCR product generated from *S. epidermidis* failed to cross-hybridize under high-stringency conditions with the genomic DNA of *S. aureus* and vice versa. To investigate whether species-specific sequences might exist within the highly conserved HSP60 genes among different staphylococci, digoxigenin-labeled HSP60 probes generated by the degenerate HSP60 primers were prepared from the six most commonly isolated *Staphylococcus* species (*S. aureus* 8325-4, *S. epidermidis* 9759, *S. haemolyticus* ATCC 29970, *S. schleiferi* ATCC 43808, *S. saprophyticus* KL122, and *S. lugdunensis* CRSN 850412). These probes were used for dot blot hybridization with genomic DNA of 58 reference and clin. isolates of *Staphylococcus* and non-*Staphylococcus* species. These six *Staphylococcus* species HSP60 probes correctly identified the entire set of staphylococcal isolates. The species specificity of these HSP60 probes was further demonstrated by dot blot hybridization with PCR-amplified DNA from mixed cultures of different *Staphylococcus* species and by the partial DNA sequences of these probes. In addition, sequence homol. searches of the NCBI BLAST databases with these partial HSP60 DNA sequences yielded the highest matching scores for both *S. epidermidis* and *S. aureus* with the corresponding species-specified probes. Finally, the HSP60 degenerate primers were shown to amplify an anticipated 600-bp PCR product from all 29 *Staphylococcus* species and from all but 2 of 30 other microbial species, including various gram-pos. and gram-neg. bacteria, mycobacteria, and fungi. These preliminary data suggest the presence of species-specific sequence variation within the highly conserved HSP60 genes of staphylococci. Further work is required to determine whether these degenerate HSP60 primers may be exploited for species-specific microbial identification and phylogenetic investigation of staphylococci and perhaps other microorganisms in general.

IT 176229-76-8

RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic

use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (PCR primer H279; HSP60 gene sequence PCR for identification of  
 coagulase-neg. staphylococci and other microbes)

RN 176229-76-8 CAPLUS

CN DNA, d(G-A-A-T-T-C-G-A-I-I-I-I-G-C-I-G-G-I-G-A-Y-G-G-I-A-C-I-A-C-I-A-C)  
 (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 176229-77-9

RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic  
 use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (PCR primer H280; HSP60 gene sequence PCR for identification of  
 coagulase-neg. staphylococci and other microbes)

RN 176229-77-9 CAPLUS

CN DNA, d(C-G-C-G-G-G-A-T-C-C-Y-K-I-Y-K-I-T-C-I-C-C-R-A-A-I-C-C-I-G-G-I-G-C-Y-  
 T-T) (9CI) (CA INDEX NAME)

NTE singlestranded

SEQ 1 cgcgggatcc ykiykitcic craaiccigg igcytt

L47 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:589449 CAPLUS

DOCUMENT NUMBER: 123:2724

TITLE: Poliovirus specific primers and methods of detection  
 utilizing the same

INVENTOR(S): Kilpatrick, David R.

PATENT ASSIGNEE(S): United States of America, USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502704	A2	19950126	WO 1994-US7881	19940711
WO 9502704	A3	19950309		

W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE,  
 HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO,  
 NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,  
 BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5585477	A	19961217	US 1993-92110	19930713
------------	---	----------	---------------	----------

CA 2167209	AA	19950126	CA 1994-2167209	19940711
------------	----	----------	-----------------	----------

AU 9473324	A1	19950213	AU 1994-73324	19940711
------------	----	----------	---------------	----------

AU 693465	B2	19980702		
-----------	----	----------	--	--

JP 09500530	T2	19970121	JP 1994-504703	19940711
-------------	----	----------	----------------	----------

EP 789782	A2	19970820	EP 1994-923465	19940711
-----------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1993-92110 A 19930713

WO 1994-US7881 W 19940711

ED Entered STN: 06 Jun 1995

AB The ability to rapidly detect wild polioviruses in clin. specimens is a  
 major concern for the worldwide eradication of polioviruses. Provided is  
 a method of detecting polioviruses of all 3 serotypes from viral isolates

of clin. specimens using a pair of degenerate PCR primers. This primer set, which uses deoxyinosine residues to compensate for third position mismatches at specific positions, recognizes nucleotide sequences near the receptor binding site of polioviruses. These sequences are unique to polioviruses and are absolutely conserved at the amino acid level. As a result, these PCR primers do not recognize nonpoliovirus enteroviruses. All poliovirus serotypes (40 polio vaccine related genotypes and 120 wild poliovirus genotypes from around the world) tested pos. All 14 prototype strains of nonpoliovirus enteroviruses tested neg. Also provided is a series of degenerate PCR primers that differentiates between the 3 wild poliovirus serotypes and a method of detecting the presence of the 3 serotypes utilizing a nucleic acid amplification technique.

IT 163584-34-7

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(PCR primer Sero 3aP3; poliovirus specific primers and methods of detection utilizing the same)

RN 163584-34-7 CAPLUS

CN DNA, d(A-R-I-G-C-I-C-Y-Y-T-G-I-G-C-I-A-C-I-T-C) (9CI) (CA INDEX NAME)

NTE singlestranded

SEQ 1 arigcicyyt gigciacitc

FILE 'HOME' ENTERED AT 14:20:59 ON 30 SEP 2005

=>

**THIS PAGE BLANK (USPTO)**